{
    "snx-2017x10k_fileoutpart64": {
        "predict": "|   | **Fiscal Years Ended November 30, ** |   |   |<NEWLINE>|   | **2017 ** | **2016 ** | **2015 ** |<NEWLINE>| --- | --- | --- | --- |<NEWLINE>| **Effective income tax rate ** | 35.2% | 34.0% | 36.2% |<NEWLINE>|",
        "target": [
            "|   | **Fiscal Years Ended November 30, ** |   |   |",
            "|   | **2017 ** | **2016 ** | **2015 ** |",
            "| --- | --- | --- | --- |",
            "| **Effective income tax rate ** | 35.2 %  | 34.0 %  | 36.2 %  |"
        ]
    },
    "ramp-20210331_fileoutpart13": {
        "predict": "|   | **2021** | **2020** | **% Change 2021-2020** |\n| --- | --- | --- | --- |\n| **Cost of revenue** |   |   |   |\n| **Gross margin (%)** | 67.5 | 59.9 |   |",
        "target": [
            "|   | **2021 ** | **2020 ** | **% Change 2021-2020 ** |",
            "| --- | --- | --- | --- |",
            "| **Cost of revenue ** | - | - | (6)%  |",
            "| **Gross margin (%) ** | 67.5 %  | 59.9 %  | - |"
        ]
    },
    "aap-20221231_fileoutpart5": {
        "predict": "| **(in millions)** |    |    | **Year Ended** |    | **2022 vs. 2021 $ Change** | **Basis Points** |\n| --- | --- | --- | --- | --- | --- | --- |\n| **Net sales** | $11,200.0 |    |    |    | $156.7 |    |\n| **Cost of sales** |    |    |    |    |    |    |\n| **Gross profit** | $5,000.0 |    |    |    | ($56.7) | (33) |\n| **SG&A** |    |    |    |    |    |    |\n| **Operating income** | $714.2 |    |    |    | ($124.6) | (122) |\n| **Interest expense** | $51.1 |    |    |    | $13.3 |    |\n| **Provision for income taxes** | $146.8 |    |    |    | ($43.0) |    |\n\nGuidelines:\n\n- Gross profit margin for 2022 was 44.5% of Net sales, a decrease of 33 basis points compared with 2021.\n- Operating income for 2022 was $714.2 million, a decrease of $124.6 million from 2021. As a percentage of Net sales, operating income was 6.4%, a decrease of 122 basis points compared with 2021.\n- Interest expense for 2022 was $51.1 million, an increase of $13.3 million compared with 2021.\n- Our Provision for income taxes for 2022 was $146.8 million compared with $189.8 million for 2021, a decrease of $43.0 million primarily due to a decrease in taxable income.\n- SG&A for 2022 was $4.2 billion, or 38.1% of Net sales, compared with $4.1 billion, or 37.2% of Net sales, for 2021, an increase of 89 basis points.\n- Net sales for 2022 were $11.2 billion, an increase of $156.7 million, or 1.4%, compared with 2021, and was primarily driven by an improvement in strategic pricing and growth in both new store openings and professional sales, partially offset by declines in DIY customer sales and units sold.\n- Gross profit in 2022 was $5.0 billion, or 44.5% of Net sales, compared with $4.9 billion, or 44.8% of Net sales, in 2021, a decrease of 33 basis points.",
        "target": [
            "| **(in millions) ** |   |   | **Year Ended ** |   | **2022 vs. 2021 $ Change ** | **Basis Points ** |",
            "|   | **December 31, 2022 ** |   | **January 1, 2022 ** |   |   |   |",
            "| --- | --- | --- | --- | --- | --- | --- |",
            "| **Net sales ** | - | - | - | - | $ 156.7  | - |",
            "| **Cost of sales ** | - | - | - | - | - | 33  |",
            "| **Gross profit ** | - | 44.5  | - | 44.8  | - | (33)  |",
            "| **SG&A ** | - | 38.1  | - | 37.2  | - | 89  |",
            "| **Operating income ** | 714.2  | 6.4  | - | - | (124.6)  | (122)  |",
            "| **Interest expense ** | (51.1)  | - | - | - | (13.3)  | - |",
            "| **Provision for income taxes ** | (146.8)  | - | (189.8)  | - | 43.0  | - |"
        ]
    },
    "drq-10q_20200930_fileoutpart23": {
        "predict": "|   | **Three months ended September 30, ** |   | **Nine months ended September 30, ** |   |\n| --- | --- | --- | --- | --- |\n| **Products ** | 72.8% |   | 71.0% |   |\n| **Services ** | 19.5% |   | 20.6% |   |\n| **Leasing ** | 7.7% |   | 8.4% |   |\n| **Total revenues ** |   |   |   |   |\n| **Total cost of sales ** |   |   |   |   |\n| **Engineering and product development ** | $4.0 million (2020) <br> $3.8 million (2019) |   | $14.9 million (2020) <br> $12.5 million (2019) | Increase of approximately $2.4 million (18.8%) |\n| **Restructuring and other charges ** | $0.5 million (2019) <br> Empty (2020) |   | $4.0 million (2019) <br> Consulting fees of approximately $0.5 million | Incurred restructuring charges consisting primarily of consulting fees of approximately $0.5 million during the three months ended September 30, 2019 |\n| **Gain on sale of assets ** | Empty (2020) <br> $0.3 million (2019) |   | $0.5 million (2020) <br> Primarily from the sale of TIW Oklahoma facility | Gain on sale of assets for the nine months ended September 30, 2020 was $0.5 million, which consisted primarily of the sale of our TIW Oklahoma facility |\n| **Foreign currency transaction (gains) and losses ** | $0.7 million loss (2020) <br> $1.1 million gain (2019) |   | Empty (2020) <br> $2.1 million gain (2019) | Reclassified approximately $1.1 million and $2.1 million of foreign currency transaction gains for the three and nine months ended September 30, 2019, respectively, from selling, general and administrative to foreign currency transaction (gains) and losses |\n| **Operating income (loss) ** |   |   |   |   |\n| **Income tax provision (benefit) ** |   |   | $8.9 million (2019) | Income tax expense for the nine months ended September 30, 2019 was $8.9 million on an income before taxes of $3.2 million, resulting in an effective income tax rate of approximately 278.3% |\n| **Selling, general and administrative expenses ** |   |   | Decrease of $8.6 million (11.1%) |   |\n| **Capital expenditures ** |   |   | $4.4 million for rental tools to support current and recently developed products, $3.5 million for machinery and equipment related to global strategic program, $2.3 million for other capital expenditures |   |\n| **Overall COVID-19 impact on cost of sales as a percentage of revenue** | 73.7% (2020) <br> 70.3% (2019) |   | 74.0% (2020) <br> 71.6% (2019) |   |\n| **Credit facility** |   |   | Total commitments of $100.0 million with up to $10.0 million available for letters of credit with JPMorgan Chase Bank, N.A., as administrative agent, and other financial institutions as lenders |   |",
        "target": [
            "|   | **Three months ended September 30, ** |   | **Nine months ended September 30, ** |   |",
            "|   | **2020 ** | **2019 ** | **2020 ** | **2019 ** |",
            "| --- | --- | --- | --- | --- |",
            "| **Products ** | 72.8%  | 75.6%  | 71.0%  | 73.3%  |",
            "| **Services ** | 19.5  | 16.5  | 20.6  | 17.3  |",
            "| **Leasing ** | 7.7  | 7.9  | 8.4  | 9.4  |",
            "| **Total revenues ** | 100.0  | 100.0  | 100.0  | 100.0  |",
            "| **Total cost of sales ** | 73.7  | 70.3  | 74.0  | 71.6  |",
            "| **Engineering and product development ** | 4.4  | 3.5  | - | - |",
            "| **Restructuring and other charges ** | - | 0.5  | - | - |",
            "| **Gain on sale of assets ** | - | (0.3)  | - | (0.5)  |",
            "| **Foreign currency transaction (gains) and losses ** | - | (1.1)  | - | (0.7)  |",
            "| **Operating income (loss) ** | (2.4)  | 0.2  | (18.8)  | - |",
            "| **Income tax provision (benefit) ** | - | 3.2  | (11.1)  | - |"
        ]
    },
    "uve-20220630_fileoutpart33": {
        "predict": "|   | **Three Months Ended June 30, ** |   | **Six Months Ended June 30, ** |   |\n| --- | --- | --- | --- | --- |\n| **2022 ** | **2021 ** | **2022 ** | **2021 ** |<NEWLINE>\n| **Basic earnings (loss) per common share ** |   |   |   |   |<NEWLINE>\n| **Diluted earnings (loss) per common share ** | $0.24 | $0.70 | $0.80 | $1.54 |<NEWLINE>",
        "target": [
            "|   | **Three Months Ended June 30, ** |   | **Six Months Ended June 30, ** |   |",
            "|   | **2022 ** | **2021 ** | **2022 ** | **2021 ** |",
            "| --- | --- | --- | --- | --- |",
            "| **Basic earnings (loss) per common share ** | $ 0.24  | $ 0.70  | - | - |",
            "| **Diluted earnings (loss) per common share ** | $ 0.24  | $ 0.70  | $ 0.80  | $ 1.54  |"
        ]
    },
    "g8692a_fileoutpart15": {
        "predict": "|   | **Three months February 28, 2019 ** | **Ended February 28, 2018 ** |\n| --- | --- | --- |\n| **Net cash (used in) operating activities ** | $84,108 | ($4,936) |\n| **Net cash provided by financing activities ** | $87,000 | $10,000 from promissory notes payable |",
        "target": [
            "|   | **Three months February 28, 2019 ** | **Ended February 28, 2018 ** |",
            "| --- | --- | --- |",
            "| **Net cash (used in) operating activities ** | $ (84,108)  | $ (4,936)  |",
            "| **Net cash provided by financing activities ** | 87,000  | 10,000  |"
        ]
    },
    "f10q0120_digeratitech_fileoutpart15": {
        "predict": "| **Description** | **Fair Value** |   |<NEWLINE>|   |   | **Significant unobservable inputs (Level 3)** |<NEWLINE>|\n| --- | --- | --- |<NEWLINE>| --- | --- | --- |<NEWLINE>|\n| **Convertible promissory notes derivative liability at July 31, 2019** |   | $927,171 |<NEWLINE>|\n| **Convertible promissory notes derivative liability at January 31, 2020** |   | $763,969 |<NEWLINE>|",
        "target": [
            "| **Description ** | **Fair Value ** |   |",
            "|   |   | **Significant unobservable inputs (Level 3) ** |",
            "| --- | --- | --- |",
            "| **Convertible promissory notes derivative liability at July 31, 2019 ** | $ 927,171  | $ 927,171  |",
            "| **Convertible promissory notes derivative liability at January 31, 2020 ** | $ 763,969  | $ 763,969  |"
        ]
    },
    "f10q0120_digeratitech_fileoutpart4": {
        "predict": "|   | **Three months ended January 31, ** |   | **Six months ended January 31, ** |   |\n| --- | --- | --- | --- | --- |\n| **2020** | **2019** | **2020** | **2019** |  |\n| **Depreciation and amortization expense** | $316,000 |  | $535,000 |  |\n| **OPERATING LOSS** | ($699,000) |  | ($1,370,000) |  |\n| **Gain (loss) on derivative instruments** |  |  |  |  |\n| **NET LOSS INCLUDING NONCONTROLLING INTEREST** | ($501,000) | ($2,530,000) | ($2,022,000) | ($3,471,000) |\n| **Less: Net loss attributable to the noncontrolling interests** | ($44,000) |  | ($57,000) | ($58,000) |\n| **NET LOSS ATTRIBUTABLE TO DIGERATI’S SHAREHOLDERS** | ($457,000) | ($2,530,000) | ($1,965,000) | ($3,413,000) |\n| **NET LOSS ATTRIBUTABLE TO DIGERATI’S COMMON SHAREHOLDERS** |  |  |  |  |\n\n*Note: Empty cells are based on the guidelines provided.*",
        "target": [
            "|   | **Three months ended January 31, ** |   | **Six months ended January 31, ** |   |",
            "|   | **2020 ** | **2019 ** | **2020 ** | **2019 ** |",
            "| --- | --- | --- | --- | --- |",
            "| **Depreciation and amortization expense ** | - | - | 316  | - |",
            "| **OPERATING LOSS ** | (699)  | (496)  | (1,370)  | (909)  |",
            "| **Gain (loss) on derivative instruments ** | - | - | 318  | - |",
            "| **NET LOSS INCLUDING NONCONTROLLING INTEREST ** | (501)  | (2,530)  | (2,022)  | (3,471)  |",
            "| **Less: Net loss attributable to the noncontrolling interests ** | 44  | - | 57  | 58  |",
            "| **NET LOSS ATTRIBUTABLE TO DIGERATI’S SHAREHOLDERS ** | (457)  | (2,499)  | (1,965)  | (3,413)  |",
            "| **NET LOSS ATTRIBUTABLE TO DIGERATI’S COMMON SHAREHOLDERS ** | $ (457)  | $ (2,499)  | $ (1,965)  | $ (3,413)  |"
        ]
    },
    "f10q0120_digeratitech_fileoutpart8": {
        "predict": "|   | **Six months ended January 31, ** |   |<NEWLINE>|   | **2020 ** | **2019 ** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Net loss ** | $2,022,000 | $3,471,000 |<NEWLINE>| **Depreciation and amortization ** | $316,000 |   |<NEWLINE>| **Stock compensation and warrant expense ** | $834,000 |   |<NEWLINE>| **Amortization of debt discount ** | $713,000 |   |<NEWLINE>| **Loss (Gain) on derivative liabilities ** | $318,000 |   |<NEWLINE>| **Accrued expenses ** |   | $301,000 |<NEWLINE>| **Deferred income ** |   | ($69,000) |<NEWLINE>| **Cash paid in acquisition of equipment ** |   | ($34,000) |<NEWLINE>| **Borrowings from convertible debt, net of original issuance cost and discounts ** | $150,000 |   |<NEWLINE>| **Principal payments on convertible notes, net ** | ($36,000) |   |<NEWLINE>| **Principal payments on related party notes, net ** | ($67,000) |   |<NEWLINE>| **CASH AND CASH EQUIVALENTS, end of period ** | $376,000 |   |\n\nNote: Some cells may remain empty based on the guidelines.",
        "target": [
            "|   | **Six months ended January 31, ** |   |",
            "|   | **2020 ** | **2019 ** |",
            "| --- | --- | --- |",
            "| **Net loss ** | $ (2,022)  | $ (3,471)  |",
            "| **Depreciation and amortization ** | 316  | - |",
            "| **Stock compensation and warrant expense ** | 834  | - |",
            "| **Amortization of debt discount ** | 713  | - |",
            "| **Loss (Gain) on derivative liabilities ** | (318)  | - |",
            "| **Accrued expenses ** | 301  | - |",
            "| **Deferred income ** | 69  | - |",
            "| **Cash paid in acquisition of equipment ** | (34)  | - |",
            "| **Borrowings from convertible debt, net of original issuance cost and discounts ** | 150  | 419  |",
            "| **Principal payments on convertible notes, net ** | (36)  | - |",
            "| **Principal payments on related party notes, net ** | (67)  | - |",
            "| **CASH AND CASH EQUIVALENTS, end of period ** | $ 376  | - |"
        ]
    },
    "cb-20210331_fileoutpart3": {
        "predict": "| **(in millions of U.S. dollars)** | **Three Months Ended March 31** |   |<NEWLINE>|   | **2021** | **2020** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Net income** | $2,300 | $252 |<NEWLINE>| **Amortization of purchased intangibles** | $72 | $73 |<NEWLINE>| **Net cash flows from operating activities** | $2,105 | $1,712 |<NEWLINE>| **Common Shares repurchased** | $519 |   |<NEWLINE>| **Repayment of repurchase agreements** |   |   |<NEWLINE>| **Net cash flows used for financing activities** | ($812) | ($645) |",
        "target": [
            "| **(in millions of U.S. dollars) ** | **Three Months Ended March 31 ** |   |",
            "|   | **2021 ** | **2020 ** |",
            "| --- | --- | --- |",
            "| **Net income ** | - | $ 252  |",
            "| **Amortization of purchased intangibles ** | 72  | 73  |",
            "| **Net cash flows from operating activities ** | 2,105  | 1,712  |",
            "| **Common Shares repurchased ** | (519)  | - |",
            "| **Repayment of repurchase agreements ** | (450)  | - |",
            "| **Net cash flows used for financing activities ** | (812)  | (645)  |"
        ]
    },
    "cb-20210331_fileoutpart35": {
        "predict": "|   | **Three Months Ended** |   |   |<NEWLINE>|   |   | **March 31** | **% Change** |<NEWLINE>| **Net premiums written** |   |   | $8.7 billion |<NEWLINE>| --- | --- | --- | --- |<NEWLINE>| **Net premiums written - constant dollars (1)** |   |   | $8.1 billion |<NEWLINE>| **Net premiums earned** |   |   | $8.2 billion |<NEWLINE>| **Net investment income** |   |   | $863 million |<NEWLINE>| **Policy benefits** |   |   |   |<NEWLINE>| **Amortization of purchased intangibles** |   |   |   |<NEWLINE>| **Net income** |   |   | $2.3 billion |\n\nGuidelines:\n- Amortization expense of purchased intangibles was $72 million and $73 million for the three months ended March 31, 2021 and 2020, respectively, and principally relates to the Chubb Corp acquisition.\n- Consolidated net premiums written were $8.7 billion, up 8.6 percent, or 7.0 percent in constant dollars.\n- For the three months ended March 31, 2021 and 2020, Policy benefits were $167 million and $129 million, respectively, which included separate account liabilities (gains) losses of $4 million and $(56) million, respectively.\n- Net income was $2.3 billion compared with $252 million in the prior year period.\n- Consolidated net premiums earned were $8.2 billion, up 5.5 percent, or 4.2 percent in constant dollars.\n- Net investment income was $863 million compared with $861 million in the prior year period.",
        "target": [
            "|   | **Three Months Ended ** |   |   |",
            "|   |   | **March 31 ** | **% Change ** |",
            "| **Net premiums written ** | - | - | 8.6 %  |",
            "| --- | --- | --- | --- |",
            "| **Net premiums written - constant dollars (1) ** |   |   | 7.0 %  |",
            "| **Net premiums earned ** | - | - | 5.5 %  |",
            "| **Net investment income ** | 863  | 861  | - |",
            "| **Policy benefits ** | 167  | 129  | - |",
            "| **Amortization of purchased intangibles ** | 72  | 73  | - |",
            "| **Net income ** | - | $ 252  | - |"
        ]
    },
    "cb-20210331_fileoutpart41": {
        "predict": "|   | **March 31** | **% Change** |\n| --- | --- | --- |\n| **(in millions of U.S. dollars, except for percentages)** | **2020** | **Q-21 vs. Q-20** |\n| **Net premiums written** | $1,141 | ($9) |\n| **Net premiums earned** | $1,276 | ($16) |\n| **CAY loss ratio excluding catastrophe losses** | 60.5% | (1.9) pts |\n| **Loss and loss expense ratio** | 79.5% | +20.4 pts |\n| **Policy acquisition cost ratio** | 20.5% | +0.5 pts |\n| **Administrative expense ratio** | 9.1% | (0.6) pts |\n\nGuidelines:\n\n- Net adverse development of $57 million in excess and umbrella portfolios, with accident years 2015 through 2019 continuing to experience higher than expected loss development, partly offset by favorable development in accident years 2014 and prior.\n- The CAY loss ratio excluding catastrophe losses decreased 1.9 percentage points reflecting a favorable year-over-year loss ratio improvement in automobile, due to lower claim frequency, and in homeowners as earned rate exceeded loss cost trends.\n- The loss and loss expense ratio increased 20.4 percentage points for the three months ended March 31, 2021, primarily due to higher catastrophe losses.\n- Net adverse development of $23 million in wholesale general liability coverages, driven by higher than expected reported loss emergence in accident years 2014 through 2019.\n- The loss and loss expense ratio increased 12.2 percentage points for the three months ended March 31, 2021, primarily due to higher catastrophe losses, partially offset by favorable prior period development.\n- The administrative expense ratio decreased 0.6 percentage points for the three months ended March 31, 2021, primarily due to continued expense management and the shutdown associated with the COVID-19 pandemic, as well as reduced pension obligations reflecting favorable market conditions.\n- Net adverse development of $49 million in excess and umbrella portfolios, with accident years 2015 through 2019 experiencing higher than expected reported development, partially offset by lower than expected emergence in accident years 2014 and prior.\n- Net premiums earned decreased $16 million, or 1.3 percent, for the three months ended March 31, 2021, reflecting the decline in net premiums written described above.\n- The policy acquisition cost ratio increased 0.5 percentage points for the three months ended March 31, 2021, primarily due to the unfavorable impact of reinstatement premiums on net premiums earned.\n- The policy acquisition cost ratio decreased 0.5 percentage points for the three months ended March 31, 2021 primarily due to a change in the mix of business, including less premiums earned from consumer A&H lines that have a higher acquisition cost ratio and higher premiums earned from commercial P&C lines that have a lower acquisition cost ratio.\n- Net premiums written decreased $9 million, or 0.8 percent, for the three months ended March 31, 2021, primarily due to the unfavorable impact of reinstatement premiums of $23 million related to 2021 winter storm losses and automobile return premiums as mandated by certain states due to the slowdown in miles driven as a result of the COVID-19 pandemic.",
        "target": [
            "|   | **March 31 ** | **% Change ** |",
            "| **(in millions of U.S. dollars, except for percentages) ** | **2020 ** | **Q-21 vs. Q-20 ** |",
            "| --- | --- | --- |",
            "| **Net premiums written ** | - | (0.8)%  |",
            "| **Net premiums earned ** | - | (1.3)%  |",
            "| **CAY loss ratio excluding catastrophe losses ** | - | (1.9) pts  |",
            "| **Loss and loss expense ratio ** | - | 12.2 pts  |",
            "| **Policy acquisition cost ratio ** | 20.4 %  | 0.5 pts  |",
            "| **Administrative expense ratio ** | - | (0.6) pts  |"
        ]
    },
    "cb-20210331_fileoutpart22": {
        "predict": "| **(in millions of U.S. dollars)** | **Three Months Ended March 31** |   |   |<NEWLINE>|   | **Long-tail** | **Short-tail** | **Total** |<NEWLINE>| --- | --- | --- | --- |<NEWLINE>| **North America Commercial P&C Insurance** | $192 | $40 | $127 |<NEWLINE>| **North America Personal P&C Insurance** |   |   |   |<NEWLINE>| **Total** |   |   |   |<NEWLINE>| **North America Commercial P&C Insurance** |   |   |   |\n\nGuidelines:\n\nNet favorable development of $81 million in short-tail business, primarily from: \n\n|   |   | **Short-tail** |   |\n| --- | --- | --- | --- |\n|   |   | $81 |   |\n\nNet favorable development of $46 million in long-tail business, primarily from: \n\n|   | **Long-tail** |   |   |\n| --- | --- | --- | --- |\n|   | $46 |   |   |\n\nPre-tax net favorable PPD for the three months ended March 31, 2021 was $192 million, with 19 percent in long-tail lines, principally from accident years 2017 and prior, and 81 percent in short-tail lines, primarily in accident and health, surety, and homeowners lines\n\n|   | **Long-tail** | **Short-tail** |   |\n| --- | --- | --- | --- |\n| Pre-tax net favorable PPD | $37 | $155 | $192 |\n\nFor the three months ended March 31, 2021, net favorable PPD was $40 million, driven by accident year 2020, which experienced better than expected non-catastrophe loss development in homeowners and valuables\n\n|   | **Short-tail** |   |   |\n| --- | --- | --- | --- |\n| Net favorable PPD | $40 |   |   |\n\nFor the three months ended March 31, 2021, net favorable PPD was $127 million, which was the net result of several underlying favorable and adverse movements, and was driven by the following principal changes: \n\n|   | **Long-tail** | **Short-tail** |   |\n| --- | --- | --- | --- |\n| Net favorable PPD | $24 | $103 | $127 |\n\nAt March 31, 2021, we had total assets of $192 billion and shareholders’ equity of $59 billion\n\n|   |   |   |   |\n| --- | --- | --- | --- |\n| Total assets |   |   | $192 |\n| Shareholders' equity |   |   | $59 |\n\nNet favorable development of $62 million in short-tail business, primarily from: \n\n|   |   | **Short-tail** |   |\n| --- | --- | --- | --- |\n|   |   | $62 |   |",
        "target": [
            "| **(in millions of U.S. dollars) ** | **Three Months Ended March 31 ** |   |   |",
            "|   | **Long-tail ** | **Short-tail ** | **Total ** |",
            "| --- | --- | --- | --- |",
            "| **North America Commercial P&C Insurance ** | $ (46)  | $ (81)  | $ (127)  |",
            "| **North America Personal P&C Insurance ** | - | (40)  | (40)  |",
            "| **Total ** | - | - | $ (192)  |",
            "| **North America Commercial P&C Insurance ** | - | $ (62)  | - |"
        ]
    },
    "cb-20210331_fileoutpart38": {
        "predict": "|   | **Three Months Ended March 31 ** |   |<NEWLINE>|   | **2021 ** | **2020 ** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Catastrophe losses ** | $700 million (9.1 percentage points of the combined ratio) | $237 million (3.3 percentage points of the combined ratio) |<NEWLINE>| **Prior period development ** | $192 million (2.6 percentage points of the combined ratio) | $118 million (1.7 percentage points of the combined ratio) |<NEWLINE>| **P&C Combined ratio ** | 91.8 percent | 89.1 percent |",
        "target": [
            "|   | **Three Months Ended March 31 ** |   |",
            "|   | **2021 ** | **2020 ** |",
            "| --- | --- | --- |",
            "| **Catastrophe losses ** | 9.1 %  | 3.3 %  |",
            "| **Prior period development ** | (2.6)%  | (1.7)%  |",
            "| **P&C Combined ratio ** | 91.8 %  | 89.1 %  |"
        ]
    },
    "cb-20210331_fileoutpart55": {
        "predict": "|   | **Three Months Ended March 31 ** |   |\n| --- | --- | --- |\n| **(in millions of U.S. dollars) ** | **2021 ** | **2020 ** |\n| --- | --- | --- |\n| **Gains (losses) from fair value changes in separate account assets (2) ** | $4 million | $(56) million |<NEWLINE>|\n| **Policy Benefits (1)** | $167 million | $129 million |<NEWLINE>|\n\n(1) Policy benefits include separate account liabilities (gains) losses.\n\n(2) Represents gains (losses) from fair value changes in separate account assets.",
        "target": [
            "|   | **Three Months Ended March 31 ** |   |",
            "| **(in millions of U.S. dollars) ** | **2021 ** | **2020 ** |",
            "| --- | --- | --- |",
            "| **Gains (losses) from fair value changes in separate account assets (2) ** | 4  | (56)  |"
        ]
    },
    "cb-20210331_fileoutpart37": {
        "predict": "| **(in millions of U.S. dollars)** | **Three Months Ended March 31** |   |<NEWLINE>|   | **2021** | **2020** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Catastrophe losses** | $700 | $237 |<NEWLINE>| **Favorable prior period development** | $192 | $118 |<NEWLINE> | **Pre-tax net favorable PPD in long-tail lines** | $37 | $33 |<NEWLINE>| **Pre-tax net favorable PPD in short-tail lines** | $155 | $85 |",
        "target": [
            "| **(in millions of U.S. dollars) ** | **Three Months Ended March 31 ** |   |",
            "|   | **2021 ** | **2020 ** |",
            "| --- | --- | --- |",
            "| **Catastrophe losses ** | $ 700  | $ 237  |",
            "| **Favorable prior period development ** | $ 192  | $ 118  |"
        ]
    },
    "f10q0321_accelerateacq_fileoutpart6": {
        "predict": "| --- | --- |\n| **Net income** | **$ 6,719,798** |\n| **Transaction costs incurred in connection with IPO** | $22,590,881 (consisting of $8,000,000 of underwriting fees, $14,000,000 of deferred underwriting fees and $590,881 of other offering costs) |\n| **Investment of cash in Trust Account** | $400,000,000 |\n| **Net cash used in investing activities** | |\n| **Proceeds from sale of Private Placement Warrants** | $11,000,000 (described in Note 5) |\n| **Net Change in Cash** | |\n| **Cash – End of period** | $1,321,004 |\n| **Deferred underwriting fee payable** | $14,000,000 (described in Note 6) |",
        "target": [
            "| --- | --- |",
            "| **Net income ** | **$ 6,719,798 ** |",
            "| **Transaction costs incurred in connection with IPO ** | 801,198  |",
            "| **Investment of cash in Trust Account ** | (400,000,000)  |",
            "| **Net cash used in investing activities ** | (400,000,000)  |",
            "| **Proceeds from sale of Private Placement Warrants ** | 11,000,000  |",
            "| **Net Change in Cash ** | 1,321,004  |",
            "| **Cash – End of period ** | $ 1,321,004  |",
            "| **Deferred underwriting fee payable ** | $ 14,000,000  |"
        ]
    },
    "f10q1222_etfmanagers1_fileoutpart27": {
        "predict": "|   | **THREE MONTHS ENDED DECEMBER 31, 2022 ** | **THREE MONTHS ENDED DECEMBER 31, 2021 ** |\n| --- | --- | --- |\n| **BREAKWAVE DRY BULK SHIPPING ETF ** |   |   |\n| **Net asset value per Share, beginning of period ** | $8.75 per Share | $35.62 per Share |\n| **Net Asset Value per Share, end of period ** | $9.38 per Share | $29.65 per Share |\n| **Market Value per Share, end of period ** | $9.19 per Share | $36.01 per Share |\n| **Expense Ratio*** ** |   |   |\n| **Total Return, at Net Asset Value** ** |   |   |\n| **Total Return, at Market Value** ** |   |   |\n\nGuidelines:\n- During the three months ended December 31, 2022, the NYSE Arca market value of each Share increased (+1.66%) from $9.04 per Share, representing the closing trade on September 30, 2022, to $9.19 per Share, representing the closing price on December 30, 2022.\n- The Share price high and low for the three months ended December 31, 2021 and related change from the closing Share price on September 30, 2022 were as follows: Shares traded from a high of $10.40 per Share (+15.04%) on October 4, 2022 to a low of $6.82 per Share (-24.56%) on November 22, 2021.\n- During the three months ended December 31, 2021, the NYSE Arca market value of each Share decreased (-18.11%) from $36.01 per Share, representing the closing trade on September 30, 2021, to $29.49 per Share, representing the closing price on December 31, 2021.\n- For the three months ended December 31, 2021, the net asset value of each Share decreased (-16.76%) from $35.62 per Share to $29.65 per Share.\n- For the three months ended December 31, 2022, the net asset value of each Share increased (+7.20%) from $8.75 per Share to $9.38 per Share.",
        "target": [
            "|   | **THREE MONTHS ENDED DECEMBER 31, 2022 ** | **THREE MONTHS ENDED DECEMBER 31, 2021 ** |",
            "|   | **BREAKWAVE DRY BULK SHIPPING ETF ** | **BREAKWAVE DRY BULK SHIPPING ETF ** |",
            "| --- | --- | --- |",
            "| **Net asset value per Share, beginning of period ** | $ 8.75  | $ 35.62  |",
            "| **Net Asset Value per Share, end of period ** | $ 9.38  | $ 29.65  |",
            "| **Market Value per Share, end of period ** | $ 9.19  | $ 29.49  |",
            "| **Expense Ratio*** ** | 5.04%  | - |",
            "| **Total Return, at Net Asset Value** ** | 7.20%  | - |",
            "| **Total Return, at Market Value** ** | 1.66%  | (18.11)%  |"
        ]
    },
    "f10q1222_etfmanagers1_fileoutpart28": {
        "predict": "|   | **SIX MONTHS ENDED DECEMBER 31, 2022 ** | **SIX MONTHS ENDED DECEMBER 31, 2021 ** |\n| --- | --- | --- |\n| **BREAKWAVE DRY BULK SHIPPING ETF ** |   |   |\n| **Net asset value per Share, beginning of period ** | $17.06 per Share | $28.88 per Share |\n| **Net Asset Value per Share, end of period ** | $9.38 per Share | $29.65 per Share |\n| **Market Value per Share, end of period ** | $9.19 per Share | $29.49 per Share |\n| **Total Return, at Net Asset Value** ** | -45.02% | +2.67% |\n| **Total Return, at Market Value** ** | -46.48% | +0.48% |",
        "target": [
            "|   | **SIX MONTHS ENDED DECEMBER 31, 2022 ** | **SIX MONTHS ENDED DECEMBER 31, 2021 ** |",
            "|   | **BREAKWAVE DRY BULK SHIPPING ETF ** | **BREAKWAVE DRY BULK SHIPPING ETF ** |",
            "| --- | --- | --- |",
            "| **Net asset value per Share, beginning of period ** | $ 17.06  | $ 28.88  |",
            "| **Net Asset Value per Share, end of period ** | 9.38  | 29.65  |",
            "| **Market Value per Share, end of period ** | $ 9.19  | $ 29.49  |",
            "| **Total Return, at Net Asset Value** ** | (45.02)%  | 2.67%  |",
            "| **Total Return, at Market Value** ** | (46.48)%  | 0.48%  |"
        ]
    },
    "f10q1222_etfmanagers1_fileoutpart8": {
        "predict": "|   | **BREAKWAVE DRY BULK SHIPPING ETF ** | **ETF MANAGERS GROUP COMMODITY TRUST I ** |\n| --- | --- | --- |\n| **Net investment income (loss) ** | $(954,646)  |   |\n| **Net realized gain (loss) ** | $(1,117,138) |   |\n| **Change in net unrealized gain (loss) ** | $(16,869,110) |   |\n| **Net Increase (decrease) in Net Assets from operations ** | $(18,940,894) |   |",
        "target": [
            "|   | **BREAKWAVE DRY BULK SHIPPING ETF ** | **ETF MANAGERS GROUP COMMODITY TRUST I ** |",
            "| --- | --- | --- |",
            "| **Net investment income (loss) ** | (954,646)  | (954,646)  |",
            "| **Net realized gain (loss) ** | (1,117,138)  | (1,117,138)  |",
            "| **Change in net unrealized gain (loss) ** | (16,869,110)  | (16,869,110)  |",
            "| **Net Increase (decrease) in Net Assets from operations ** | (18,940,894)  | (18,940,894)  |"
        ]
    },
    "f10q1222_etfmanagers1_fileoutpart10": {
        "predict": "|   | **BREAKWAVE DRY BULK SHIPPING ETF ** | **ETF MANAGERS GROUP COMMODITY TRUST I ** |\n| --- | --- | --- |\n| **Net investment gain (loss) ** | $-1,749,765 |   |\n| **Net realized loss ** |   | $18,463,560 |\n| **Change in net unrealized gain (loss) ** |   | $-18,595,890 |\n| **Net Increase (Decrease) in Net Assets from operations ** | $-1,882,095 |   |",
        "target": [
            "|   | **BREAKWAVE DRY BULK SHIPPING ETF ** | **ETF MANAGERS GROUP COMMODITY TRUST I ** |",
            "| --- | --- | --- |",
            "| **Net investment gain (loss) ** | (1,749,765)  | (1,749,765)  |",
            "| **Net realized loss ** | 18,463,560  | 18,463,560  |",
            "| **Change in net unrealized gain (loss) ** | (18,595,890)  | (18,595,890)  |",
            "| **Net Increase (Decrease) in Net Assets from operations ** | (1,882,095)  | (1,882,095)  |"
        ]
    },
    "lxrp_10q_fileoutpart23": {
        "predict": "|   | **May 31 2020 $** | **May 31 2019 $** |\n| --- | --- | --- |\n| **Product sales** | **119,709** | **7,284** |\n| **Licensing revenue** | $130,509 (delays in usage fee revenues from existing licensees in Canada waiting for product approval from Health Canada on products, other licensees attempting to ramp up their production and the impact of the COVID-19 pandemic on some of our licensees) | $90,000 |",
        "target": [
            "|   | **May 31 2020 $ ** | **May 31 2019 $ ** |",
            "| --- | --- | --- |",
            "| **Product sales ** | **119,709 ** | **7,284 ** |",
            "| **Licensing revenue ** | 130,509  | 90,000  |"
        ]
    },
    "lxrp_10q_fileoutpart37": {
        "predict": "|   | **May 31 2020** | **May 31 2019** |\n| --- | --- | --- |\n| **Cash Flows** | **$** | **$** |\n| --- | --- | --- |\n| **Cash flows (used in) provided by operating activities** | $1,981,314 | $2,268,946 |\n| **Cash flows (used in) provided by investing activities** | ($13,205) | ($736,079) |\n| **Cash flows (used in) provided by financing activities** | $2,743,383 | $3,273,683 |\n\nGuidelines:\n- Net cash provided from financing activities was $2,743,383 during the period ended May 31, 2020 from two private placements and option exercise compared to net cash provided of $3,273,683 ($2,273,683 from private placements and exercises and $1,000,000 from the 16.67% acquisition of Lexaria Nicotine by Altria) during the same period in 2019.\n- Net cash used in investing activities was $13,205 (2019 $736,079) for the period to support patent filings.\n- Net cash used in operating activities was $1,981,314 for the period compared with cash used in operating activities of $2,268,946 during the same period in 2019.",
        "target": [
            "|   | **May 31 2020 ** | **May 31 2019 ** |",
            "| **Cash Flows ** | **$ ** | **$ ** |",
            "| --- | --- | --- |",
            "| **Cash flows (used in) provided by operating activities ** | (1,981,314)  | (2,268,946)  |",
            "| **Cash flows (used in) provided by investing activities ** | (13,205)  | (736,079)  |",
            "| **Cash flows (used in) provided by financing activities ** | 2,743,383  | 3,273,683  |"
        ]
    },
    "form10q_03312019_fileoutpart2": {
        "predict": "|   | **Three Months Ended March 31, ** |   |\n| --- | --- | --- |\n| **Revenues ** | $4,076 | $56,590 |\n| **Cost of revenues ** | $2,718 | $43,339 |\n| **Research and development expenses ** | $2,386 | - |\n| **Operating loss ** | $390,504 | $186,058 |\n| **Interest expense ** | $885 | $1,380 |\n| **Net loss ** | $391,389 | $192,430 |\n| **Net loss attributable to common shareholders ** | $391,389 | $192,430 |\n| **Basic and diluted net loss per average share available to common shareholders ** | - | - |\n\nGuidelines:\nABI reported revenue for the quarter ended March 31, 2019, of $4,076 from sales of the newly developed and marketed liposomal nutraceuticals.\n\nDuring the three months ended March 31, 2019, interest expense was $885, compared to $1,380 for the three months ended March 31, 2018.\n\nRevenue for the same period in 2018 was $56,590 also from the sales of the nutraceutical program.\n\nThe Company's operating loss was $390,504 which was $204,446 (110%) higher for 2019 than 2018 mostly due to the SG&A expense increase constituted by salary increases (Dr. [empty cell]).\n\nNet loss attributable to common shareholders was $391,389 which was $198,959 (103%) more during 2019 than 2018.\n\nThe R&D activity in 2019 was $2,386 as compared to 2018 when there were no direct R&D expenses.\n\nThe cost of sales for the first quarter of 2019 was $2,718 as compared to $43,339 for cost of sales in 2018.\n\n39,664,199 shares of common stock, par value $0.01 per share, outstanding as of May 17, 2019.",
        "target": [
            "|   | **Three Months Ended March 31, ** |   |",
            "|   | **2019 ** | **2018 ** |",
            "| --- | --- | --- |",
            "| **Revenues ** | $ 4,076  | $ 56,590  |",
            "| **Cost of revenues ** | (2,718)  | (43,339)  |",
            "| **Research and development expenses ** | 2,386  | - |",
            "| **Operating loss ** | (390,504)  | - |",
            "| **Interest expense ** | (885)  | (1,380)  |",
            "| **Net loss ** | (391,389)  | - |",
            "| **Net loss attributable to common shareholders ** | $ (391,389)  | - |",
            "| **Basic and diluted net loss per average share available to common shareholders ** | $ (0.01)  | $ (0.01)  |"
        ]
    },
    "acbm_10q_fileoutpart6": {
        "predict": "|   | **Six Months ended June 30, ** |   |<NEWLINE>| --- | --- | --- |<NEWLINE>|   | **2021 ** | **2020 ** |<NEWLINE>| **Net income (loss) ** | $(854,181) | $17,417 |<NEWLINE>| **Imputed interest - related parties ** | $3,870 | $1,369 |<NEWLINE>| **Stock based compensation ** | $804,650 |   |<NEWLINE>| **Inventories ** | $448,000 |   |<NEWLINE>| **Purchase deposit for inventory ** | $12,000 |   |<NEWLINE>| **Accounts payable and accrued expenses ** | $12,662 | $22,762 |<NEWLINE>| **Deferred revenue ** |   | $17,464 |<NEWLINE>| **Net cash provided by (used in) operating activities ** | $424,390 | $(97,845) |<NEWLINE>| **Advances from related parties ** |   | $97,315 |<NEWLINE>| **Repayment to related parties ** | $(241,851) | $0 |<NEWLINE>| **Net cash (used in) provided by ﬁnancing activities ** | $(227,019) |   |<NEWLINE>| **Cash at end of period ** | $215,494 |   |\n\nGuidelines applied to the table:\n\n- The Company has imputed interest at the rate of 4% on the advances made to the Company in the amount of $3,870 and $1,369 during the six months ended June 30, 2021 and 2020, respectively\n- At June 30, 2021 and December 31, 2020, the Company owed $14,832 and $241,851 to a stockholder who is not a 5% stockholder for non-interest-bearing advances made to or paid expenses on behalf of the Company, respectively\n- For the six months ended June 30, 2020 we had revenues of $687,964, all of which was generated during the first quarter, cost of revenue of $528,560, a gross profit of $159,404, selling, general and administrative expenses of $140,618, related primarily to expenses and professional fees relating to our status as a public company, interest expense to a related party of $1,369, and net income of $17,417, or $0.00 per share (basic and diluted)\n- Cash provided by financing activities for the six months ended June 30, 2020 represented advances from related parties of $97,315\n- Cash used in financing activities of $227,019 for the six months ended June 30, 2021 primarily reflected payments to related parties of $241,851\n- At June 30, 2021, we had $215,494 of cash, $448,000 of inventory of cordyceps products and a $12,000 purchase deposit for cordyceps products inventory\n- As a result, we had a net loss of $854,181 or $(0.02) per share (basic and diluted)\n- Cash provided by operating activities of 424,390 for the six months ended June 30, 2021 reflected primarily our net loss of $854,181, increased primarily by stock-based compensation of $804,650, increased by Fa decrease in inventory of $490,000 and a decrease in accounts payable and accrued expenses of $12,662\n- During the six months ended June 30, 2021, we recorded stock-based compensation of $804,650 and had deferred stock compensation of $18,506,950 as of June 30, 2021\n- During the six months ended June 30, 2021 and 2020, a",
        "target": [
            "|   | **Six Months ended June 30, ** |   |",
            "| --- | --- | --- |",
            "|   | **2021 ** | **2020 ** |",
            "| **Net income (loss) ** | $ (854,181)  | $ 17,417  |",
            "| **Imputed interest - related parties ** | 3,870  | 1,369  |",
            "| **Stock based compensation ** | 804,650  | - |",
            "| **Inventories ** | 490,000  | (59,440)  |",
            "| **Purchase deposit for inventory ** | - | (12,000)  |",
            "| **Accounts payable and accrued expenses ** | (12,662)  | (22,762)  |",
            "| **Deferred revenue ** | - | (17,464)  |",
            "| **Net cash provided by (used in) operating activities ** | 424,390  | (97,845)  |",
            "| **Advances from related parties ** | 14,832  | 97,315  |",
            "| **Repayment to related parties ** | (241,851)  | - |",
            "| **Net cash (used in) provided by ﬁnancing activities ** | (227,019)  | 97,315  |",
            "| **Cash at end of period ** | $ 215,494  | - |"
        ]
    },
    "acbm_10q_fileoutpart3": {
        "predict": "|   | **Three Months Ended June 30, ** |   | **Six Months ended June 30, ** |   |\n| --- | --- | --- | --- | --- |\n|   | **2021** | **2020** | **2021** | **2020** |<NEWLINE>\n| **Revenues** | $500,000 | $0 | $599,500 | $687,964 |<NEWLINE>\n| **Cost of revenues** | $420,000 | $0 | $490,000 | $528,560 |<NEWLINE>\n| **Gross profit** | $80,000 | $0 | $109,500 | $159,404 |<NEWLINE>\n| **Selling, general and administrative** | $162,925 | $62,771 | $155,161 | $140,618 |<NEWLINE>\n| **Research and development** | $641,725 | $0 | $641,725 | $0 |<NEWLINE>\n| **Total operating expenses** | $873,320 | $62,771 | $959,811 | $140,618 |<NEWLINE>\n| **Income (loss) from operations** | $(793,320)| $(62,771) | $(850,311) | $18,786 |<NEWLINE>\n| **Interest expense - related party** | $1,367 | $928 | $3,870 | $1,369 |<NEWLINE>\n| **Total other expenses** |   |   |   |   |<NEWLINE>\n| **Income (loss) before income tax credit** | $(794,687) | $(63,699) | $(854,181) | $17,417 |<NEWLINE>\n| **Net income (loss)** | $(794,687) | $(63,699) | $(854,181) | $17,417 |<NEWLINE>\n| **Basic and diluted income (loss) per share of common stock** | $(0.02) | $(0.00) | $(0.02) | $0.00 |<NEWLINE>\n\nNote:\n- For the three months ended June 30, 2020, there were no revenues, resulting in a net loss of $63,699.\n- For the six months ended June 30, 2021, there was a net loss of $854,181, primarily due to net loss of $793,320 and interest expenses of $3,870 and $1,367.\n- For the six months ended June 30, 2020, there were revenues of $687,964, resulting in a net income of $17,417.",
        "target": [
            "|   | **Three Months Ended June 30, ** |   | **Six Months ended June 30, ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2021 ** | **2020 ** | **2021 ** | **2020 ** |",
            "| **Revenues ** | $ 500,000  | - | $ 599,500  | $ 687,964  |",
            "| **Cost of revenues ** | 420,000  | - | 490,000  | 528,560  |",
            "| **Gross proﬁt ** | 80,000  | - | 109,500  | 159,404  |",
            "| **Selling, general and administrative ** | - | 62,771  | - | 140,618  |",
            "| **Research and development ** | 641,725  | - | 641,725  | - |",
            "| **Total operating expenses ** | 873,320  | 62,771  | 959,811  | 140,618  |",
            "| **Income (loss) from operations ** | - | (62,771)  | - | - |",
            "| **Interest expense - related party ** | 1,367  | 928  | 3,870  | 1,369  |",
            "| **Total other expenses ** | 1,367  | 928  | 3,870  | 1,369  |",
            "| **Income (loss) before income tax credit ** | (794,687)  | (63,699)  | (854,181)  | 17,417  |",
            "| **Net income (loss) ** | $ (794,687)  | $ (63,699)  | $ (854,181)  | $ 17,417  |",
            "| **Basic and diluted income (loss) per share of common stock ** | $ (0.02)  | $ (0.00)  | $ (0.02)  | $ 0.00  |"
        ]
    },
    "acbm_10q_fileoutpart11": {
        "predict": "|   | **Six months Ended June 30, ** |   |\n| --- | --- | --- |\n|   | **2021** | **2020** |\n| **Cash provided by (used in) operating activities** | $424,390 | ($97,845) |\n| **Cash used in (provided by) ﬁnancing activities** | ($227,019) | $97,315 |\n| **Cash at end of period** | $215,494 |   |\n\nGuidelines:\n- Cash provided by financing activities for the six months ended June 30, 2020 represented advances from related parties of $97,315\n- Cash used in financing activities of $227,019 for the six months ended June 30, 2021 primarily reflected payments to related parties of $241,851\n- At June 30, 2021, we had $215,494 of cash, $448,000 of inventory of cordyceps products and a $12,000 purchase deposit for cordyceps products inventory\n- Cash provided by operating activities of 424,390 for the six months ended June 30, 2021 reflected primarily our net loss of $854,181, increased primarily by stock-based compensation of $804,650, increased by a decrease in inventory of $490,000 and a decrease in accounts payable and accrued expenses of $12,662\n- During the six months ended June 30, 2021 and 2020, a stockholder paid expenses of $14,832 and $97,315 on behalf of the Company and the Company repaid $241,851 and $0 to a stockholder, respectively\n- Cash used in operating activities of $97,845 for the six months ended June 30, 2020 reflected primarily our net income of $17,417 decreased by an increase in inventory of $59,440, a decrease in accounts payable and accrued expenses of $22,762, and a decrease in deferred revenue of $17,464",
        "target": [
            "|   | **Six months Ended June 30, ** |   |",
            "| --- | --- | --- |",
            "|   | **2021 ** | **2020 ** |",
            "| **Cash provided by (used in) operating activities ** | $ 424,390  | $ (97,845)  |",
            "| **Cash used in (provided by) ﬁnancing activities ** | (227,019)  | 97,315  |",
            "| **Cash at end of period ** | 215,494  | - |"
        ]
    },
    "irt-20220630_fileoutpart12": {
        "predict": "| **Investments in Unconsolidated Real Estate** | **Location** | **Units(1) (Unaudited)** | **June 30, 2022** | **December 31, 2021** |\n| --- | --- | --- | --- | --- |\n| **Views of Music City / The Jackson** | Nashville, TN | 1,492 | $28,302 | $24,999 |\n| **Virtuoso** |   |   |   |   |\n| **Lakeline Station** | Austin, TX | 378 | $7,876 |   |\n| **Total** |   | 1,870 | $36,178 | $24,999 |\n\nGuidelines:\n- As of June 30, 2022, we owned interests in four unconsolidated joint ventures that are developing multifamily apartment communities that will contain, in aggregate, 1,588 units upon completion\n- On April 6, 2022, we purchased, for $25.4 million, the Views of Music City (Phase 1), a 96-unit community in Nashville, TN, from one of our unconsolidated joint ventures (discussed below)\n- On March 31, 2022, we formed a joint venture to acquire and own a project comprised of 400 single family home rental units in Huntsville, AL\n- On June 3, 2022, we entered into a joint venture for the development of Lakeline Station, a 378-unit community to be built in Austin, TX\n- On April 6, 2022, we acquired Views of Music City (phase I), a 96-unit property (unaudited) located in Nashville, TN for $25,440\n- In September 2021, we formed a joint venture to acquire and own the Views of Music City (comprised of Phase 1 and Phase 2) and The Jackson, each a multifamily community in Nashville, TN\n- As of June 30, 2022 and December 31, 2021, the carrying value of our investments in joint ventures totaled $54,178 and $24,999, respectively, and were recorded as a separate line item on the face of our consolidated balance sheet.",
        "target": [
            "| **Investments in Unconsolidated Real Estate ** | **Location ** | **Units(1) (Unaudited) ** | **June 30, 2022 ** | **December 31, 2021 ** |",
            "| --- | --- | --- | --- | --- |",
            "| **Views of Music City / The Jackson ** | Nashville, TN  | - | - | - |",
            "| **Virtuoso ** | Huntsville, AL  | 400  | - | —  |",
            "| **Lakeline Station ** | Austin, TX  | 378  | - | —  |",
            "| **Total ** |   | 1,588  | $ 54,178  | $ 24,999  |"
        ]
    },
    "f10qoct21_privacy_fileoutpart2": {
        "predict": "| **Affiliate revenue** | $139 |<NEWLINE>| --- | --- |<NEWLINE>| **Total Income** |  |<NEWLINE>| **General and administrative** | $57,565 |<NEWLINE>| **Net Loss:** | $(57,426) |<NEWLINE>| **Net loss per share – basic and diluted** |  |<NEWLINE>| **Weighted average shares outstanding – basic and diluted** | 201,115,000 |",
        "target": [
            "| **Affiliate revenue ** | $ 139  |",
            "| --- | --- |",
            "| **Total Income ** | 139  |",
            "| **General and administrative ** | 57,565  |",
            "| **Net Loss: ** | (57,426)  |",
            "| **Net loss per share – basic and diluted ** | (0)  |",
            "| **Weighted average shares outstanding – basic and diluted ** | 201,115,000  |"
        ]
    },
    "f10qoct21_privacy_fileoutpart4": {
        "predict": "|   | **$** |<NEWLINE>| --- | --- |<NEWLINE>| **Net loss for the period** | $(57,426) |<NEWLINE>| **Net cash used in operating activities** | $(159,720) |<NEWLINE>| **Software** |   |<NEWLINE>| **Net cash used in investing activities** | $(160,000) |<NEWLINE>| **Common stock** |   |<NEWLINE>| **Net cash used in financing activities** | $22,300 |<NEWLINE>| **Cash – beginning of period** |   |<NEWLINE>| **Cash – end of period** | $29,607 |\n\nGuidelines:\n- The Company has incurred a net loss for the period of $(57,426) and resulting in an accumulated deficit of $(71,774) as of October 31, 2021\n- Net cash flows generated from financing activities were $22,300 in the three-month period ended October 31, 2021 relating to our sale of 1,115,000 shares of common stock at a price of $0.02 pursuant to our registration statement on Form S-1, as amended\n- During the period ended October 31, 2021, the Company issued 1,115,000 shares of common stock for total cash proceeds of $22,300\n- For the period ended October 31, 2021, our cash flows used in investing activities were $160,000 which consisted of the purchase costs of fixed assets and software related to the development and sale of the Privacy and Value computer monitoring software\n- For the three-month period ended October 31, 2021, net cash flows used in operating activities were $159,720 consisting of a net loss of $57,426, which was offset by non-cash components of accounts payable and accrued liabilities, as well as prepayments and deposits\n- The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the FDIC. As of October 31, 2021, the Company had $29,607 in cash.",
        "target": [
            "|   | **$ ** |",
            "| --- | --- |",
            "| **Net loss for the period ** | (57,426)  |",
            "| **Net cash used in operating activities ** | 159,720  |",
            "| **Software ** | (160,000)  |",
            "| **Net cash used in investing activities ** | (160,000)  |",
            "| **Common stock ** | 22,300  |",
            "| **Net cash used in investing activities ** | 22,300  |",
            "| **Cash – beginning of period ** | 7,587  |",
            "| **Cash – end of period ** | 29,607  |"
        ]
    },
    "shengshielevator3_10q_fileoutpart5": {
        "predict": "|   | **Common Stock** |   | **Accumulated Deﬁcit** | **Total** |\n| --- | --- | --- | --- | --- |\n|   | **Shares** | **Amount** |   |   |\n| **Balance, January 1, 2021** |   |   |   |   |\n| **Net loss** |   |   |   |   |\n| **Balance, March 31, 2021** | 603,970,000 |   | ($8,989,269) | ($8,989,269) |\n|   |   |   |   |   |\n|   |   |   |   |   |\n|   |   |   |   |   |\n|   |   |   |   |   |\n|   |   |   |   |   |\n|   |   |   |   |   |\n|   |   |   |   |   |\n|   |   |   |   |   |\n|   |   |   |   |   |\n| **Shares Outstanding as of August 18, 2021** | 603,970,000 |   |   |   |",
        "target": [
            "|   | **Common Stock ** |   | **Accumulated Deﬁcit ** | **Total** |",
            "| --- | --- | --- | --- | --- |",
            "|   | **Shares ** | **Amount ** |   |   |",
            "| **Balance, January 1, 2021 ** | 603,970,000  | $ 603,970  | - | - |",
            "| **Net loss ** | - | - | (2,000)  | (2,000)  |",
            "| **Balance, March 31, 2021 ** | 603,970,000  | $ 603,970  | $ (8,989,269)  | - |"
        ]
    },
    "form10-qa_fileoutpart3": {
        "predict": "|   | **For the Three Months Ended April 30, ** |   | **For the Nine Months Ended April 30, ** |   |\n| --- | --- | --- | --- | --- |\n|   | **2023** | **2022** | **2023** | **2022** |\n| **Commission income** | $769,150 | $693,591 | $2,478,230 | $1,478,189 |\n| **Commission expense** | $213,305 | $230,235 | $736,628 | $636,692 |\n| **Commission expense – related party** | $200,000 | $213,395 | $670,900 | $268,825 |\n| **Gross margin** | $355,845 | $249,431 | $1,070,702 | $572,672 |\n| **Stock based compensation** |   |   |   |   |\n| **Professional fees** | $80,750 | $11,455 | $88,114 | $51,463 |\n| **Payroll expense** | $63,009 | $65,507 | $179,487 | $181,005 |\n| **General and administrative** | $144,083 | $125,456 | $327,522 | $404,263 |\n| **(Loss) income from operations** |   |   |   |   |\n| **Interest expense** | $5,217 | $0 | $5,217 | $0 |\n| **Impairment expense** |   |   |   | $33,333 |\n| **Gain of forgiveness of debt** |   |   |   | $82,335 |\n| **Total other (expense) income** |   |   |   |   |\n| **Net (loss) income before income tax** |   |   |   |   |\n| **Net (Loss) Income** | ($1,519,286) | $47,013 | ($1,111,710) | $15,057 |\n\nGuidelines:\n- We incurred interest expense of $5,217 for the three months ended April 30, 2023, compared to $0 for the three months ended April 30, 2022\n- Shah earned commissions of $213,925 and $268,825, respectively\n- For the nine months ended April 30, 2023, we had a net loss of $1,111,710 ($1,582,072 of which was non-cash expense) and used $140,538 of cash in operations\n- Our commission expense – related party, for the nine months ended April 30, 2023 and 2022, was $670,900 and $268,825, respectively, an increase of $402,075 or 149.6%\n- General and administrative expense for the nine months ended April 30, 2023 and 2022, was $327,522 and $404,263, respectively, a decrease of $76,741 or 19.0%\n- Professional fees for the nine months ended April 30, 2023 and 2022, were $88,114 and $51,463, respectively, an increase of $36,651 or 71.2%\n- Our cash flows used in operating activities is primarily a result of (i) our net loss of $1,111,710, adjusted for non-cash activity of $1,428,413 and (ii) an increase in accounts receivables and related party receivables of $457,617\n- The decrease from net income to net loss is the result of $1,582,072 of non-cash expense incurred for the issuance of warrants\n- Payroll expense for the three months ended April 30, 2023 and 2022, was $63",
        "target": [
            "|   | **For the Three Months Ended April 30, ** |   | **For the Nine Months Ended April 30, ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2023 ** | **2022 ** | **2023 ** | **2022 ** |",
            "| **Commission income ** | $ 769,150  | $ 693,591  | $ 2,478,230  | $ 1,478,189  |",
            "| **Commission expense ** | 213,305  | 230,235  | 736,628  | 636,692  |",
            "| **Commission expense – related party ** | 200,000  | 213,925  | 670,900  | 268,825  |",
            "| **Gross margin ** | 355,845  | 249,431  | 1,070,702  | 572,672  |",
            "| **Stock based compensation ** | 1,582,072  | - | 1,582,072  | - |",
            "| **Professional fees ** | 80,750  | 11,455  | 88,114  | 51,463  |",
            "| **Payroll expense ** | 63,009  | 65,507  | 179,487  | 181,005  |",
            "| **General and administrative ** | 144,083  | 125,456  | 327,522  | 404,263  |",
            "| **(Loss) income from operations ** | - | 47,013  | - | - |",
            "| **Interest expense ** | (5,217)  | - | (5,217)  | - |",
            "| **Impairment expense ** | - | - | - | (33,333)  |",
            "| **Gain of forgiveness of debt ** | - | - | - | 82,335  |",
            "| **Total other (expense) income ** | (5,217)  | - | (5,217)  | - |",
            "| **Net (loss) income before income tax ** | (1,519,286)  | 47,013  | (1,111,710)  | (15,057)  |",
            "| **Net (Loss) Income ** | $ (1,519,286)  | $ 47,013  | $ (1,111,710)  | $ (15,057)  |"
        ]
    },
    "form10-qa_fileoutpart5": {
        "predict": "|   | **For the Nine Months Ended April 30, ** |   |<NEWLINE>| --- | --- | --- |<NEWLINE>|   | **2023 ** | **2022 ** |<NEWLINE>| **Net loss ** | $1,111,710 | $15,057 |<NEWLINE>| **Impairment expense ** |   | $33,333 |<NEWLINE>| **Gain of forgiveness of debt ** |   | $82,335 |<NEWLINE>| **Stock based compensation ** |   |   |<NEWLINE>| **Depreciation expense ** | $32,379 | $25,903 |<NEWLINE>| **Net cash (used) provided by operating activities ** | ($140,538) | $29,279 |<NEWLINE>| **Purchase of property and equipment ** |   | $53,918 |<NEWLINE>| **Net cash used by investing activities ** |   | ($53,918) |<NEWLINE>| **Loan payable – related party ** | $48,060 |   |<NEWLINE>| **Contributions to capital by controlling shareholder ** | $27,639 |   |<NEWLINE>| **Net cash provided by financing activities ** |   |   |\n\nGuidelines:\n- Depreciation expense for the nine months ended April 30, 2023, and 2022, was $32,379 and $25,903, respectively\n- During the nine months ended April 30, 2023, we received $48,060 of cash from related party loans compared to $27,639 of contributed capital for the nine months ended April 30, 2022\n- During the nine months ended April 30, 2023, Reddington Partners LLC, a majority shareholder, advanced the Company $48,060 to pay for general operating expenses\n- The increase is the result of the $1,582,072 of non-cash expense incurred for the issuance of warrants\n- For the nine months ended April 30, 2023, we had a net loss of $1,111,710 ($1,582,072 of which was non-cash expense) and used $140,538 of cash in operations\n- Using the Black-Scholes option pricing model, the fair value for the warrants was calculated to be $1,582,072\n- During the nine months ended April 30, 2023, we used $140,538 of cash in operating activities\n- For the three months ended April 30, 2023, we recognized $1,582,072 for the fair value of warrants issued\n- We recognized $1,582,072 for the fair value of warrants issued\n- In the prior period operating activities provided $29,279 of cash\n- We had a net loss of $1,111,710 for nine months ended April 30, 2023, compared to $15,057 for the nine months ended April 30, 2022\n- For the nine months ended April 30, 2022, we also recognized impairment expense of $33,333 and a gain of forgiveness of debt of $82,335\n- We used no cash in investing activities for nine months ended April 30, 2023, compared to $53,918 used in the prior period to purchase property and equipment\n- Our cash flows used in operating activities is primarily a result of (i) our net loss of $1,111,710, adjusted for non-cash activity of $1,428,413 and (ii) an increase in accounts receivables and related party receivables of $457,617\n- The decrease from net income to net loss is the result of $1,582,072 of non-cash expense incurred for the issuance of warrants",
        "target": [
            "|   | **For the Nine Months Ended April 30, ** |   |",
            "| --- | --- | --- |",
            "|   | **2023 ** | **2022 ** |",
            "| **Net loss ** | $ (1,111,710)  | $ (15,057)  |",
            "| **Impairment expense ** | - | 33,333  |",
            "| **Gain of forgiveness of debt ** | - | (82,335)  |",
            "| **Stock based compensation ** | 1,582,072  | - |",
            "| **Depreciation expense ** | 32,379  | 25,903  |",
            "| **Net cash (used) provided by operating activities ** | (140,538)  | 29,279  |",
            "| **Purchase of property and equipment ** | - | (53,918)  |",
            "| **Net cash used by investing activities ** | - | (53,918)  |",
            "| **Loan payable – related party ** | 48,060  | - |",
            "| **Contributions to capital by controlling shareholder ** | - | 27,639  |",
            "| **Net cash provided by financing activities ** | 48,060  | 27,639  |"
        ]
    },
    "form10-qa_fileoutpart9": {
        "predict": "|   | **Number of Warrants** | **Weighted Average Exercise Price** |\n| --- | --- | --- |\n| **Issued** | 5,000,000 | $0.50 |\n| **Outstanding, April 30, 2023** |   |   |\n\nGuidelines: As the Company’s common stock is not trading and there have been no current sales of common stock for cash management used the price of warrants recently issued ($0.50) for valuing the shares issued for services\n\nNote: Some cells may remain empty based on the guidelines.",
        "target": [
            "|   | **Number of Warrants ** | **Weighted Average Exercise Price ** |",
            "| --- | --- | --- |",
            "| **Issued ** | 5,000,000  | $ 0.50  |",
            "| **Outstanding, April 30, 2023 ** | 5,000,000  | $ 0.50  |"
        ]
    },
    "form10-qa_fileoutpart6": {
        "predict": "|   | **Nine months Ended September 30, 2021 ** | **For the Period from August 21, 2020 (Inception) Through September 30, 2020 ** |\n| --- | --- | --- |\n| **Net loss ** | $1,601,809 | $1,000 |\n| **Interest earned on investments held in Trust Account ** | $5,627 |   |\n| **Net cash used in operating activities ** | $893,655 |   |\n| **Cash – End of period ** | $8,413 | $8,413 |\n\nGuidelines:\n- For the nine months ended September 30, 2021, cash used in operating activities was $893,655\n- Net loss of $1,601,809 was impacted by interest earned on marketable securities held in the Trust Account of $5,627\n- As of September 30, 2021, the Company had cash of $8,413 held outside of the Trust Account, $116,155,627 held in the Trust Account to be used for a Business Combination, and adjusted working capital deficit of $1,037,663, which excludes $150,000 of franchise taxes payable\n- For the nine months ended September 30, 2021, we had a net loss of $1,601,809, which consisted of general and administrative expenses of $1,607,436 offset by interest earned on marketable securities held in the Trust Account of $5,627\n- For the period from August 21, 2020 (inception) through September 30, 2020, we had a net loss of $1,000, which consisted of formation and operating costs\n- As of September 30, 2021, we had cash of $8,413",
        "target": [
            "|   | **Nine months Ended September 30, 2021 ** | **For the Period from August 21, 2020 (Inception) Through September 30, 2020 ** |",
            "| --- | --- | --- |",
            "| **Net loss ** | $ (1,601,809)  | $ (1,000)  |",
            "| **Interest earned on investments held in Trust Account ** | (5,627)  | - |",
            "| **Net cash used in operating activities ** | (893,655)  | - |",
            "| **Cash – End of period ** | $ 8,413  | - |"
        ]
    },
    "kss-20221029_fileoutpart23": {
        "predict": "|   | **Change** | **Change** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **SG&A** |   |   |<NEWLINE>| **As a percent of total revenue** |   |   |\n| --- | --- | --- |<NEWLINE>| Year to date 2022 | $119 million | 3.1% |<NEWLINE>|  |  |  |\n| --- | --- | --- |<NEWLINE>| 2021 to 2022 |  |  |<NEWLINE>| -306 basis points |  |  |\n| --- | --- | --- |<NEWLINE>| 2021 to 2022 |  |  |<NEWLINE>| -120 basis points |  |  |\n| --- | --- | --- |<NEWLINE>| Last year |  |  |<NEWLINE>| -120 basis points | 3.3% |  |\n| Q3 2022 | $46 million | 3.3% |<NEWLINE>|  |  |<NEWLINE>|  |  |  |",
        "target": [
            "|   | **Change ** | **Change ** |",
            "| --- | --- | --- |",
            "| **SG&A ** | $(46)  | $119  |",
            "| **As a percent of total revenue ** | 120 bps  | 306 bps  |"
        ]
    },
    "kss-20221029_fileoutpart26": {
        "predict": "| **(Dollars in Millions)** | **Three Months Ended** |   | **Nine Months Ended** |   |\n| --- | --- | --- | --- | --- |\n|   | **October 29, 2022** | **October 30, 2021** | **October 29, 2022** | **October 30, 2021** |\n| **Effective tax rate** | 18.3% | 24.3% | 21.1% | 23.4% |",
        "target": [
            "| **(Dollars in Millions) ** | **Three Months Ended ** |   | **Nine Months Ended ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **October 29, 2022 ** | **October 30, 2021 ** | **October 29, 2022 ** | **October 30, 2021 ** |",
            "| **Effective tax rate ** | 18.3%  | 24.3%  | 21.1%  | 23.4%  |"
        ]
    },
    "kss-20221029_fileoutpart29": {
        "predict": "|   | **Nine Months Ended ** |   |\n| --- | --- | --- |\n| **(Dollars in Millions) ** | **October 29, 2022 ** | **October 30, 2021 ** |\n| **Operating activities ** | $(425) | $1,800 |\n| **Investing activities ** | $(702) | $(391) |\n| **Financing activities ** | $(266) | $(1,800) |",
        "target": [
            "|   | **Nine Months Ended ** |   |",
            "| --- | --- | --- |",
            "| **(Dollars in Millions) ** | **October 29, 2022 ** | **October 30, 2021 ** |",
            "| **Operating activities ** | $(425)  | - |",
            "| **Investing activities ** | (702)  | (391)  |",
            "| **Financing activities ** | (266)  | - |"
        ]
    },
    "kss-20221029_fileoutpart4": {
        "predict": "|   | **Nine Months Ended ** |   |\n| --- | --- | --- |\n| **(Dollars in Millions) ** | **October 29, 2022 ** | **October 30, 2021 ** |\n| **Loss on extinguishment of debt ** |   | $201 million |\n| **Net cash (used in) provided by operating activities ** | ($425) million | $1.8 billion |\n| **Net cash used in investing activities ** | ($702) million | ($391) million |\n| **Net borrowings under revolving credit facility ** | $668 million |   |\n| **Treasury stock purchases ** | $658 million | $807 million |\n| **Dividends paid ** | $184 million ($1.50 per share) | $114 million ($0.75 per share) |\n| **Premium paid on redemption of debt ** |   | $192 million |\n| **Net cash used in financing activities ** | ($266) million | ($1.8) billion |\n| **Cash and cash equivalents at end of period ** | $194 million | $1.9 billion |",
        "target": [
            "|   | **Nine Months Ended ** |   |",
            "| --- | --- | --- |",
            "| **(Dollars in Millions) ** | **October 29, 2022 ** | **October 30, 2021 ** |",
            "| **Loss on extinguishment of debt ** | - | 201  |",
            "| **Net cash (used in) provided by operating activities ** | (425)  | - |",
            "| **Net cash used in investing activities ** | (702)  | (391)  |",
            "| **Net borrowings under revolving credit facility ** | 668  | - |",
            "| **Treasury stock purchases ** | (658)  | (807)  |",
            "| **Dividends paid ** | (184)  | (114)  |",
            "| **Premium paid on redemption of debt ** | - | (192)  |",
            "| **Net cash used in financing activities ** | (266)  | - |",
            "| **Cash and cash equivalents at end of period ** | $194  | - |"
        ]
    },
    "kss-20221029_fileoutpart22": {
        "predict": "| **(Dollars in Millions)** | **Three Months Ended October 29, 2022** | **Change** | **Nine Months Ended October 29, 2022** | **Change** |\n| --- | --- | --- | --- | --- |\n| **Gross margin as a percent of net sales** | 37.3% | -263 basis points | 38.4% | -215 basis points |",
        "target": [
            "| **(Dollars in Millions) ** | **Three Months Ended ** |   | **Nine Months Ended ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **October 29, 2022 ** | **Change ** | **October 29, 2022 ** | **Change ** |",
            "| **Gross margin as a percent of net sales ** | 37.3%  | (263) bps  | 38.4%  | (215) bps  |"
        ]
    },
    "msgentertainmentcorp10_fileoutpart50": {
        "predict": "|   | **Three Months Ended March 31, ** |   | **Change ** |\n| --- | --- | --- | --- |\n|   | **2020 ** | **2019 ** | **Amount ** |\n| **Operating loss ** | $145,541 | $18,619 | $126,922 |\n| **Share-based compensation ** | $8,836 | $8,726 | $110 |\n| **Depreciation and amortization (a) ** | $26,196 | $26,768 | ($572) |\n| **Impairment of intangibles, long-lived assets and goodwill (b) ** | $102,211 |   |   |\n| **Adjusted operating income (loss) ** | ($7,230) | $17,944 | ($25,174) |\n\nGuidelines:\n- Operating loss for the three months ended March 31, 2020 increased $126,922 to $145,541 as compared to the prior year period\n- Share-based compensation expense was $8,836 and $8,726 for the three months ended March 31, 2020 and 2019, respectively, and $29,294 and $27,929 for the nine months ended March 31, 2020 and 2019, respectively\n- Depreciation and amortization for the three months ended March 31, 2020 decreased $572, or 2%, to $26,196 as compared to the prior year period\n- For the three and nine months ended March 31, 2020, the Company recorded a non-cash impairment charge of $102,211 associated with Tao Group Hospitality. This included impairment charges associated with one venue within Tao Group Hospitality of $3,541 and $17,972, related to a tradename and certain long-lived asset, respectively, and an impairment charge of $80,698 related to goodwill associated with the Tao Group Hospitality reporting unit.\n- Adjusted operating loss for the three months ended March 31, 2020 was $7,230 as compared to adjusted operating income of $17,944 in the prior year period.",
        "target": [
            "|   | **Three Months Ended March 31, ** |   | **Change ** |",
            "| --- | --- | --- | --- |",
            "|   | **2020 ** | **2019 ** | **Amount ** |",
            "| **Operating loss ** | $ (145,541)  | - | $ (126,922)  |",
            "| **Share-based compensation ** | 8,836  | 8,726  |   |",
            "| **Depreciation and amortization (a) ** | 26,196  | - |   |",
            "| **Impairment of intangibles, long-lived assets and goodwill (b) ** | 102,211  | - |   |",
            "| **Adjusted operating income (loss) ** | $ (7,230)  | $ 17,944  | - |"
        ]
    },
    "msgentertainmentcorp10_fileoutpart11": {
        "predict": "|   | **Madison Square Garden Sports Corp. Investment ** | **Total Company Divisional Equity ** | **Non -redeemable Noncontrolling Interests ** | **Total Divisional Equity ** | **Redeemable Noncontrolling Interests ** |\n| --- | --- | --- | --- | --- | --- |\n| **Net income (loss) ** |   |   |   |   |   |\n| **Comprehensive income (loss) ** |   |   |   |   |   |\n| **Noncontrolling interest non-cash acquisition ** |   |   |   |   |   |\n| **Redeemable noncontrolling interest adjustment to redemption fair value ** |   |   |   |   |   |\n| **Balance as of March 31, 2020 ** |   |   |   |   |   |\n\nDuring the three and nine months ended March 31, 2020, the Company reduced the carrying value of redeemable noncontrolling interests by $37,715 to reflect a non-cash purchase of an additional 15% of common equity interest in Tao Group Hospitality on January 22, 2020 (see Note 2). Concurrently, the redeemable noncontrolling interests carrying value was increased by $16,939 to align with its fair value of $23,000 as of March 31, 2020.\n\nIn connection with the acquisition of the additional 15% of common equity interest in Tao Group Hospitality, the Company recorded a decrease of $37,715 in the carrying value of the redeemable noncontrolling interests and an offset of the same amount in the Madison Square Garden Sports Corp.\n\nFor the nine months ended March 31, 2020, the Company recorded $23,851 of net loss attributable to redeemable noncontrolling interests, including a proportional share of expenses related to impairment charges of $22,997 and PPA Expenses, which total $25,547, and $38 of net loss attributable to nonredeemable noncontrolling interests, including $171 of PPA Expenses, as compared to $3,662 of net loss attributable to redeemable noncontrolling interests, including $5,499 of PPA Expenses, and $3,121 of net loss attributable to nonredeemable noncontrolling interests, including $261 of PPA Expenses, for the nine months ended March 31, 2019.",
        "target": [
            "|   | **Madison Square Garden Sports Corp. Investment ** | **Total Company Divisional Equity ** | **Non -redeemable Noncontrolling Interests ** | **Total Divisional Equity ** | **Redeemable Noncontrolling Interests ** |",
            "| --- | --- | --- | --- | --- | --- |",
            "| **Net income (loss) ** | - | - | 38  | - | (23,851)  |",
            "| **Comprehensive income (loss) ** | - | - | 38  | - | (23,851)  |",
            "| **Noncontrolling interest non-cash acquisition ** | 37,715  | 37,715  | - | 37,715  | (37,715)  |",
            "| **Redeemable noncontrolling interest adjustment to redemption fair value ** | (16,939)  | (16,939)  | - | (16,939)  | 16,939  |",
            "| **Balance as of March 31, 2020 ** | - | - | - | - | $ 23,000  |"
        ]
    },
    "msgentertainmentcorp10_fileoutpart5": {
        "predict": "|   | **Three Months Ended March 31, ** |   |\n| --- | --- | --- |\n|   | **2020** | **2019** |\n| **Revenues (a)** |   |   |\n| **Direct operating expenses (b)** |   |   |\n| **Selling, general and administrative expenses (c)** |   |   |\n| **Impairment for intangibles, long-lived assets, and goodwill** |   |   |\n| **Operating income (loss)** |   |   |\n| **Net income (loss)** |   |   |\n| **Less: Net income (loss) attributable to nonredeemable noncontrolling interests** |   |   |\n| **Net income (loss) attributable to the Company** |   |   |\n| **Basic and diluted earnings (loss) per common share attributable to the Company (f)** |   |   |\n\nGuidelines:\n- For the three months ended March 31, 2022, we had a net income of $4,515,091 which consisted of if operating costs of $247,267 and a non-cash change in fair value of warrant liabilities of $4,743,400 and reinvested interest income on funds held in trust of $18,958\n- During the three months ended March 31, 2023, the Company paid $94,489,075 from the funds held in Trust related to redemption of Class A Common Stock as a result of the Special Meeting that occurred in February 2023 to extend the business combination date\n- During the three months ended March 31, 2023, we entered into a promissory note with a related party for up to $600,000 to fund working capital\n- For the three months ended March 31, 2023, we had a net loss of $2,413,318 which consisted of operating costs of $450,901 and a non-cash change in fair value of warrant liabilities of $3,344,000 and reinvested interest income on funds held in trust of $1,504,345 and $231,189 unrealized gain on investments held in Trust, and a provision for income taxes of $353,951\n- At March 31, 2023, we had cash of $188,532 held outside of the Trust Account\n- Pursuant to the terms of such note, Trident Point 2 had the option at any time prior to August 15, 2023 to convert amounts outstanding, up to $600,000, into warrants to purchase the Company’s shares of Class A common stock at a conversion price of $1.00 per warrant, with each warrant entitling the holder to \n- During the three months ended March 31, 2023, the Company used $70,735 of interest earned in the Trust Account to pay taxes\n- Additionally, during the three months ended March 31, 2023, our Sponsor loaned us $1,384,408 to fund costs related to the extension of the date by which the Company must consummate an initial business combination pursuant to the Company’s Amended and Restated Certificate of Incorporation\n- For the three months ended March 31, 2023 cash used in financing activities included proceeds of $600,000 from a Note Payable – Related Party, and $94,489,075 payment to redeeming stockholders\n- Net income of $4,515,091 was affected by a non-cash charge for the change in fair value of warrant liability of $4,743,400 deferred income taxes of $4,908 and interest earned on marketable securities held in the Trust Account of $18,958\n- On May 19, 2023, the Company issued an amended and restated unsecured promissory note, dated as of January 20, 2023 to",
        "target": [
            "|   | **Three Months Ended March 31, ** |   |",
            "| --- | --- | --- |",
            "|   | **2020 ** | **2019 ** |",
            "| **Revenues (a) ** | $ 199,861  | $ 250,018  |",
            "| **Direct operating expenses (b) ** | - | 158,710  |",
            "| **Selling, general and administrative expenses (c) ** | 84,186  | - |",
            "| **Impairment for intangibles, long-lived assets, and goodwill ** | 102,211  | —  |",
            "| **Operating income (loss) ** | (145,541)  | (18,619)  |",
            "| **Net income (loss) ** | (150,838)  | (12,616)  |",
            "| **Less: Net income (loss) attributable to nonredeemable noncontrolling interests ** | 195  | - |",
            "| **Net income (loss) attributable to the Company ** | $ (128,586)  | - |",
            "| **Basic and diluted earnings (loss) per common share attributable to the Company (f) ** | $ (5.36)  | - |"
        ]
    },
    "msgentertainmentcorp10_fileoutpart14": {
        "predict": "| **Property and equipment, net of accumulated depreciation and amortization ** | $104,781 |<NEWLINE>| --- | --- |<NEWLINE>| **Indefinite-lived intangible assets ** | $540 |<NEWLINE>| **Goodwill ** | $2,864 |\n\nGuidelines:\n\n(a) In connection with the execution of the MIPA on March 24, 2020, pursuant to which the Company agreed to sell the Forum in Inglewood to CAPSS LLC (see Note 3), the Company allocated $2,864 of goodwill associated with the Forum to assets held for sale in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other, ASC subtopics 350-20-40-1 to 350-20-40-7\n\n(a) In connection with the execution of the MIPA on March 24, 2020, pursuant to which the Company agreed to sell the Forum in Inglewood to CAPSS LLC (see Note 3), the Company reclassified $540 of indefinite-lived intangible assets associated with the Forum to the assets held for sale in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other, ASC subtopics 350-20-40-1 to 350-20-40-7\n\n(a) In connection with the execution of the MIPA on March 24, 2020, pursuant to which the Company agreed to sell the Forum in Inglewood to CAPSS LLC (see Note 3), the Company reclassified $104,781 of property and equipment, net of accumulated depreciation and amortization of $47,609 to assets held for sale.",
        "target": [
            "| **Property and equipment, net of accumulated depreciation and amortization ** | 104,781  |",
            "| --- | --- |",
            "| **Indefinite-lived intangible assets ** | 540  |",
            "| **Goodwill ** | 2,864  |"
        ]
    },
    "msgentertainmentcorp10_fileoutpart9": {
        "predict": "|   | **Madison Square Garden Sports Corp. Investment ** | **Total Company Divisional Equity ** | **Non -redeemable Noncontrolling Interests ** | **Total Divisional Equity ** | **Redeemable Noncontrolling Interests ** |\n| --- | --- | --- | --- | --- | --- |\n| **Net income (loss) ** |   |   |   |   |   |\n| **Comprehensive income (loss) ** |   |   |   |   |   |\n| **Noncontrolling interests non-cash acquisition ** |   |   |   |   |   |\n| **Redeemable noncontrolling interest adjustment to redemption fair value ** |   |   |   |   |   |\n| **Balance as of March 31, 2020 ** |   |   |   |   |   |\n\nDuring the three and nine months ended March 31, 2020, the Company reduced the carrying value of redeemable noncontrolling interests by $37,715 to reflect a non-cash purchase of an additional 15% of common equity interest in Tao Group Hospitality on January 22, 2020 (see Note 2). Concurrently, the redeemable noncontrolling interests carrying value was increased by $16,939 to align with its fair value of $23,000 as of March 31, 2020.\n\nFor the three months ended March 31, 2020, the Company recorded $22,447 of net loss attributable to redeemable noncontrolling interests, including a proportional share of expenses related to impairment charges of $22,997 and purchase accounting adjustments (“PPA Expenses”), which total $22,257 and $195 of net loss attributable to nonredeemable noncontrolling interests, including $57 of PPA Expenses as compared to $7 of net loss attributable to redeemable noncontrolling interests including $1,595 of PPA Expenses and $680 of net loss attributable to nonredeemable noncontrolling interests including $87 of PPA Expenses for the three months ended March 31, 2019.\n\nIn connection with the acquisition of the additional 15% of common equity interest in Tao Group Hospitality, the Company recorded a decrease of $37,715 in the carrying value of the redeemable noncontrolling interests and an offset of the same amount in the Madison Square Garden Sports Corp.",
        "target": [
            "|   | **Madison Square Garden Sports Corp. Investment ** | **Total Company Divisional Equity ** | **Non -redeemable Noncontrolling Interests ** | **Total Divisional Equity ** | **Redeemable Noncontrolling Interests ** |",
            "| --- | --- | --- | --- | --- | --- |",
            "| **Net income (loss) ** | - | - | 195  | - | (22,447)  |",
            "| **Comprehensive income (loss) ** | - | - | 195  | - | (22,447)  |",
            "| **Noncontrolling interests non-cash acquisition ** | 37,715  | 37,715  | - | 37,715  | (37,715)  |",
            "| **Redeemable noncontrolling interest adjustment to redemption fair value ** | (16,939)  | (16,939)  | - | (16,939)  | 16,939  |",
            "| **Balance as of March 31, 2020 ** | - | - | - | - | $ 23,000  |"
        ]
    },
    "msgentertainmentcorp10_fileoutpart47": {
        "predict": "|   | **Three Months Ended March 31, ** |   | **Change (a) ** |   |\n| --- | --- | --- | --- | --- |\n|   | **2020 ** | **2019 ** | **Amount ** | **Percentage ** |\n| **Revenues ** | $199,861 | $250,018 | ($50,157) | (20%) |\n| **Direct operating expenses ** | $132,809 | $158,710 | ($25,901) | (16%) |\n| **Selling, general and administrative expenses ** | $84,186 | $83,159 | $1,027 | 1% |\n| **Depreciation and amortization ** | $26,196 | $26,768 | ($572) | (2%) |\n| **Impairment of intangibles, long-lived assets and goodwill ** |   |   | ($102,211) |   |\n| **Operating loss ** | ($145,541) | ($18,619) | ($126,922) |   |\n| **Loss in equity method investments ** | ($1,096) | ($2,881) | $1,785 | 62% |\n| **Interest income, net ** | $3,054 | $4,740 | ($1,686) | (36%) |\n| **Miscellaneous income (expense), net ** | ($17,381) | $4,613 | ($22,994) |   |\n| **Income tax benefit (expense) ** | $10,126 | ($1,115) | $11,241 |   |\n| **Less: Net loss attributable to redeemable noncontrolling interests ** | ($22,447) | ($7) | ($22,440) |   |\n| **Less: Net income (loss) attributable to nonredeemable noncontrolling interests ** | ($195) | $593 | ($788) |   |\n|   |   |   |   |   |\n|   | **Nine Months Ended March 31, ** |   | **Change (a) ** |   |\n| --- | --- | --- | --- | --- |\n|   | **2020 ** | **2019 ** | **Amount ** | **Percentage ** |\n| **Revenues ** | $767,038 | $832,384 | ($65,346) | (8%) |\n| **Direct operating expenses ** | $472,582 | $507,249 | ($34,667) | (7%) |\n| **Selling, general and administrative expenses ** | $257,970 | $231,038 | $26,932 | 12% |\n| **Depreciation and amortization ** | $80,271 | $81,606 | ($1,335) | (2%) |\n| **Impairment of intangibles, long-lived assets and goodwill ** |   |   | ($102,211) |   |\n| **Operating loss ** | ($145,996) | $12,491 | ($158,487) |   |\n| **Loss in equity method investments ** | ($3,739) | $17,131 | ($20,870) |   |\n| **Interest income, net ** | $15,388 | $11,944 | $3,444 | 29% |\n| **Miscellaneous income (expense), net ** | $2,893 | $4,118 | ($1,225) | (30%) |\n| **Income tax benefit (expense) ** | $8,686 | ($1,253) | $9,939 |   |\n| **Less: Net loss attributable to redeemable noncontrolling interests ** | ($23,851) | ($3,662) | ($20,189) |   |\n| **Less: Net income (loss) attributable",
        "target": [
            "|   | **Three Months Ended March 31, ** |   | **Change (a) ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2020 ** | **2019 ** | **Amount ** | **Percentage ** |",
            "| **Revenues ** | 199,861  | - | (50,157)  | (20)%  |",
            "| **Direct operating expenses ** | 132,809  | - | (25,901)  | (16)%  |",
            "| **Selling, general and administrative expenses ** | 84,186  | - | 1,027  | 1%  |",
            "| **Depreciation and amortization ** | 26,196  | - | (572)  | (2)%  |",
            "| **Impairment of intangibles, long-lived assets and goodwill ** | 102,211  | - | 102,211  | - |",
            "| **Operating loss ** | (145,541)  | - | (126,922)  | - |",
            "| **Loss in equity method investments ** | (1,096)  | - | 1,785  | 62 %  |",
            "| **Interest income, net ** | 3,054  | - | (1,686)  | (36)%  |",
            "| **Miscellaneous income (expense), net ** | (17,381)  | 4,613  | - | - |",
            "| **Income tax benefit (expense) ** | 10,126  | (469)  | - | - |",
            "| **Less: Net loss attributable to redeemable noncontrolling interests ** | (22,447)  | (7)  | - | - |",
            "| **Less: Net income (loss) attributable to nonredeemable noncontrolling interests ** | 195  | (680)  | - | - |",
            "| **Revenues ** | $ 767,038  | - | $ (65,346)  | (8)%  |",
            "| **Direct operating expenses ** | 472,582  | - | (34,667)  | (7)%  |",
            "| **Selling, general and administrative expenses ** | 257,970  | - | 26,932  | 12 %  |",
            "| **Depreciation and amortization ** | 80,271  | - | (1,335)  | (2)%  |",
            "| **Impairment of intangibles, long-lived assets and goodwill ** | 102,211  | - | 102,211  | - |",
            "| **Operating income (loss) ** | (145,996)  | 12,491  | - | - |",
            "| **Earnings (loss) in equity method investments ** | (3,739)  | 17,131  | - | - |",
            "| **Interest income, net ** | 15,388  | - | 3,444  | 29 %  |",
            "| **Miscellaneous expense, net ** | (2,893)  | - | 1,225  | 30 %  |",
            "| **Income tax benefit (expense) ** | 8,686  | (1,253)  | - | - |",
            "| **Less: Net loss attributable to redeemable noncontrolling interests ** | (23,851)  | (3,662)  | - | - |",
            "| **Less: Net income (loss) attributable to nonredeemable noncontrolling interests ** | 38  | (3,121)  | - | - |"
        ]
    },
    "msgentertainmentcorp10_fileoutpart51": {
        "predict": "|   | **Nine Months Ended March 31, ** |   | **Change ** |   |\n| --- | --- | --- | --- | --- |\n|   | **2020 ** | **2019 ** | **Amount ** | **Percentage ** |\n| **Operating income (loss) ** | ($145,996) | $12,491 | $-158,487 | (1,267)% |\n| **Share-based compensation ** | $8,836 | $8,726 | $110 | 1% |\n| **Depreciation and amortization (a) ** | $80,271 | $81,606 | $-1,335 | (2)% |\n| **Impairment of intangibles, long-lived assets and goodwill (b) ** | $102,211 |   |   |   |\n| **Adjusted operating income ** | $70,244 | $125,743 | $-55,499 | (44)% |\n\nGuidelines:\n(b) For the three and nine months ended March 31, 2020, the Company recorded a non-cash impairment charge of $102,211 associated with Tao Group Hospitality.\n\nShare-based compensation expense was $8,836 and $8,726 for the three months ended March 31, 2020 and 2019, respectively, and $29,294 and $27,929 for the nine months ended March 31, 2020 and 2019, respectively.\n\nOperating loss for the nine months ended March 31, 2020 was $145,996 as compared to an operating income of $12,491 in the prior year period.\n\nBased upon the results of the Company’s interim quantitative impairment test, the Company concluded that the carrying value of the Tao Group Hospitality reporting unit exceeded its estimated fair value (“Fair Value Deficit”) as of the interim testing date by $102,211.\n\nDepreciation and amortization for the nine months ended March 31, 2020 decreased $1,335, or 2%, to $80,271 as compared to the prior year period.\n\nAdjusted operating income for the nine months ended March 31, 2020 decreased $55,499, or 44%, to $70,244 as compared to the prior year period.\n\nBased on this evaluation, the Company recorded a non-cash impairment charge of $102,211 for the three and nine months ended March 31, 2020, which included impairment charges associated with one venue within Tao Group Hospitality of $3,541 and $17,972, related to a tradename and certain long-lived asset, respectively, and an impairment charge of $80,698 related to goodwill associated with the Tao Group Hospitality reporting unit.",
        "target": [
            "|   | **Nine Months Ended March 31, ** |   | **Change ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2020 ** | **2019 ** | **Amount ** | **Percentage ** |",
            "| **Operating income (loss) ** | $ (145,996)  | $ 12,491  | - | - |",
            "| **Share-based compensation ** | 29,294  | 27,929  |   |   |",
            "| **Depreciation and amortization (a) ** | 80,271  | - |   |   |",
            "| **Impairment of intangibles, long-lived assets and goodwill (b) ** | 102,211  | - |   |   |",
            "| **Adjusted operating income ** | $ 70,244  | - | $ (55,499)  | (44)%  |"
        ]
    },
    "rivn-20210930_fileoutpart19": {
        "predict": "|   | **2021** | **2021** |\n| --- | --- | --- |\n| **Revenues** | +$1 million |   |\n| **Cost of revenues** | -$83 million |   |\n| **Gross profit** | -$82 million |   |\n| **Interest expense** |   |   |\n\nGuidelines:\n- Depreciation and amortization expense was $7 million and $49 million for the three months ended September 30, 2020 and 2021, respectively.\n- We generated negative gross profit of $(82) million for the three and nine month periods ended September 30, 2021.\n- Export controls apply to (1) items that are produced in the United States, wherever they are geographically located; (2) all items located in the United States, even if only moving in transit through the United States; and (3) certain foreign-produced items, including those that incorporate more than de minimis levels of controlled U.S.-origin content.\n- The increase was primarily due to an $83 million increase in payroll and related expenses, a $21 million increase in facilities and other occupancy costs driven by office location expansions, an $18 million increase in professional and outsourced services fees, and increases in other operating expenses.\n- Revenues increased by approximately $1 million for the three and nine months ended September 30, 2021, compared to the three and nine months ended September 30, 2020.\n- Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.\n- Our amended and restated certificate of incorporation provides that, unless we otherwise consent in writing, (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, other employee or stockholder of ours to us or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended or restated) or as to which the DGCL confers exclusive jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware shall, to the fullest extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware or, if such court does not have subject matter jurisdiction thereof, the federal district court of the State of Delaware; and (B) the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act; however, there is uncertainty as to whether a court would enforce such provision, and investors cannot waive compliance with federal securities laws and the rules and regulations thereunder.\n- Cost of revenues increased by $83 million for the three and nine months ended September 30, 2021, compared to the three and nine months ended September 30, 2020, as a result of the manufacture and sale of our first production vehicles.",
        "target": [
            "|   | **2021 ** | **2021 ** |",
            "| --- | --- | --- |",
            "| **Revenues ** | $ 1  | $ 1  |",
            "| **Cost of revenues ** | 83  | 83  |",
            "| **Gross profit ** | (82)  | (82)  |",
            "| **Interest expense ** | (1)  | (7)  |"
        ]
    },
    "rivn-20210930_fileoutpart4": {
        "predict": "|   | **2021** | **2021** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Revenues** | $1 million | $1 million |<NEWLINE>| **Cost of revenues** | $83 million | $83 million |<NEWLINE>| **Gross profit** | $(82) million | $(82) million |<NEWLINE>| **Interest expense** |   |   |<NEWLINE>\n\nNote: Depreciation and amortization expense information is not included in the table as it does not have a specific column for it.",
        "target": [
            "|   | **2021 ** | **2021 ** |",
            "| --- | --- | --- |",
            "| **Revenues ** | $ 1  | $ 1  |",
            "| **Cost of revenues ** | 83  | 83  |",
            "| **Gross profit ** | (82)  | (82)  |",
            "| **Interest expense ** | - | (7)  |"
        ]
    },
    "rivn-20210930_fileoutpart10": {
        "predict": "|   | **2021 Convertible Notes ** |<NEWLINE>| --- | --- |<NEWLINE>| **Loss on issuance ** | $549 million |<NEWLINE>| **Issue-date estimated fair value ** | $3,049 million |<NEWLINE>| **Gain on change in fair value ** | $91 million |<NEWLINE>| **Fair value as of September 30, 2021 ** | $2,958 million |",
        "target": [
            "|   | **2021 Convertible Notes ** |",
            "| --- | --- |",
            "| **Loss on issuance ** | 549  |",
            "| **Issue-date estimated fair value ** | 3,049  |",
            "| **Gain on change in fair value ** | (91)  |",
            "| **Fair value as of September 30, 2021 ** | $ 2,958  |"
        ]
    },
    "tgt-20211030_fileoutpart23": {
        "predict": "| **RedCard Penetration** |   | **Nine Months Ended** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **October 31, 2020** | **October 30, 2021** |<NEWLINE>| **Total RedCard Penetration** |   |   |\n|---|---|---|<NEWLINE>| 20.5% | 18.9% |   |<NEWLINE>|   |   |   |\n|**Cash Flow from Operating Activities** |   |   |<NEWLINE>|   |   |   |<NEWLINE>| $7.0 billion | $5.6 billion (20.5% decrease) |   |\n|**Effective Tax Rates (TTM)** |   |   |<NEWLINE>|   |   |   |<NEWLINE>| 21.5% | 21.3% |   |",
        "target": [
            "| **RedCard Penetration ** |   | **Nine Months Ended ** |",
            "| --- | --- | --- |",
            "|   | **October 31, 2020 ** | **October 30, 2021 ** |",
            "| **Total RedCard Penetration ** | 21.5 %  | 20.5 %  |"
        ]
    },
    "tgt-20211030_fileoutpart17": {
        "predict": "| **Rate Analysis ** | **Three Months Ended ** |   | **Nine Months Ended ** |   |\n| --- | --- | --- | --- | --- |\n|   | **October 30, 2021 ** | **October 31, 2020 ** | **October 30, 2021 ** | **October 31, 2020 ** |\n| **Gross margin rate ** | 28.0% | 30.6% | 29.5% | 29.1% |\n| **SG&A expense rate ** | 18.9% | 20.5% | 19.0% | 20.2% |<NEWLINE>\n\nGuidelines:\nFor the three months ended October 30, 2021, our SG&A expense rate was 18.9 percent compared with 20.5 percent for the three months ended October 31, 2020.\n\nFor the nine months ended October 30, 2021, our SG&A expense rate was 19.0 percent compared with 20.2 percent for the nine months ended October 31, 2020.\n\nFor the three months ended October 30, 2021, our gross margin rate was 28.0 percent compared with 30.6 percent in the comparable prior-year period.\n\nCash flow provided by operating activities was $5.6 billion for the nine months ended October 30, 2021, a decrease of $1.4 billion, or (20.5) percent, from $7.0 billion for the nine months ended October 31, 2020.\n\nFor the nine months ended October 30, 2021, our gross margin rate was 29.5 percent compared with 29.1 percent in the comparable prior-year period.",
        "target": [
            "| **Rate Analysis ** | **Three Months Ended ** |   | **Nine Months Ended ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **October 30, 2021 ** | **October 31, 2020 ** | **October 30, 2021 ** | **October 31, 2020 ** |",
            "| **Gross margin rate ** | 28.0 %  | 30.6 %  | 29.5 %  | 29.1 %  |",
            "| **SG&A expense rate ** | 18.9  | 20.5  | 19.0  | 20.2  |"
        ]
    },
    "tdy-20210704_fileoutpart40": {
        "predict": "| **(dollars in millions)** | **Second Quarter** |   | **Six Months** |   |\n| --- | --- | --- | --- | --- |\n|   | **2021** | **2020** | **2021** | **2020** |\n| **Selling, general and administrative expenses** | $5.9 | $7.8 | $12.5 | $14.4 |\n| **Cost of sales as a % of net sales** |   |   | 81.1% | 81.3% |\n| **Selling, general and administrative expenses as a % of net sales** | 6.0% | 7.8% | 6.1% | 7.4% |\n\nGuidelines:\n\n- Selling, general and administrative expenses, including research and development expense, decreased to $12.5 million for the first six months of 2021, compared with $14.4 million for the first six months of 2020\n- Selling, general and administrative expense was $5.9 million for the second quarter of 2021, compared with $7.8 million\n- Cost of sales as a percentage of sales for the first six months of 2021 decreased slightly to 81.1% from 81.3%\n- The selling, general and administrative expense percentage decreased to 6.1% for the first six months of 2021 compared with 7.4%\n- Second quarter 2021 selling, general and administrative expenses increased $5.9 million, primarily as a result of higher net sales\n- Research and development expense was lower by $7.8 million in the first six months of 2021, and primarily reflected lower spending for aerospace electronics\n- Interest expense, net of interest income, was $56.9 million for the first six months of 2021, compared with $7.8 million and primarily reflected interest and debt expense on the debt incurred to fund the cash portion of the FLIR acquisition\n- Stock option compensation expense was $7.8 million for the first six months of 2021 and was $13.1 million for the first six months of 2020\n- Cost of sales as a percentage of net sales for the second quarter of 2021 increased to 82.8% from 81.3%\n- The second quarter of 2021 cost of sales increased $5.9 million\n- The selling, general and administrative expense percentage was 6.0% for the second quarter of 2021 compared with 7.8%\n- In the first six months of 2021 and 2020, we recorded a total of $7.8 million and $13.1 million, respectively, in stock option compensation expense.",
        "target": [
            "| **(dollars in millions) ** | **Second Quarter ** |   | **Six Months ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2021 ** | **2020 ** | **2021 ** | **2020 ** |",
            "| **Selling, general and administrative expenses ** | $ 5.9  | $ 7.8  | $ 12.5  | $ 14.4  |",
            "| **Cost of sales as a % of net sales ** | 82.8 %  | 81.3 %  | 81.1 %  | 81.3 %  |",
            "| **Selling, general and administrative expenses as a % of net sales ** | 6.0 %  | 7.8 %  | 6.1 %  | 7.4 %  |"
        ]
    },
    "tdy-20210704_fileoutpart27": {
        "predict": "|   | **Second Quarter** |   | **Six Months** |   |\n| --- | --- | --- | --- | --- |\n|   | **2021** | **2020** | **2021** | **2020** |\n| **Service cost — benefits earned during the period (in millions)** |   |   |   |   |\n| **Pension non-service income** | $2.8 million | $3.2 million |   |   |\n| **Pension service expense** | $2.7 million | $2.6 million | $5.4 million | $5.2 million |<NEWLINE>\n\nNote: Some cells may remain empty based on the guidelines.",
        "target": [
            "|   | **Second Quarter ** |   | **Six Months ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2021 ** | **2020 ** | **2021 ** | **2020 ** |",
            "| **Service cost — benefits earned during the period (in millions) ** | $ 2.7  | $ 2.6  | $ 5.4  | $ 5.2  |",
            "| **Pension non-service income ** | - | $ (3.2)  | - | - |"
        ]
    },
    "tdy-20210704_fileoutpart6": {
        "predict": "|   | **Six Months ** |   |\n| --- | --- | --- |\n|   | **2021** | **2020** |\n| **Net cash provided by operating activities** | $336.2 million | $232.2 million |\n| **Purchases of property, plant and equipment** | $38.4 million | $36.8 million |\n| **Net cash used in investing activities** | $3,761.8 million | $65.7 million |\n| **Proceeds from exercise of stock options** | $15.9 million | $28.2 million |\n| **Net cash provided by financing activities** | $3,451.4 million | $27.8 million |",
        "target": [
            "|   | **Six Months ** |   |",
            "| --- | --- | --- |",
            "|   | **2021 ** | **2020 ** |",
            "| **Net cash provided by operating activities ** | 336.2  | 232.2  |",
            "| **Purchases of property, plant and equipment ** | (38.4)  | (36.8)  |",
            "| **Net cash used in investing activities ** | (3,761.8)  | (65.7)  |",
            "| **Proceeds from exercise of stock options ** | 15.9  | 28.2  |",
            "| **Net cash provided by financing activities ** | 3,451.4  | 27.8  |"
        ]
    },
    "tdy-20210704_fileoutpart35": {
        "predict": "| **(dollars in millions)** | **Second Quarter** | **% Change** | **Six Months** | **% Change** |\n| --- | --- | --- | --- | --- |\n|   | **2021** | **2020** | **2021** | **2020** |\n| **Digital Imaging (b)** |   |   |   |   |\n| **Instrumentation** |   |   |   |   |\n| **Aerospace and Defense Electronics** |   |   |   |   |\n| **Engineered Systems** |   |   |   |   |\n| **Total net sales** |   |   |   |   |\n| **Digital Imaging (b)** |   |   |   |   |\n| **Instrumentation** |   |   |   |   |\n| **Aerospace and Defense Electronics** |   |   |   |   |\n| **Engineered Systems** |   |   |   |   |\n| **Corporate expense (c)** |   |   |   |   |\n| **Total operating income** |   |   |   |   |\n\nGuidelines:\n- The Engineered Systems segment’s first six months of 2021 net sales increased 3.4%\n- The first six months of 2021 net sales reflected $15.0 million of higher sales for defense and space electronics, partially offset by lower sales of $10.8 million for aerospace electronics\n- The Aerospace and Defense Electronics segment’s second quarter of 2021 net sales increased 6.5%. Operating income for the second quarter of 2021 increased 62.3%.\n- The Instrumentation segment’s first six months 2021 net sales increased 5.4%\n- Operating income for the second quarter of 2021 decreased 4.9%\n- The Digital Imaging segment’s second quarter of 2021 net sales increased 143.9%\n- The Engineered Systems segment’s second quarter of 2021 net sales decreased 1.5%\n- Corporate expense, which is included in selling, general and administrative expenses, was $84.2 million for the second quarter of 2021, compared with $13.8 million and reflected $70.5 million in acquisition-related transaction and purchase accounting expenses\n- The Aerospace and Defense Electronics segment’s second quarter of 2021 net sales increased 6.5%\n- Operating income for the first six months of 2021 increased 12.1%\n- Operating income for the first six months of 2021 increased 83.5%\n- The Digital Imaging segment’s first six months of 2021 net sales increased 74.0%\n- Operating income for the second quarter of 2021 increased 33.2%\n- Our second quarter of 2021 net sales increased 50.8%\n- Operating income for the second quarter of 2020 increased 1.9%\n- The Instrumentation segment’s second quarter of 2021 net sales increased 10.6%\n- The Aerospace and Defense Electronics segment’s first six months of 2021 net sales increased 1.4%\n- Operating income for the first six months of 2021 increased 16.7%\n- Operating income for the first six months of 2021 increased 50.8%\n- Operating income for the second quarter of 2021 increased 80.8%\n- Our first six months of 2021 net sales increased 26.1% and included $301.4 million in incremental net sales from the acquisition FLIR\n- Operating income for the first six months of 2021 increased of 24.9%\n- Corporate expense was $103.6 million in the first six months of 2021 compared with $29.2 million and reflected $76.4 million in acquisition-related transaction and purchase accounting expenses related to the FLIR acquisition in 2021\n\n",
        "target": [
            "| **(dollars in millions) ** | **Second Quarter ** |   | **% Change ** | **Six Months ** |   | **% Change** |",
            "| --- | --- | --- | --- | --- | --- | --- |",
            "|   | **2021 ** | **2020 ** |   | **2021 ** | **2020 ** |   |",
            "| **Digital Imaging (b) ** | - | - | 143.9 %  | - | - | 74.0 %  |",
            "| **Instrumentation ** | - | - | 10.6 %  | - | - | 5.4 %  |",
            "| **Aerospace and Defense Electronics ** | - | - | 6.5 %  | - | - | 1.4 %  |",
            "| **Engineered Systems ** | - | - | (1.5)%  | - | - | 3.4 %  |",
            "| **Total net sales ** | - | - | 50.8 %  | - | - | 26.1 %  |",
            "| **Digital Imaging (b) ** | - | - | 80.8 %  | - | - | 50.8 %  |",
            "| **Instrumentation ** | - | - | 33.2 %  | - | - | 24.9 %  |",
            "| **Aerospace and Defense Electronics ** | - | - | 62.3 %  | - | - | 83.5 %  |",
            "| **Engineered Systems ** | - | 10.8  | 1.9 %  | - | - | 16.7 %  |",
            "| **Corporate expense (c) ** | (84.2)  | (13.8)  | - | (103.6)  | (29.2)  | - |",
            "| **Total operating income ** | - | - | (4.9)%  | - | - | 12.1 %  |"
        ]
    },
    "tdy-20210704_fileoutpart39": {
        "predict": "| **(dollars in millions)** | **Second Quarter** |   | **Six Months** |   |\n| --- | --- | --- | --- | --- |\n|   | **2021** | **2020** | **2021** | **2019** |\n| **Selling, general and administrative expenses** | $23.9 | $29.0 | $47.0 | $60.9 |\n| **Acquired intangible asset amortization** |   |   |   |   |\n| **Operating income** |   |   |   |   |\n| **Cost of sales as a % of net sales** | 56.7% |   |   |   |\n| **Selling, general and administrative expenses as a % of net sales** | 15.7% | 20.3% | 15.5% | 20.4% |\n\n**Guidelines:**\n\n- Net income for the second quarter of 2021 decreased 30.9%\n- The first six months of 2021 selling, general and administrative expenses increased by $0.4 million\n- Selling, general and administrative expenses, including research and development expense, decreased to $47.0 million in the first six months of 2021, compared with $60.9 million for the first six months of 2020 and impact of lower severance, facility consolidation and lower research and development expense\n- Selling, general and administrative expenses, including research and development expense, decreased to $23.9 million in the second quarter of 2021 from $29.0 million and reflected the impact of impact of lower severance, facility consolidation and lower research and development expense, partially offset by the impact of higher net sales\n- The selling, general and administrative expense percentage decreased to 15.7% in the second quarter of 2021 from 20.3% and reflected the impact of lower severance, facility consolidation and lower research and development expense\n- Cost of sales as a percentage of net sales for the second quarter of 2021 decreased slightly to 56.7% from 57.1%\n- The second quarter of 2021 cost of sales increased $0.2 million\n- Cost of sales as a percentage of net sales for the second quarter of 2021 decreased to 65.6% from 67.4% and reflected impact of lower severance and facility consolidation expense\n- The selling, general and administrative expense percentage decreased to 15.5% in the first six months of 2021, compared with 20.4% and reflected impact of lower severance, facility consolidation and lower research and development expense\n- Cost of sales as a percentage of sales for the first six months of 2021 decreased to 65.7% from 69.2% in the first six months of 2021 and reflected impact of lower severance and facility consolidation costs",
        "target": [
            "| **(dollars in millions) ** | **Second Quarter ** |   | **Six Months ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2021 ** | **2020 ** | **2021 ** | **2019 ** |",
            "| **Selling, general and administrative expenses ** | $ 23.9  | $ 29.0  | $ 47.0  | $ 60.9  |",
            "| **Acquired intangible asset amortization ** | $ 0.2  | $ 0.2  | $ 0.4  | $ 0.4  |",
            "| **Operating income ** | - | - | $ 56.7  | $ 30.9  |",
            "| **Cost of sales as a % of net sales ** | 65.6 %  | 67.4 %  | 65.7 %  | 69.2 %  |",
            "| **Selling, general and administrative expenses as a % of net sales ** | 15.7 %  | 20.3 %  | 15.5 %  | 20.4 %  |"
        ]
    },
    "tdy-20210704_fileoutpart38": {
        "predict": "| **(dollars in millions)** | **Second Quarter** |   | **Six Months** |   |\n| --- | --- | --- | --- | --- |\n|   | **2021** | **2020** | **2021** | **2020** |\n| **Acquired intangible asset amortization** |   |   |   |   |\n| **Cost of sales as a % of net sales** | 52.7% |   |   |   |\n| **Selling, general and administrative expenses as a % of net sales** | 23.3% |   | 23.2% |   |<NEWLINE>|\n\nGuidelines applied:\n\n- The selling, general and administrative expense percentage decreased slightly to 23.3% in the second quarter of 2021 from 23.6%\n- The cost of sales percentage decreased to 53.5% from 55.7%\n- Cost of sales as a percentage of net sales for the second quarter of 2021 decreased to 52.7% from 56.1%\n- The selling, general and administrative expense percentage decreased to 23.2% in the first six months of 2021 from 24.4%\n- Some cells remain empty based on the guidelines.",
        "target": [
            "| **(dollars in millions) ** | **Second Quarter ** |   | **Six Months ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2021 ** | **2020 ** | **2021 ** | **2020 ** |",
            "| **Acquired intangible asset amortization ** | $ 5.2  | $ 5.1  | - | - |",
            "| **Cost of sales as a % of net sales ** | 52.7 %  | 56.1 %  | 53.5 %  | 55.7 %  |",
            "| **Selling, general and administrative expenses as a % of net sales ** | 23.3 %  | 23.6 %  | 23.2 %  | 24.4 %  |"
        ]
    },
    "f10q0321_victoryoil_fileoutpart11": {
        "predict": "|   | **Three Months Ended March 31, ** |   |\n| --- | --- | --- |\n|   | **2021** | **2020** |\n| **Net cash used in operating activities** | $152,243 | $2,162 |\n| **Net cash used in investing activities** | $32,998 | $6,797 |\n| **Net cash provided by financing activities** | $231,722 | $207,869 |\n\nGuidelines:\n- Net cash used in operating activities for the three months ended March 31, 2021 was $152,243\n- This compares to cash used in operating activities for the three months ended March 31, 2020 of $2,162 after the net loss adjusted for non-cash items for that period used cash of $210,799\n- Net cash used in investing activities for the three months ended March 31, 2021 was $32,998 due to fixed asset purchases\n- This compares to $6,797 used by investing activities for the three months ended March 31, 2020\n- Net cash provided by financing activities for the three months ended March 31, 2021 was $231,722 compared to $207,869 in net cash provided by financing activities during the three months ended March 31, 2020",
        "target": [
            "|   | **Three Months Ended March 31, ** |   |",
            "| --- | --- | --- |",
            "|   | **2021 ** | **2020 ** |",
            "| **Net cash used in operating activities ** | $ (152,243)  | $ (2,162)  |",
            "| **Net cash used in investing activities ** | (32,998)  | (6,797)  |",
            "| **Net cash provided by financing activities ** | - | 207,869  |"
        ]
    },
    "f10q0321_victoryoil_fileoutpart9": {
        "predict": "|   | **Three months ended March 31, ** |   |\n| --- | --- | --- |\n|   | **2021 ** | **2020 ** |\n| **Net loss ** | $(144,654) | $(273,049) |\n| **Basic weighted average common shares outstanding ** | 28,037,713 | 28,037,713 |\n| **Diluted weighted average common shares outstanding ** | 28,037,713 | 28,037,713 |\n| **Basic ** | $(0.01) | $(0.01) |\n| **Diluted ** | $(0.01) | $(0.01) | <NEWLINE>\n\nGuidelines:\nBasic and diluted weighted average number of common shares outstanding was 28,037,713 and 28,037,713 for the three months ended March 31, 2021 and 2020, respectively.\n\nThe weighted average number of common shares outstanding was 28,037,713 at each of March 31, 2021 and 2020.\n\nAs of September 10, 2021, there were 28,037,713 shares of common stock, par value $0.001, issued and outstanding.\n\nAs a result of the foregoing, loss applicable to common stockholders for the three months ended March 31, 2021 was $(144,654), or $(0.01) per share, compared to a loss applicable to common stockholders of $(273,049), or $(0.01) per share, for the three months ended March 31, 2020 on weighted average shares of 28,037,713 and 28,037,713, respectively.\n\nThe weighted average number of common shares outstanding was 28,037,713 and 28,037,713, at each of March 31, 2021 and 2020.",
        "target": [
            "|   | **Three months ended March 31, ** |   |",
            "| --- | --- | --- |",
            "|   | **2021 ** | **2020 ** |",
            "| **Net loss ** | $ (144,654)  | $ (273,049)  |",
            "| **Basic weighted average common shares outstanding ** | 28,037,713  | 28,037,713  |",
            "| **Diluted weighted average common shares outstanding ** | 28,037,713  | 28,037,713  |",
            "| **Basic ** | $ (0.01)  | $ (0.01)  |",
            "| **Diluted ** | $ (0.01)  | $ (0.01)  |"
        ]
    },
    "f10q0622_eaststoneacq_fileoutpart2": {
        "predict": "| **Operating costs** | $956,470 | $553,983 |   |   |   |\n| --- | --- | --- | --- | --- |<NEWLINE>|\n| **Loss from operations** | $(956,470) | $(553,983) |   |   |   |\n| **Change in fair value of derivative warrant liabilities** | $570,000 | $1,019,000 | $(18,900) | $35,600 |   |\n| **Extension incentive paid by Founder Shares transferred** | $(1,900,800) | $0 |   |   |   |\n| **Change in fair value of Forward Purchase Agreement** | $0 | $0 |   | $(2,069,000) |   |\n| **Interest earned on investments held in the trust account** | $40,526 | $38,374 | $6,902 | $3,479 |   |\n| **Net loss** | $(1,317,744) | $(1,534,609) | $(1,033,891) | $(944,077) |   |\n| **Weighted average shares outstanding of redeemable ordinary shares** | 13,800,000 | 3,264,744 | 13,800,000 | 3,903,500 | 3,264,856 |\n| **Basic and diluted net loss per redeemable ordinary share** | $(0.05) | $(0.21) | $(0.05) | $(0.21) | $(0.18) |\n| **Weighted average shares outstanding of non-redeemable ordinary shares** | $3,903,500 | $3,903,500 | $3,903,500 | $3,903,500 | $3,903,500 |\n| **Basic and diluted net loss per non-redeemable ordinary share** | $(0.05) | $(0.21) | $(0.05) | $(0.21) | $(0.18) |",
        "target": [
            "| **Operating costs ** | $ 553,983  | $ 966,456  | $ 956,470  | $ 1,076,393  |",
            "| --- | --- | --- | --- | --- |",
            "| **Loss from operations ** | (553,983)  | (966,456)  | (956,470)  | (1,076,393)  |",
            "| **Change in fair value of derivative warrant liabilities ** | (1,019,000)  | 18,900  | (570,000)  | 35,600  |",
            "| **Extension incentive paid by Founder Shares transferred ** | - | - | (1,900,800)  | - |",
            "| **Change in fair value of Forward Purchase Agreement ** | - | - | 2,069,000  | - |",
            "| **Interest earned on investments held in the trust account ** | 38,374  | 3,479  | 40,526  | 6,902  |",
            "| **Net loss ** | $ (1,534,609)  | $ (944,077)  | $ (1,317,744)  | $ (1,033,891)  |",
            "| **Weighted average shares outstanding of redeemable ordinary shares ** | 3,264,744  | 13,800,000  | 3,264,856  | 13,800,000  |",
            "| **Basic and diluted net loss per redeemable ordinary share ** | $ (0.21)  | $ (0.05)  | $ (0.18)  | $ (0.06)  |",
            "| **Weighted average shares outstanding of non-redeemable ordinary shares ** | 3,903,500  | 3,903,500  | 3,903,500  | 3,903,500  |",
            "| **Basic and diluted net loss per non-redeemable ordinary share ** | $ (0.21)  | $ (0.05)  | $ (0.18)  | $ (0.06)  |"
        ]
    },
    "f10q0622_eaststoneacq_fileoutpart5": {
        "predict": "|   | **For the Six Months Ended June 30, ** |   |\n| --- | --- | --- |\n|   | **2022** | **2021** |\n| **Net loss** | $1,317,744 | $1,033,891 |\n| **Change in fair value of derivative warrant liabilities** | $570,000 | $35,600 |\n| **Change in fair value of forward purchase agreement** |   |   |\n| **Extension incentive paid by Founder Shares transferred** | ($1,900,800) | $0 |\n| **Interest earned on investments held in the trust account** | $40,526 | $6,902 |\n| **Cash Withdrawn from trust account upon redemption of 361 ordinary shares** | ($3,704) |   |\n| **Investment of cash for extension into trust account** |   |   |\n| **Net cash provided by (used in) investing activities** |   |   |\n| **Proceeds from promissory note - ICONIQ** |   |   |\n| **Proceeds from extension loans - related party** | $1,380,000 | $1,380,000 |\n| **Cash - End of period** | $3,719 | $33,541,649 |\n\nGuidelines:\n- For the six months ended June 30, 2022 and 2021, we had net loss of $1,317,744 and $1,033,891, respectively, which consists of operating costs of $956,470 and $1,076,393, decrease in fair value of founder share transfer incentive of $1,900,800 and $0, respectively, offset by increase in fair value of derivative warrant liabilities of $570,000 and $35,600, respectively, share purchase of $2,069,000 and $0, respectively, and interest income of $40,526 and $6,902 on investments held in the trust account.\n- In connection with the approval of the extension on February 24, 2022, shareholders elected to redeem an aggregate of 361 ordinary shares, of which the Company paid cash from the trust account in the aggregate amount of approximately $3,704 (approximately $10.26 per share) to redeeming shareholders.\n- As of June 30, 2022, the Company had $3,719 in its operating bank account and $33,541,649 in money market funds held in the trust account to be used for a Business Combination or to repurchase or redeem its ordinary shares in connection therewith.\n- On May 21, 2021 and August 20, 2021, an aggregate of $1,380,000 and $1,380,000, respectively, was deposited by JHD into the trust account to extend the date by which the Company had to consummate a Business Combination from May 24, 2021 to August 24, 2021, and from August 24, 2021 to November 24, 2021.\n- As such, the Company recorded a $3,723,000, $2,069,000 and $0 derivate liability related to the FPA as of November 24, 2021, December 31, 2021 and June 30, 2022, respectively, on the Company’s consolidated balance sheet.\n- On May 21, 2021, an aggregate of $1,380,000 was deposited by JHD Holdings (Cayman) Limited, a Cayman Islands company (“JHD”), into the trust account of the Company for the Company’s public shareholders, representing $0.10 per public share, which enabled the Company to extend the period of time it had to consummate its Business Combination by three months to August 24, 2021.\n- As of June 30, 2022, the",
        "target": [
            "|   | **For the Six Months Ended June 30, ** |   |",
            "| --- | --- | --- |",
            "|   | **2022 ** | **2021 ** |",
            "| **Net loss ** | $ (1,317,744)  | $ (1,033,891)  |",
            "| **Change in fair value of derivative warrant liabilities ** | 570,000  | (35,600)  |",
            "| **Change in fair value of forward purchase agreement ** | (2,069,000)  | - |",
            "| **Extension incentive paid by Founder Shares transferred ** | 1,900,800  | - |",
            "| **Interest earned on investments held in the trust account ** | (40,526)  | (6,902)  |",
            "| **Cash Withdrawn from trust account upon redemption of 361 ordinary shares ** | 3,704  | - |",
            "| **Investment of cash for extension into trust account ** | - | (1,380,000)  |",
            "| **Net cash provided by (used in) investing activities ** | - | (1,380,000)  |",
            "| **Proceeds from promissory note - ICONIQ ** | 568,000  | - |",
            "| **Proceeds from extension loans - related party ** | - | 1,380,000  |",
            "| **Cash - End of period ** | $ 3,719  | - |"
        ]
    },
    "f10q0622_eaststoneacq_fileoutpart1": {
        "predict": "|   | **June 30, 2022** | **December 31, 2021** |\n| --- | --- | --- |\n| **Cash** | $3,719 |   |\n| **Investments held in trust account** | $33,541,649 (including $2,760,000 deposited for the two three-month extensions from May 24, 2021 to November 24, 2021) | $33,504,825 |\n| **Promissory note payable to shareholders** |   |   |\n| **Promissory note payable** |   |   |\n| **Promissory note payable to ICONIQ** |   |   |\n| **Extension loan** | $2,760,000 | $2,760,000 |\n| **Deferred underwriting commission** |   | $402,500 (payable at the consummation of the Business Combination) |\n| **Derivative liabilities of forward share purchase, an option to sell 2,923,974 redeemable ordinary shares, no par value, at December 31, 2021** |   | $2,069,000 |\n| **Ordinary shares subject to possible redemption, no par value, 3,264,744 and 3,265,105 at June 30, 2022 and December 31, 2021, at redemption value of approximately $10.27 and $10.26 per share, respectively** |   |   |\n\nGuidelines:\n\n- As of June 30, 2022, the Company had investments held in the trust account of $33,541,649 (including $2,760,000 deposited for the two three-month extensions from May 24, 2021 to November 24, 2021).\n- As of June 30, 2022 and December 31, 2021, the Company had an extension loan balance of $2,760,000.\n- The deferred underwriting commission of $402,500 is to be paid out of the trust account to I-Bankers and EarlyBird only on completion of the Company’s Business Combination.\n- Recognized a decrease in the fair value of forward share purchase of $2,069,000.\n- As of June 30, 2022, the Company had fully drawn down the Yellow River Note of $200,000 (see Note 6).\n- As of June 30, 2022 and December 31, 2021, the outstanding balance of the Yellow River Note payable was at $200,000.\n- Chunyi (Charlie) Hao, the Company’s Chairman of the Board and Chief Financial Officer, has loaned the Company $471,459 as Working Capital Loans.\n- As of June 30, 2022, the Company had $3,719 in its operating bank account and $33,541,649 in money market funds held in the trust account to be used for a Business Combination or to repurchase or redeem its ordinary shares in connection therewith. \n- In accordance with the Business Combination Agreement, JHD has loaned to the Company a sum of $2,760,000 on the Sponsor’s behalf in order to support the Extension.\n- Of the total $4,154,255 transactions cost, the cash transaction costs amounted to $3,083,255, of which $2,415,000 of underwriting fees, including $402,500 of deferred underwriting fees, payable at the consummation of the Business Combination (as described below), and $668,255 of other offering costs of legal, accounting and other expenses incurred through the IPO that are directly related to the IPO.\n- Chunyi (Charlie) Hao had loaned to the Company an aggregate of $471,459 of Working Capital Loans.\n- As of June 30, 2022, we had cash of $3,719 held outside",
        "target": [
            "|   | **June 30, 2022 ** | **December 31, 2021 ** |",
            "| --- | --- | --- |",
            "| **Cash ** | $ 3,719  | - |",
            "| **Investments held in trust account ** | 33,541,649  | 33,504,825  |",
            "| **Promissory note payable to shareholders ** | 471,459  | 350,000  |",
            "| **Promissory note payable ** | 200,000  | 200,000  |",
            "| **Promissory note payable to ICONIQ ** | 568,000  | - |",
            "| **Extension loan ** | 2,760,000  | 2,760,000  |",
            "| **Deferred underwriting commission ** | 402,500  | 402,500  |",
            "| **Derivative liabilities of forward share purchase, an option to sell 2,923,974 redeemable ordinary shares, no par value, at December 31, 2021 ** | - | 2,069,000  |",
            "| **Ordinary shares subject to possible redemption, no par value, 3,264,744 and 3,265,105 at June 30, 2022 and December 31, 2021, at redemption value of approximately $10.27 and $10.26 per share, respectively ** | 33,541,649  | - |"
        ]
    },
    "msb-20210731x10q_fileoutpart7": {
        "predict": "|   | **Unallocated Reserve** | **Total** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Net income** |   |   |<NEWLINE>| **Balances at July 31, 2021** |   |   |\n|---|---|---|---|---|---|---|---|---|---|\n|As of January 31, 2021|   |   |   |   |   |   |   |   |   |\n|Increase in Unallocated Reserve| $22,472,290 |   |   |   |   |   |   |   |   |\n|Unallocated Reserve as of July 31, 2021| $38,949,336 |   |   |   |   |   |   |   |   |\n|---|---|---|---|---|---|---|---|---|---|\n|Net income for the six months ended July 31, 2021| $35,329,900 |   |   |   |   |   |   |   |   |\n|Increase in Net income| $27,042,276 |   |   |   |   |   |   |   |   |\n|---|---|---|---|---|---|---|---|---|---|\n|Balances at July 31, 2021|   |   |   |   |   |   |   |   |   |",
        "target": [
            "|   | **Unallocated Reserve ** | **Total ** |",
            "| --- | --- | --- |",
            "| **Net income ** | 35,329,900  | 35,329,900  |",
            "| **Balances at July 31, 2021 ** | $ 38,949,336  | - |"
        ]
    },
    "msb-20210731x10q_fileoutpart2": {
        "predict": "| **Accrued income receivable** |   |   |\n| --- | --- | --- |\n| As of July 31, 2021, the Trust recorded accrued income receivable of $12,634,653 (unaudited) |   |   |\n| As of January 31, 2021, the Trust recorded accrued income receivable of $249,477 |   |   |\n\n| **Contract asset** |   |   |\n| --- | --- | --- |\n| As of January 31, 2021, the Trust recorded a net contract asset of $177,251 |   |   |\n| Contract asset | $239,132 |   |\n| Contract liability | ($61,881) |   |\n\n| **Contract liability** |   |   |\n| --- | --- | --- |\n| As of July 31, 2021, a net contract liability of $896,931 is reflected on the Condensed Balance Sheet (unaudited) |   |   |\n\n| **Unallocated reserve** |   |   |\n| --- | --- | --- |\n| As of July 31, 2021, the Trust's Unallocated Reserve increased by $22,472,290 to $38,949,336 (unaudited) |   |   |\n| As of July 31, 2020, Unallocated Reserve was $12,115,431 |   |   |",
        "target": [
            "| **Accrued income receivable ** | 12,634,653  | 249,477  |",
            "| --- | --- | --- |",
            "| **Contract asset ** | - | 177,251  |",
            "| **Contract liability ** | 896,931  | - |",
            "| **Unallocated reserve ** | 38,949,336  | - |"
        ]
    },
    "msb-20210731x10q_fileoutpart11": {
        "predict": "| **Three Months Ended** | **Pellets Produced from Trust Lands (Tons)** | **Pellets Shipped from Trust Lands (Tons)** |\n| --- | --- | --- |\n| **July 31, 2021** | 1,157,588 | 1,446,876 |\n| **July 31, 2020** | (22,898) | 973,744 |",
        "target": [
            "| **Three Months Ended ** | **Pellets Produced from Trust Lands (Tons) ** | **Pellets Shipped from Trust Lands (Tons) ** |",
            "| --- | --- | --- |",
            "| **July 31, 2021 ** | 1,157,588  | 1,446,876  |",
            "| **July 31, 2020 ** | (22,898)  | 973,744  |"
        ]
    },
    "msb-20210731x10q_fileoutpart8": {
        "predict": "|   | **Unallocated Reserve** | **Total** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Net income** |   |   |<NEWLINE>| **Balances at July 31, 2021** |   |   |\n|---|---|---|---|---|---|---|---|---|---|---|\n| As of July 31, 2020 | $12,115,431 |   |<NEWLINE>|   |   |   |   |   |   |   |\n| As of July 31, 2021 | $38,949,336 |   |<NEWLINE>|   |   |   |   |   |   |   |\n| Increase | $22,472,290 |   |<NEWLINE>|   |   |   |   |   |   |   |\n| Fiscal year ended January 31, 2021 |   |   |<NEWLINE>|   |   |   |   |   |   |   |\n| Three months ended July 31, 2020 |   |   |<NEWLINE>| $6,676,003 |   |   |   |   |   |   |\n| Three months ended July 31, 2021 |   |   |<NEWLINE>| $26,756,030 |   |   |   |   |   |   |\n| Increase |   |   |<NEWLINE>| $20,080,027 |   |   |   |   |   |   |",
        "target": [
            "|   | **Unallocated Reserve ** | **Total ** |",
            "| --- | --- | --- |",
            "| **Net income ** | 26,756,030  | 26,756,030  |",
            "| **Balances at July 31, 2021 ** | $ 38,949,336  | - |"
        ]
    },
    "msb-20210731x10q_fileoutpart18": {
        "predict": "|   | **July 31, 2021** | **January 31, 2021** |\n| --- | --- | --- |\n| **Accrued Income Receivable** | $12,634,653 | $249,477 |\n| **Contract Asset** | $239,132 | $239,132 |\n|   |   | ($61,881) |\n| **Contract Liability** |   | ($896,931) |\n| **Unallocated Reserve** | $38,949,336 | $12,115,431 |",
        "target": [
            "|   | **July 31, 2021 ** | **January 31, 2021 ** |",
            "| --- | --- | --- |",
            "| **Accrued Income Receivable ** | $12,634,653  | $ 249,477  |",
            "| **Contract Asset ** | - | 177,251  |",
            "| **Contract Liability ** | (896,931)  | - |",
            "| **Unallocated Reserve ** | $38,949,336  | - |"
        ]
    },
    "bzrd10q_q3o_fileoutpart4": {
        "predict": "|   | **Blubuzzard, Inc. of Operations (Unaudited) For the Three Months Ended September 30, 2022 ** | **For the Three Months Ended September 30, 2021 ** | **For the Nine Months Ended September 30, 2022 ** | **For the Nine Months Ended September 30, 2021 ** |\n| --- | --- | --- | --- | --- |\n| **General and administrative expenses** |   |   |   |   |\n| **Total operating expenses** | $4,833 | $16,109 | $29,667 | $23,397 |\n| **Net loss** | $4,833 | $16,109 | $29,667 | $23,397 |\n| **Weighted average number of common shares - Basic and Diluted** | 729,483,160 |   | 729,483,160 |   |",
        "target": [
            "|   | **Blubuzzard, Inc. of Operations (Unaudited) For the Three Months Ended September 30, 2022 ** | **For the Three Months Ended September 30, 2021 ** | **For the Nine Months Ended September 30, 2022 ** | **For the Nine Months Ended September 30, 2021 ** |",
            "| --- | --- | --- | --- | --- |",
            "| **General and administrative expenses ** | $ 4,833  | $ 16,109 $  | 29,667 $  | 23,397  |",
            "| **Total operating expenses ** | 4,833  | 16,109  | 29,667  | 23,397  |",
            "| **Net loss ** | $ (4,833)  | (16,109) $  | (29,667) $  | (23,397)  |",
            "| **Weighted average number of common shares - Basic and Diluted ** | 729,483,160  | 729,483,160  | 729,483,160  | 729,483,160  |"
        ]
    },
    "j111921010q_fileoutpart3": {
        "predict": "|   | **For the Three Months Ended September 30, ** |   | **For the Nine Months Ended September 30, ** |   |\n| --- | --- | --- | --- | --- |\n|   | **2021** | **2020** | **2021** | **2020** |<NEWLINE>\n| **Compensation** |   |   |   |   |<NEWLINE>\n| **Total operating expenses** | $32,056 | $10,231 | $34,540 | $21,385 |<NEWLINE>\n| **Operating Loss** |   |   |   |   |<NEWLINE>\n| **Other income** |   |   | $886 (related to forgiveness of PPP loan) |   |<NEWLINE>\n| **Net loss before taxes** |   |   |   |   |<NEWLINE>\n| **Net Loss** | $32,056 | $10,231 | $33,656 | $21,385 |<NEWLINE>\n| **Internet Sciences, Inc.** |   |   |   |   |<NEWLINE>\n| **Comprehensive Loss** |   |   |   |   |\n\nGuidelines:\n\n- Total operating expenses and loss from operations for the nine months ended September 30, 2021 were $34,540 an increase of $13,155, or approximately 62%, from total operating expenses and loss from operations for the comparable nine months ended September 30, 2020 of $21,385\n- There was other income $886 for the nine months ended September 30, 2021, related to forgiveness of our PPP loan, and no other income or expense for the nine months ended September 30, 2020\n- Net cash flows used in operating activities for the nine months ended September 30, 2020 amounted to $7,836 and was attributable to our net loss of $21,385, stock based compensation of $6,300, a decrease in prepaid expenses of $1,000, an increase in security deposits of $1,800, and increases in accounts payable and accrued liabilities of $4,449\n- Net cash flows used in operating activities for the nine months ended September 30, 2021 amounted to $16,942 and was attributable to our net loss of $33,656, stock based compensation of $17,600, and forgiveness of PPP loan of $886\n- For the nine months ended September 30, 2021, the Company had a net loss of $33,656 and cash used in operating activities of $16,942\n- Total operating expenses and loss from operations for the three months ended September 30, 2021 were $32,056 an increase of $21,825, or approximately 213%, from total operating expenses and loss from operations for the comparable three months ended September 30, 2020 of $10,231\n- We reported a net loss of $32,056 and $33,656 for the three and nine months ended September 30, 2021, respectively, as compared to a net loss of $10,231 and $21,385 for the three and nine months ended September 30, 2020 due to the factors noted above",
        "target": [
            "|   | **For the Three Months Ended September 30, ** |   | **For the Nine Months Ended September 30, ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2021 ** | **2020 ** | **2021 ** | **2020 ** |",
            "| **Compensation ** | - | - | 17,600  | 6,300  |",
            "| **Total operating expenses ** | 32,056  | 10,231  | 34,540  | 21,385  |",
            "| **Operating Loss ** | (32,056)  | (10,231)  | (34,540)  | (21,385)  |",
            "| **Other income ** | - | - | 886  | - |",
            "| **Net loss before taxes ** | (32,056)  | (10,231)  | (33,656)  | (21,385)  |",
            "| **Net Loss ** | $ (32,056)  | $ (10,231)  | (33,656)  | (21,385)  |",
            "| **Internet Sciences, Inc. ** | (32,056)  | (10,231)  | (33,656)  | (21,385)  |",
            "| **Comprehensive Loss ** | $ (32,056)  | $ (10,231)  | $ (33,656)  | $ (21,385)  |"
        ]
    },
    "j111921010q_fileoutpart2": {
        "predict": "|   | **September 30, 2021** | **December 31, 2020** |\n| --- | --- | --- |\n| **Accounts payable and accrued liabilities** | $54,965 | $54,970 |\n| **Accounts payable and accrued liabilities – related party** | $4,985 | $20,985 |\n| **Due to related party** | $102,187 | $85,225 |\n| **Loans payable** | $881 |   |\n| **Common Stock Class A, 81,200,000 shares designated, 1,378,000 and 1,051,000 shares issued and outstanding, respectively** | $1,378 | $1,051 |\n| **Common Stock Class B, 18,800,000 shares designated, 18,800,000 shares issued and outstanding** | 18,800,000 | 18,800,000 |\n| **Accumulated deficit** | $348,615 |   |\n| **Total stockholders’ deficit** | ($162,117) |   |\n| **Total Stockholders' Deficit** | ($162,117) |   |\n\n**Guidelines:**\n\n- Accrued expenses and accounts payable for related party were $4,985 and $20,985, respectively as of September 30, 2021 and December 31, 2020\n- As of September 30, 2021 and December 31, 2020, the Company had 1,387,000 and 1,051,000, respectively, shares of common stock-class A issued and outstanding with a par value of $0.001 per share\n- Total accrual at September 30, 2021 and December 31, 2020 was $4,985 and $20,985, respectively\n- On May 7, 2020, the Company received an $881 loan pursuant to the Paycheck Protection Program established under the Cares Act (the “PPP Loan”)\n- As of September 30, 2021, the Company had an accumulated deficit of $348,615, a stockholders’ deficit of $162,117 and a working capital deficiency of $162,117\n- Our working capital deficit was $162,117 at September 30, 2021\n- As of September 30, 2021 and December 31, 2020, the Company had 18,800,000 shares of common stock-class B issued and outstanding\n- As of November 22, 2021 we had 1,387,000 Class A shares; 18,800,000 Class B Shares outstanding\n- As of September 30, 2021 and December 31, 2020, there was $102,187 and $85,225, respectively, due to the Company’s CEO\n- Accrued expenses and accounts payable were $54,965 and $54,970, respectively as of September 30, 2021 and December 31, 2020\n- The Company has authorized 100,000,000 shares of common stock, par value of $0.001 per share, with 81,200,000 shares of common stock -class A designated and 18,800,000 shares of common stock -class B designated\n- Net cash flows provided by financing activities were $7,815 for the nine months ended September 30, 2020, consisting of proceeds from related parties of $4,034, proceeds from issuance of common stock for $12,300, and PPP loan proceeds of $881, offset by repayments to our CEO of $9,400",
        "target": [
            "|   | **September 30, 2021 ** | **December 31, 2020 ** |",
            "| --- | --- | --- |",
            "| **Accounts payable and accrued liabilities ** | $ 54,965  | $ 54,970  |",
            "| **Accounts payable and accrued liabilities – related party ** | 4,985  | 20,985  |",
            "| **Due to related party ** | 102,187  | 85,225  |",
            "| **Loans payable ** | - | 881  |",
            "| **Common Stock Class A, 81,200,000 shares designated, 1,378,000 and 1,051,000 shares issued and outstanding, respectively ** | 1,387  | 1,051  |",
            "| **Common Stock Class B, 18,800,000 shares designated, 18,800,000 shares issued and outstanding ** | 18,800  | 18,800  |",
            "| **Accumulated deficit ** | (348,615)  | - |",
            "| **Total stockholders’ deficit ** | (162,117)  | - |",
            "| **Total Stockholders' Deficit ** | (162,117)  | - |"
        ]
    },
    "j111921010q_fileoutpart5": {
        "predict": "|   | **Nine Months Ended September 30, ** |   |\n| --- | --- | --- |\n|   | **2021 ** | **2020 ** |\n| **Net loss ** | $33,656 | $21,385 |\n| **Stock based compensation ** | $17,600 | $6,300 |\n| **Forgiveness of PPP loan ** | $886 |   |\n| **Prepaid expenses ** |   | -$1,000 |\n| **Security deposit ** |   | $1,800 |\n| **Net cash used in operating activities ** | -$16,942 | -$7,836 |\n| **Proceeds from related party ** | $16,962 | $4,034 |\n| **Proceeds from issuance of common stock ** | $0 | $12,300 |\n| **Repayment to related party ** |   | -$9,400 |\n| **Proceeds from loans ** |   | $881 |\n| **Net cash provided by financing activities ** | $16,962 | $7,815 |\n| **Cash at end of period ** | $20 |   |\n| **Issuance of common shares for repayment of related party accruals ** |   |   |\n\nNote: \n- Net loss for the nine months ended September 30, 2021 includes forgiveness of PPP loan of $886.\n- Prepaid expenses decreased by $1,000 for the nine months ended September 30, 2020.\n- Security deposit increased by $1,800 for the nine months ended September 30, 2020.\n- Net cash used in operating activities for the nine months ended September 30, 2021 was attributable to net loss of $33,656, stock based compensation of $17,600, and forgiveness of PPP loan of $886.\n- Proceeds from issuance of common stock for the nine months ended September 30, 2021 and 2020 are for services rendered and satisfaction of previously accrued compensation, respectively.\n- The Company had no further obligations related to the PPP Loan after the forgiveness application and accrued interest totaling $886 was approved in full during April 2021.\n- During the nine months ended September 30, 2021 and 2020, the Company received advances from its CEO totaling $16,962 and $4,034, respectively, and repaid $0 and $9,400, respectively.\n- Accrued wages totaling $16,000 owed to the Chief Executive Officer were recorded during the year ended December 31, 2020.\n- The increase in total operating expenses and loss from operations for the nine months ended September 30, 2021 as compared to the same period in 2020 is approximately 62% or $13,155.\n- There was other income of $886 related to forgiveness of PPP loan for the nine months ended September 30, 2021, and no other income or expense for the same period in 2020.\n- The Company issued 50,000 shares of class A common stock to its CEO for $5,000 in services rendered, 13,000 share of class A common stock to independent contractors for $1,300 in services rendered, and 123,000 shares of class A common stock to independent investors for $12,300 in cash for the nine months ended September 30, 2020.",
        "target": [
            "|   | **Nine Months Ended September 30, ** |   |",
            "| --- | --- | --- |",
            "|   | **2021 ** | **2020 ** |",
            "| **Net loss ** | $ (33,656)  | $ (21,385)  |",
            "| **Stock based compensation ** | 17,600  | 6,300  |",
            "| **Forgiveness of PPP loan ** | (886)  | - |",
            "| **Prepaid expenses ** | - | 1,000  |",
            "| **Security deposit ** | - | 1,800  |",
            "| **Net cash used in operating activities ** | (16,942)  | (7,836)  |",
            "| **Proceeds from related party ** | 16,962  | 4,034  |",
            "| **Proceeds from issuance of common stock ** | - | 12,300  |",
            "| **Repayment to related party ** | - | (9,400)  |",
            "| **Proceeds from loans ** | - | 881  |",
            "| **Net cash provided by financing activities ** | 16,962  | 7,815  |",
            "| **Cash at end of period ** | $ 20  | - |",
            "| **Issuance of common shares for repayment of related party accruals ** | $ 16,000  | - |"
        ]
    },
    "jksm_10q_fileoutpart6": {
        "predict": "|   | **Three Months ended March 31, 2023 ** | **Three Months ended March 31, 2022 ** |\n| --- | --- | --- |\n| **Machine sales ** | $343,000 | $1,033,123 |\n| **Non-Machine sales ** | $285,425 | $743,952 |\n| **Total sales ** | $628,425 | $1,770,075 |",
        "target": [
            "|   | **Three Months ended March 31, 2023 ** | **Three Months ended March 31, 2022 ** |",
            "| --- | --- | --- |",
            "| **Machine sales ** | $ 343,000  | $ 1,033,123  |",
            "| **Non-Machine sales ** | 285,425  | 743,952  |",
            "| **Total sales ** | $ 628,425  | - |"
        ]
    },
    "jksm_10q_fileoutpart3": {
        "predict": "|   | **March 31, 2023** | **March 31, 2022** |\n| --- | --- | --- |\n| **Sales** | $628,425 (machine sales: $343,000; non-machine sales: $285,425) | $1,770,075 (machine sales: $1,033,123; non-machine sales: $743,952) |\n| **Cost of sales** | $405,312 | $1,358,438 |\n| **Salaries and wages (including contractors)** | $112,887 | $267,644 |\n| **Other selling, general and administrative expenses** | $130,736 | $149,613 |\n| **Total operating expenses** | $243,623 | $417,257 |\n| **Income (loss) from operations** | ($20,510) | $1,380 |\n| **Derivative gain (loss)** | $123,301 | $287,098 |\n| **Interest expense** | $47,362 | $259,094 |\n| **Net income (loss)** | $55,429 | $29,384 |\n| **Basic** |   |   |",
        "target": [
            "|   | **March 31, 2023 ** | **March 31, 2022 ** |",
            "| --- | --- | --- |",
            "| **Sales ** | $ 628,425  | - |",
            "| **Cost of sales ** | 405,312  | 1,358,438  |",
            "| **Salaries and wages (including contractors) ** | 112,887  | 267,644  |",
            "| **Other selling, general and administrative expenses ** | 130,736  | 149,613  |",
            "| **Total operating expenses ** | 243,623  | 417,257  |",
            "| **Income (loss) from operations ** | (20,510)  | 1,380  |",
            "| **Derivative gain (loss) ** | 123,301  | 287,098  |",
            "| **Interest expense ** | (47,362)  | (259,094)  |",
            "| **Net income (loss) ** | 55,429  | 29,384  |",
            "| **Basic ** | 81,088,719  | - |"
        ]
    },
    "jksm_10q_fileoutpart10": {
        "predict": "|   | **March 31, 2023** | **December 31, 2022** |\n| --- | --- | --- |\n| **SBA loan May 2020** | $143,901 | $144,739 |\n| **Note payable September 2021** |   | $52,475 |\n| **Note Payable September 2022** | $635,658 (-$94,095) | $730,783 (-$121,310) |\n| **Less: discount and deferred ﬁnance costs** |   |   |\n\nGuidelines:\n- As of March 31, 2023 and December 31, 2022, the Company owed a principal amount of $143,901 and $144,739 under the SBA loan May 2020.\n- In December 2022, the Company received cash proceeds of $52,475 under an unsecured short term financing agreement for the Note payable September 2021.\n- As of March 31, 2023 and December 31, 2022, the Company owed a principal amount of $635,658 and $730,783 under the Note Payable September 2022, with remaining unamortized discount of $94,095 and $121,310, respectively.",
        "target": [
            "|   | **March 31, 2023 ** | **December 31, 2022 ** |",
            "| --- | --- | --- |",
            "| **SBA loan May 2020 ** | $ 143,901  | $ 144,739  |",
            "| **Note payable September 2021 ** | - | 635,658  |",
            "| **Note Payable September 2022 ** | - | 52,475  |",
            "| **Less: discount and deferred ﬁnance costs ** | - | (94,095)  |"
        ]
    },
    "mepw_2022mar21-10q_fileoutpart4": {
        "predict": "|   | ** Common Stock  Shares ** | **Accumulated Deﬁcit  ** | **Total Stockholders' Deﬁciency ** |\n| --- | --- | --- | --- |\n| **Balance at December 31, 2021** | 227,375,000 | ($95,676) | ($95,676) |\n| **Net Loss for the Three Months Ended March 31, 2022** |   | ($1,469) | ($1,469) |\n| **Balance at March 31, 2022** | 227,375,000 | ($97,145) | ($97,145) | \n\nGuidelines:\n- Operating expenses for the three months ended March 31, 2022 were $1,469, compared with $1,599 for the three months ended March 31, 2021. This information is reflected in the \"Net Loss for the Three Months Ended March 31, 2022\" row under the \"Accumulated Deﬁcit\" and \"Total Stockholders' Deﬁciency\" columns.\n- As at March 31, 2022, the company had a working capital deficit of $43,589 compared with a working capital of $42,120 as at December 31, 2021. This information is not reflected in the table as there is no specific column for working capital.\n- Net loss for the three months ended March 31, 2022 was $1,469, compared with $1,599 for the three months ended March 31, 2021. This information is reflected in the \"Net Loss for the Three Months Ended March 31, 2022\" row under the \"Accumulated Deﬁcit\" and \"Total Stockholders' Deﬁciency\" columns.\n- There were 227,375,000 common shares issued and outstanding at December 31, 2021 and March 31, 2022. This information is reflected in the \"Common Stock Shares\" column for both the \"Balance at December 31, 2021\" and \"Balance at March 31, 2022\" rows.\n- The Company has incurred a loss since Inception (October 28, 2014) resulting in an accumulated deficit of $95,676 as of March 31, 2022 and further losses are anticipated in the development of its business. This information is reflected in the \"Accumulated Deﬁcit\" column for both the \"Balance at December 31, 2021\" and \"Balance at March 31, 2022\" rows.\n- As at March 31, 2022, the company had total liabilities of $43,589 compared with total liabilities of $42,120 as at December 31, 2021. This information is not reflected in the table as there is no specific column for total liabilities.\n- There were 227,375,000 shares issued and outstanding at December 31, 2021 and March 31, 2022. This information is reflected in the \"Common Stock Shares\" column for both the \"Balance at December 31, 2021\" and \"Balance at March 31, 2022\" rows.\n- As of March 31, 2022, the Company had net operating loss carry forwards of approximately $95,676 that may be available to reduce future years' taxable income in varying amounts through 2042. This information is not reflected in the table as there is no specific column for net operating loss carry forwards.",
        "target": [
            "|   | ** Common Stock  Shares ** | **Accumulated Deﬁcit  ** | **Total Stockholders' Deﬁciency ** |",
            "| --- | --- | --- | --- |",
            "| **Balance at December 31, 2021 ** | 227,375,000  | - | $ (42,120)  |",
            "| **Net Loss for the Three Months Ended March 31, 2022 ** | - | $ (1,469)  | $ (1,469)  |",
            "| **Balance at March 31, 2022 ** | 227,375,000  | $ (95,676)  | $ (43,589)  |"
        ]
    },
    "mepw_2022mar21-10q_fileoutpart8": {
        "predict": "|   | **As at March      31, 2022 ** | **As at December 31, 2021 ** |\n| --- | --- | --- |\n| **Current Assets** | $0 | $0 |\n| **Current Liabilities** | $43,589 | $42,120 |\n| **Working Capital (deficiency)** | $(43,589)$ | $42,120$ |",
        "target": [
            "|   | **As at March      31, 2022 ** | **As at December 31, 2021 ** |",
            "| --- | --- | --- |",
            "| **Current Assets ** | $ 0  | $ 0  |",
            "| **Current Liabilities ** | $ 43,589  | $ 42,120  |",
            "| **Working Capital (deficiency) ** | $ (43,589)  | $ (42,120)  |"
        ]
    },
    "mepw_2022mar21-10q_fileoutpart9": {
        "predict": "| **Cash Flows** | **Three months Ended March 31, 2022** | **Three months Ended March 31, 2021** |\n| --- | --- | --- |\n| **Net cash used in operating activities** | $1,940 | $0 |\n| **Net cash used in investing activities** |  |  |\n| **Net cash provided by financing activities** | $1,940 | $0 |",
        "target": [
            "| **Cash Flows ** | **Three months Ended March 31, 2022 ** | **Three months Ended March    31, 2021 ** |",
            "| --- | --- | --- |",
            "| **Net cash used in operating activities ** | $ (1,940)  | $ 0  |",
            "| **Net cash used in investing activities ** | $ 0  | - |",
            "| **Net cash provided by financing activities ** | $ 1,940  | $ 0  |"
        ]
    },
    "iraa-20220630x10q_fileoutpart3": {
        "predict": "|   | **Class B Common Stock ** | **Additional Paid-in Capital ** | **Accumulated Deficit ** | **Total Stockholders’ Deficit** |\n| --- | --- | --- | --- | --- |\n|   | **Shares ** |   |   |   |\n| **Balance - December 31, 2021 ** | 6,900,000 |   |   |   |\n| **Balance as of March 31, 2022 (Unaudited) ** | 6,900,000 |   |   |   |\n| **Forgiveness of payable due to an affiliate of the Sponsor ** |   |   |   |   |\n| **Net income ** |   |   | ($3,712,688) |   |\n| **Balance as of June 30, 2022 (Unaudited) ** | 6,900,000 |   | ($3,712,688) | ($3,712,688) |\n\nGuidelines:\n\nFor the three months ended June 30, 2022, we had net income of approximately $3,712,688, which consisted of a $4,211,660 gain on the change in fair value of warrants and interest income on investments held in the Trust Account of $161,103, partially offset by unrealized losses on investments held in the Trust Account of $368,082 and $291,993 of formation and operating costs.\n\nAs of August 18, 2022, there were 27,600,000 shares of the registrant’s Class A common stock, par value $0.0001 per share, issued and outstanding, and 6,900,000 shares of the registrant’s Class B common stock, par value $0.0001 per share, issued and outstanding.\n\nFollowing the withdrawal of Tribe as a member of the Sponsor, the $140,000 of administrative expense payable as of June 1, 2022 was forgiven and reclassified as a capital contribution.\n\nIn February 2021, the Company effected a stock dividend of 0.2 shares for each share of Class B common stock outstanding, resulting in the Sponsor holding an aggregate of 6,900,000 Founder Shares (up to an aggregate of 900,000 of which were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option is exercised).\n\nAt both June 30, 2022 and December 31, 2021, there were 6,900,000 shares of Class B common stock outstanding.",
        "target": [
            "|   | **Class B Common Stock ** | **Additional Paid-in Capital ** | **Accumulated Deficit ** | **Total Stockholders’ Deficit** |",
            "| --- | --- | --- | --- | --- |",
            "|   | **Shares ** |   |   |   |",
            "| **Balance - December 31, 2021 ** | 6,900,000  | - | - | - |",
            "| **Balance as of March 31, 2022 (Unaudited) ** | 6,900,000  | - | - | - |",
            "| **Forgiveness of payable due to an affiliate of the Sponsor ** | - | 140,000  | - | 140,000  |",
            "| **Net income ** | - | - | 3,712,688  | 3,712,688  |",
            "| **Balance as of June 30, 2022 (Unaudited) ** | 6,900,000  | $140,000  | - | - |"
        ]
    },
    "iraa-20220630x10q_fileoutpart2": {
        "predict": "|   | **Three Months Ended June 30, ** |   | **Six Months Ended June 30, ** |   |\n| --- | --- | --- | --- | --- |\n|   | **2022** | **2021** | **2022** | **2021** |\n| **Formation and operating costs** |   | $291,993 |   | $793,254 |\n| **Loss from operations** |   |   |   |   |\n| **Change in fair value of warrant liability** | $4,211,660 | $229,859 | $8,605,210 | ($430,086) |\n| **Interest income on marketable securities held in Trust Account** | $161,103 | $4,310 | $167,910 | $4,310 |\n| **Unrealized loss on investments held in Trust Account** | ($368,082) |   | ($368,082) |   |\n| **Offering costs** |   |   |   | $606,622 |\n| **Excess of fair value of Private Warrants over proceeds received** |   |   |   | $298,825 |\n| **Net income (loss)** | $3,712,688 | ($161,064) | $7,528,415 | ($2,124,477) |\n| **Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption** |   |   |   |   |\n| **Basic and diluted weighted average shares outstanding, Class B common stock** |   |   |   |   |\n\nNote: All amounts in USD thousands.\n\nGuidelines used to generate table:\n\n- For the three months ended June 30, 2021, we had a net loss of $161,064, which consisted of approximately $395,233 of formation and operating costs, partially offset by a gain on the change in fair value of warrants $229,859 and interest income on investments held in the Trust Account for $4,310.\n- Offering costs totaled $15,627,893 (consisting of $5,520,000 of underwriting discount, $9,660,000 of deferred underwriting discount, and $447,893 of other offering costs) were recognized, of which $606,622 was (i) allocated to the public warrants and Private Warrants and (ii) included in the statement of operations, and $15,021,271 was charged directly to stockholders’ equity.\n- For the three months ended June 30, 2022, we had net income of approximately $3,712,688, which consisted of a $4,211,660 gain on the change in fair value of warrants and interest income on investments held in the Trust Account of $161,103, partially offset by unrealized losses on investments held in the Trust Account of $368,082 and $291,993 of formation and operating costs.\n- As of August 18, 2022, there were 27,600,000 shares of the registrant’s Class A common stock, par value $0.0001 per share, issued and outstanding, and 6,900,000 shares of the registrant’s Class B common stock, par value $0.0001 per share, issued and outstanding.\n- For the six months ended June 30, 2021, net cash used in operating activities was $859,128, which was due to our net loss of $2,124,477, change in operating assets and liabilities of $65,874, and interest earned on investments held.\n- At both June 30, 2022 and December 31, 2021, there were 27,600,000 shares issued and outstanding, all of which are subject to possible redemption.\n- For the six months ended June 30, 2022, we had net income",
        "target": [
            "|   | **Three Months Ended June 30, ** |   | **Six Months Ended June 30, ** |   |",
            "| --- | --- | --- | --- | --- |",
            "|   | **2022 ** | **2021 ** | **2022 ** | **2021 ** |",
            "| **Formation and operating costs ** | $ 291,993  | $ 395,233  | $ 876,623  | $ 793,254  |",
            "| **Loss from operations ** | (291,993)  | (395,233)  | (876,623)  | (793,254)  |",
            "| **Change in fair value of warrant liability ** | 4,211,660  | 229,859  | 8,605,210  | (430,086)  |",
            "| **Interest income on marketable securities held in Trust Account ** | 161,103  | 4,310  | 167,910  | 4,310  |",
            "| **Unrealized loss on investments held in Trust Account ** | (368,082)  | - | (368,082)  | - |",
            "| **Offering costs ** | - | - | - | (606,622)  |",
            "| **Excess of fair value of Private Warrants over proceeds received ** | - | - | - | (298,825)  |",
            "| **Net income (loss) ** | $ 3,712,688  | $ (161,064)  | $ 7,528,415  | $ (2,124,477)  |",
            "| **Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption ** | 27,600,000  | 27,600,000  | 27,600,000  | 27,600,000  |",
            "| **Basic and diluted weighted average shares outstanding, Class B common stock ** | 6,900,000  | 6,900,000  | 6,900,000  | 6,900,000  |"
        ]
    },
    "iraa-20220630x10q_fileoutpart5": {
        "predict": "|   | **Six Months Ended June 30, ** |   |\n| --- | --- | --- |\n|   | **2022** | **2021** |\n| **Net income (loss)** | $7,528,415 | ($2,124,477) |\n| **Excess of fair value of Private Warrants over proceeds received** |   | $298,825 |\n| **(Gain) loss on change in fair value of warrant liability** | ($8,605,210) | ($430,086) |\n| **Interest earned on cash and Investments held in Trust Account** | $167,910 | $4,310 |\n| **Unrealized loss on Investments held in Trust Account** | ($368,082) |   |\n| **Offering Costs** |   | $606,622 |\n| **Franchise tax payable** |   |   |\n| **Net cash used in operating activities** | ($585,799) | ($859,128) |\n| **Cash Deposited in Trust Account** |   | $276,000,000 |\n| **Net cash used in investing activities** |   | ($276,000,000) |\n| **Proceeds from sale of Units, net of offering costs** |   | $275,552,107 |\n| **Proceeds from issuance of Private Warrants** | $7,520,000 |   |\n| **Payment of underwriter discount** | ($5,520,000) |   |\n| **Proceeds from promissory note – related party** | $300,000 |   |\n| **Net cash provided by financing activities** | $300,000 | $277,552,107 |\n| **Cash, beginning of period** | $336,228 |   |\n| **Cash, end of period** | $50,429 |   |\n| **Deferred underwriting fee payable charged to additional paid-in capital** |   | $9,660,000 |\n| **Forgiveness of payable due to an affiliate of the Sponsor** |   | $140,000 |\n\nGuidelines:\n\n- For the six months ended June 30, 2021, we had a net loss of $2,124,477, which consisted of $793,254 of formation and operating costs, a loss on the change in fair value of warrants of $430,086, $606,622 in expensed offering costs, and $298,825 in excess fair value of Private Warrants over proceeds received, partially offset by interest income on investments held in the Trust Account of $4,310.\n- Offering costs totaled $15,627,893 (consisting of $5,520,000 of underwriting discount, $9,660,000 of deferred underwriting discount, and $447,893 of other offering costs) were recognized, of which $606,622 was (i) allocated to the public warrants and Private Warrants and (ii) included in the statement of operations, and $15,021,271 was charged directly to stockholders’ equity.\n- Following the closing of the IPO on March 9, 2021, $276,000,000 (approximately $10.00 per Unit) from the net proceeds of the sale of the Units in the IPO, including the proceeds from the sale of the Private Warrants, was deposited in a trust account (“Trust Account”), located in the United States with Continental Stock Transfer & Trust Company acting as trustee, and will be invested only in U.S.\n- The Company paid an underwriting fee at the closing of the IPO of $5,520,000.\n- For the six months ended June 30, 2022, we had net income of $7,528,415, which consisted of a change in the fair value of warrant of $8,605,210 and interest income on investments held in the Trust Account of $167",
        "target": [
            "|   | **Six Months Ended June 30, ** |   |",
            "| --- | --- | --- |",
            "|   | **2022 ** | **2021 ** |",
            "| **Net income (loss) ** | $ 7,528,415  | $ (2,124,477)  |",
            "| **Excess of fair value of Private Warrants over proceeds received ** | - | 298,825  |",
            "| **(Gain) loss on change in fair value of warrant liability ** | (8,605,210)  | 430,086  |",
            "| **Interest earned on cash and Investments held in Trust Account ** | (167,910)  | (4,310)  |",
            "| **Unrealized loss on Investments held in Trust Account ** | 368,082  | - |",
            "| **Offering Costs ** | - | 606,622  |",
            "| **Franchise tax payable ** | 100,000  | 100,000  |",
            "| **Net cash used in operating activities ** | (585,799)  | (859,128)  |",
            "| **Cash Deposited in Trust Account ** | - | (276,000,000)  |",
            "| **Net cash used in investing activities ** | - | (276,000,000)  |",
            "| **Proceeds from sale of Units, net of offering costs ** | - | 275,552,107  |",
            "| **Proceeds from issuance of Private Warrants ** | - | 7,520,000  |",
            "| **Payment of underwriter discount ** | - | (5,520,000)  |",
            "| **Proceeds from promissory note – related party ** | 300,000  | - |",
            "| **Net cash provided by financing activities ** | 300,000  | 277,552,107  |",
            "| **Cash, beginning of period ** | 336,228  | - |",
            "| **Cash, end of period ** | $ 50,429  | - |",
            "| **Deferred underwriting fee payable charged to additional paid-in capital ** | - | $ 9,660,000  |",
            "| **Forgiveness of payable due to an affiliate of the Sponsor ** | $ 140,000  | - |"
        ]
    },
    "pacq20200331_10q_fileoutpart3": {
        "predict": "|   | **For the three months ended March 31, ** |   |<NEWLINE>|   | **2020 ** | **2019 ** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Administrative expenses ** | $30,000 | $30,000 |<NEWLINE>| **General expenses ** |   |   |<NEWLINE>| **Franchise taxes ** | $50,450 | $57,968 |<NEWLINE>| **Other income - investment income on Trust Account ** | $1,182,962 | $2,434,969 |<NEWLINE>| **Income tax provision ** | $229,081 | $500,833 |<NEWLINE>| **Net income (loss) attributable to common shares ** | ($311,195) | $1,745,005 |<NEWLINE>| **Class A common stock ** |   |   |<NEWLINE>| **Class B common stock ** |   |   |\n\nGuidelines:\n\n- At March 31, 2020, the Company had a cash balance of $107,532, which excludes interest income of $1,182,962 earned during the year from the Company’s investments in the Trust Account, which is available to the Company for its tax obligations.\n- If we are unable to deliver registered shares of Class A common stock to the holder upon exercise of warrants issued in connection with the 41,400,000 units during the exercise period, the warrants will expire worthless, except to the extent that they may be exercised on a cashless basis in the circumstances described in the agreement governing the warrants.\n- As of May 14, 2020, there were 35,616,199 shares of Class A common stock, par value $0.0001 per share, and 10,350,000 shares of Class B common stock, par value $0.0001 per share, outstanding.\n- For the three months ended March 31, 2019, we had a net income of $1,745,005 which consisted of interest income held in the Trust Account of $2,434,969 partially offset by operating costs of $101,163, administrative service fees of $30,000, franchise taxes of $57,968 and an income tax provision of $500,833.\n- The Company incurred expenses of $30,000 and $30,000 for administrative services for three months ended March 31, 2020 and 2019, respectively.\n- If we are unable to deliver registered shares of Class A common stock to the holder upon exercise of warrants issued in connection with the 41,400,000 units during the exercise period, the warrants will expire worthless, except to the extent that they may be exercised on a cashless basis in the circumstances described in the agreement governing the warrants.\n- At March 31, 2020, our Sponsor, our initial stockholders and our independent directors held, collectively, 10,350,000 founders’ shares.\n- On April 17, 2018 (the “IPO Closing Date”), we consummated our initial public offering of 41,400,000 units, representing a complete exercise of the over-allotment option, at a purchase price of $10.00 per unit, generating gross proceeds of $414,000,000 before underwriting discounts and expenses (the “Public Offering”).\n- In April 2018, we effected a stock dividend of 0.2 shares of Class B common stock for each outstanding share of Class B common stock, resulting in our Sponsor and independent director nominees holding an aggregate of 10,350,000 founders’ shares.\n- Net income per common share for basic and diluted for Class A common stock is calculated by dividing the interest income earned on the Trust Account of $1,182,962 and $2,434,969, respectively, net of applicable",
        "target": [
            "|   | **For the three months ended March 31, ** |   |",
            "|   | **2020 ** | **2019 ** |",
            "| --- | --- | --- |",
            "| **Administrative expenses ** | 30,000  | 30,000  |",
            "| **General expenses ** | 1,184,626  | 101,163  |",
            "| **Franchise taxes ** | 50,450  | 57,968  |",
            "| **Other income - investment income on Trust Account ** | 1,182,962  | 2,434,969  |",
            "| **Income tax provision ** | 229,081  | 500,833  |",
            "| **Net income (loss) attributable to common shares ** | $ (311,195)  | $ 1,745,005  |",
            "| **Class A common stock ** | 36,819,386  | 41,400,000  |",
            "| **Class B common stock ** | 10,350,000  | 10,350,000  |"
        ]
    },
    "lcahu-20210930x10q_fileoutpart2": {
        "predict": "|   | **Three months ended September 30, 2021 ** | **Nine months ended September 30, 2021 ** | **For the period from August 13, 2020 (inception) through September 30, 2020 ** |\n| --- | --- | --- | --- |\n| **Interest income ** |   |   |   |\n| **Gain (loss) on warrant derivative liability ** | $1,250,000 | $12,500,000 |   |\n| **Income before taxes ** |   |   |   |\n| **Net income ** | $321,123 | $10,268,480 |   |\n| **Net income per share ** | $0.01 | $0.16 |   |\n| **Basic and diluted weighted average number of shares outstanding ** |   |   |   |\n| **Net income per share ** |   |   |   |\n\nGuidelines:\n- For the three and nine months ended September 30, 2021, we recorded a gain related to the change in fair value of warrant derivative liability of $1,250,000 and $12,500,000, respectively, in other income and expense on our statement of operations.\n- For the three and nine months ended September 30, 2021, the Company reported income available to common shareholders of $0.01 and $0.16, respectively.\n- For the nine months ended September 30, 2021, we had a net income of $10,268,480 related to $1,172,311 of general and administrative costs related to the formation of the Company and on-going expenses as we search for a Business Combination and $140,000 in management fees, and $942,390 in offering costs expensed, offset by a $12,500,000 gain of related to the change in the fair value of the warrant derivative liability and $23,181 in earnings on the Trust Account assets.\n- As of September 30, 2021, JFG and TJF each owned 6,250,000 Founder Shares.\n- For the three months ended September 30, 2021, we had a net income of $321,123 related to $876,559 of general and administrative costs related to expenses as we search for a Business Combination and $60,000 in management fees, offset by a $1,250,000 gain related to the change in the fair value of the warrant derivative liability, and $7,682 in earnings on the Trust Account assets.",
        "target": [
            "|   | **Three months ended September 30, 2021 ** | **Nine months ended September 30, 2021 ** | **For the period from August 13, 2020 (inception) through September 30, 2020 ** |",
            "| **Interest income ** | 7,682  | 23,181  | - |",
            "| --- | --- | --- | --- |",
            "| **Gain (loss) on warrant derivative liability ** | 1,250,000  | - | - |",
            "| **Income before taxes ** | 321,123  | 10,268,480  | - |",
            "| **Net income ** | $ 321,123  | $ 10,268,480  | - |",
            "| **Net income per share ** | $ 0.01  | $ 0.16  | - |",
            "| **Basic and diluted weighted average number of shares outstanding ** | - | - | 6,250,000  |",
            "| **Net income per share ** | $ 0.01  | $ 0.16  | - |"
        ]
    },
    "lcahu-20210930x10q_fileoutpart4": {
        "predict": "|   | **Nine months ended September 30, 2021 ** |<NEWLINE>| --- | --- |<NEWLINE>| **Net income ** | $10,268,480 |<NEWLINE>| **Trust account interest income ** | $23,181 |<NEWLINE>| **Decrease (increase) in prepaid expenses ** | $(1,258,499) |<NEWLINE>| **Increase (decrease) in accounts payable and accrued liabilities ** | $120,000 |<NEWLINE>| **Cash deposited in trust account ** | $500,000,000 |<NEWLINE>| **Proceeds from public offering ** | $500,000,000 |<NEWLINE>| **Proceeds from affiliate notes payable ** |   |<NEWLINE>| **Payment of offering costs in affiliate notes payable ** |   |<NEWLINE>| **Cash at end of period ** | $500,136,083 |<NEWLINE>| **Deferred underwriting commissions ** | $17,500,000 |\n\nGuidelines:\n- For the nine months ended September 30, 2021, we had a net income of $10,268,480 related to $1,172,311 of general and administrative costs related to the formation of the Company and on-going expenses as we search for a Business Combination and $140,000 in management fees, and $942,390 in offering costs expensed, offset by a $12,500,000 gain of related to the change in the fair value of the warrant derivative liability and $23,181 in earnings on the Trust Account assets.\n- As of September 30, 2021, Prepaid expenses of $1,258,499 consist of premiums for directors and officers’ insurance.\n- Accounts payable and accrued liabilities are $120,000 as of September 30, 2021, and primarily consist of Delaware franchise tax expenses.\n- As of September 30, 2021, we had an unrestricted balance of $113,902 as well as cash and marketable securities held in the Trust Account of $500,023,181.\n- Following the closing of the Public Offering and the Private Placement, $500,000,000 was placed in the Trust Account, comprised of $490,000,000 of the proceeds from the Public Offering (which amount includes $17,500,000 of the underwriters’ deferred discount) and $10,000,000 of the proceeds of the Private Placement and paid $10,000,000 in underwriting discounts.\n- Upon closing of the Public Offering and Private Placement on March 29, 2021, $500,000,000 in proceeds (including $17,500,000 of deferred underwriting commissions) from the public offering and private placement was placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee.\n- The Public Shares have been recorded at their redemption amount and classified as temporary equity (“Redeemable Shares”), in accordance with the Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 480, “Distinguishing Liabilities from Equity.” The amount in the Trust Account was initially $10.00 per Public Share ($500,000,000 held in the Trust Account divided by 50,000,000 Public Shares).\n- These loans of $197,315 were repaid in full as of September 30, 2021.\n- The Company consummated the Public Offering of 50,000,000 units (the “Units”) at $10.00 per Unit on March 29, 2021, generating gross proceeds of $500,000,000.\n- A portion of the purchase price of the Sponsor Warrants was added to the proceeds from the Public Offering to be held in the Trust Account such that at closing of the Public Offering, $500,000,000 was placed in the Trust Account.\n- The",
        "target": [
            "|   | **Nine months ended September 30, 2021 ** |",
            "| --- | --- |",
            "| **Net income ** | $ 10,268,480  |",
            "| **Trust account interest income ** | (23,181)  |",
            "| **Decrease (increase) in prepaid expenses ** | (1,258,499)  |",
            "| **Increase (decrease) in accounts payable and accrued liabilities ** | 120,000  |",
            "| **Cash deposited in trust account ** | (500,000,000)  |",
            "| **Proceeds from public offering ** | 500,000,000  |",
            "| **Proceeds from affiliate notes payable ** | 853,712  |",
            "| **Payment of offering costs in affiliate notes payable ** | (197,315)  |",
            "| **Cash at end of period ** | $ 113,902  |",
            "| **Deferred underwriting commissions ** | $ 17,500,000  |"
        ]
    },
    "lcahu-20210930x10q_fileoutpart1": {
        "predict": "|   | **September 30, 2021 (unaudited)** |<NEWLINE>| --- | --- |<NEWLINE>| **Cash** | $113,902 |<NEWLINE>| **Prepaid expenses** | $1,258,499 |<NEWLINE>| **Cash and marketable securities held in trust account** | $500,023,181 |<NEWLINE>| **Accounts payable and accrued liabilities** | $120,000 |<NEWLINE>| **Notes payable, affiliates** | $853,712 |<NEWLINE>| **Deferred underwriting commissions** | $17,500,000 |<NEWLINE>| **Class A common stock subject to possible redemption, 50,000,000 shares at redemption value of $10.00 per share** |   |\n\nGuidelines:\n- As of September 30, 2021, total assets held in trust were $500,023,181\n- Upon closing of the Public Offering and Private Placement on March 29, 2021, $500,000,000 in proceeds (including $17,500,000 of deferred underwriting commissions) from the public offering and private placement was placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee\n- The Public Shares have been recorded at their redemption amount and classified as temporary equity (“Redeemable Shares”), in accordance with the Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 480, “Distinguishing Liabilities from Equity.” The amount in the Trust Account was initially $10.00 per Public Share ($500,000,000 held in the Trust Account divided by 50,000,000 Public Shares)\n- As of September 30, 2021, the Company borrowed $426,856 from each Sponsor, or $853,712 in the aggregate, under the Convertible Notes\n- Underwriting commissions for the Public Offering were $27,500,000, of which $17,500,000 have been deferred until the completion of the Business Combination\n- Accounts payable and accrued liabilities are $120,000 as of September 30, 2021, and primarily consist of Delaware franchise tax expenses\n- As of September 30, 2021, we had an unrestricted balance of $113,902 as well as cash and marketable securities held in the Trust Account of $500,023,181\n- September 30, 2021, Prepaid expenses of $1,258,499 consist of premiums for directors and officers’ insurance",
        "target": [
            "|   | **September 30, 2021 (unaudited) ** |",
            "| --- | --- |",
            "| **Cash ** | $ 113,902  |",
            "| **Prepaid expenses ** | 1,258,499  |",
            "| **Cash and marketable securities held in trust account ** | 500,023,181  |",
            "| **Accounts payable and accrued liabilities ** | $ 120,000  |",
            "| **Notes payable, affiliates ** | 853,712  |",
            "| **Deferred underwriting commissions ** | 17,500,000  |",
            "| **Class A common stock subject to possible redemption, 50,000,000 shares at redemption value of $10.00 per share ** | $ 500,000,000  |"
        ]
    },
    "brhc10025986_10q_fileoutpart7": {
        "predict": "|   | **Three Months Ended March 31, 2021 ** |<NEWLINE>| --- | --- |<NEWLINE>| **Interest Income ** | $31,721 |<NEWLINE>| **Class A Ordinary Shares, Basic and Diluted ** | 27,600,000 |<NEWLINE>| **Net Income ** | $5,572,126 |<NEWLINE>| **Class B Ordinary Shares, Basic and Diluted ** | 6,900,000 |\n\nGuidelines:\n- At March 31, 2021 and December 31, 2020, there were 6,900,000 Class B ordinary shares issued and outstanding. \n- As of June 22, 2021, there were 27,600,000 Class A ordinary shares, $0.0001 par value and 6,900,000 Class B ordinary shares, $0.0001 par value, issued and outstanding. \n- On November 27, 2020, the Company consummated the Initial Public Offering of 27,600,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units sold, the “Public Shares”) which includes the full exercise by the underwriters of their over-allotment option in the amount of 3,600,000 Units, at $10.00 per Unit, generating gross proceeds of $276,000,000 which is described in Note 3. \n- On November 23, 2020, the Company effected a 1,150,000 share dividend, resulting in 6,900,000 Founder Shares outstanding. \n- For the three months ended March 31, 2021, we had a net income of $5,572,126, which consisted of a gain from change in fair value of warrant liability (Public Warrants and Initial Private Placement Warrants) of $7,328,958, a loss in change in fair value of FPA liability of $1,603,769 and interest earned on marketable securities held in the Trust Account of $31,721, offset by operating costs of $184,784 which consisted of $70,402 in legal and professional fees, $37,295 in accounting related costs, $30,000 in administrative support fees, $31,250 in insurance costs, and $15,837 in miscellaneous costs.",
        "target": [
            "|   | **Three Months Ended March 31, 2021 ** |",
            "| --- | --- |",
            "| **Interest Income ** | $ 31,721  |",
            "| **Class A Ordinary Shares, Basic and Diluted ** | 27,600,000  |",
            "| **Net Income ** | $ 5,572,126  |",
            "| **Class B Ordinary Shares, Basic and Diluted ** | 6,900,000  |"
        ]
    },
    "brhc10025986_10q_fileoutpart4": {
        "predict": "| **Operating costs** | **$ 184,784** |\n| --- | --- |\n| **Loss from operations** | **$ (184,784)** |\n| **Interest earned on marketable securities held in Trust Account** | **$ 31,721** |\n| **Change in fair value of warrant liability** | **$ 7,328,958** |\n| **Change in fair value of FPA liability** | **$ (1,603,769)** |\n| **Net Income** | **$ 5,572,126** |\n| **Weighted average shares outstanding of Class A ordinary shares** | **27,600,000** |\n| **Weighted average shares outstanding of Class B ordinary shares** | **6,900,000** |",
        "target": [
            "| **Operating costs ** | **$ 184,784 ** |",
            "| --- | --- |",
            "| **Loss from operations ** | (184,784)  |",
            "| **Interest earned on marketable securities held in Trust Account ** | 31,721  |",
            "| **Change in fair value of warrant liability ** | 7,328,958  |",
            "| **Change in fair value of FPA liability ** | (1,603,769)  |",
            "| **Net Income ** | $ 5,572,126  |",
            "| **Weighted average shares outstanding of Class A ordinary shares ** | 27,600,000  |",
            "| **Weighted average shares outstanding of Class B ordinary shares ** | 6,900,000  |"
        ]
    },
    "f-20220630_fileoutpart58": {
        "predict": "|   | **June 30, 2022** |   |\n| --- | --- | --- |\n| **Company Cash** | $28.7 billion |   |\n| **Liquidity** | $45.1 billion | Including approximately $2 billion of Rivian marketable securities |\n| **Debt** | $19.4 billion | Excluding Ford Credit |\n",
        "target": [
            "|   | **June 30, 2022 ** |",
            "| --- | --- |",
            "| **Company Cash ** | $ 28.7  |",
            "| **Liquidity ** | 45.1  |",
            "| **Debt ** | (19.4)  |"
        ]
    },
    "f-20220630_fileoutpart73": {
        "predict": "|   | **Second Quarter ** |   |\n| --- | --- | --- |\n| **Interest expense on Company debt excluding Ford Credit ** | $312 million |   |\n| **Provision for/(Benefit from) income taxes ** | $153 million (provision) | $576 million (benefit) |\n| **Net income/(loss) attributable to Ford Motor Company ** | $667 million |   |\n|<NEWLINE>|   | **Company excluding Ford Credit ** | **Consolidated ** |\n| --- | --- | --- |\n| **Interest expense on Company debt excluding Ford Credit ** | $312 million |   |\n| **Provision for/(Benefit from) income taxes ** | $153 million (provision) | $576 million (benefit) |\n| **Net income/(loss) attributable to Ford Motor Company ** | $667 million |   |",
        "target": [
            "|   | **Second Quarter ** |   |",
            "|   | **Company excluding Ford Credit ** | **Consolidated ** |",
            "| --- | --- | --- |",
            "| **Interest expense on Company debt excluding Ford Credit ** | 312  | 312  |",
            "| **Provision for/(Benefit from) income taxes ** | - | 153  |",
            "| **Net income/(loss) attributable to Ford Motor Company ** | - | $ 667  |"
        ]
    },
    "f-20220630_fileoutpart42": {
        "predict": "|   |   |   | **First Half** |   |\n| --- | --- | --- | --- | --- |\n|   | **2022** | **H / (L)** | **2021** | **H / (L)** |\n|   | $B |   | $B |   |\n| **Cash Flows from Operating Activities ($B)** |   |   |   |   |\n|   | $2.9 | +$2.2B |   |   |\n| **Net Income/(Loss) ($M)** |   |   |   |   |\n|   | $667 |   |   |   |\n| **Net Income/(Loss) Margin (%)** |   |   |   |   |\n|   | 1.7% | -0.4 |   |   |\n| **Company Adj. Free Cash Flow ($B)** |   |   |   |   |\n|   | $3.6 | +$8.7B |   |   |\n| **Company Adj. EBIT ($M)** |   |   |   |   |\n|   | $3,722 |   |   |   |\n| **Company Adj. EBIT Margin (%)** |   |   |   |   |\n|   | 9.3% | +5.4 |   |   |\n| **Adjusted EPS (Diluted)** |   |   |   |   |\n|   | $0.68 |   |   | $0.16 |\n\nNote: Some cells may remain empty based on the guidelines provided. \n\nFor full-year 2022, we expect adjusted EBIT of $11.5 billion to $12.5 billion, which would represent 15% to 25% growth from last year, and adjusted free cash flow of $5.5 billion to $6.5 billion, with a significant portion coming from Automotive operations. \n\nEurope’s second quarter 2022 EBIT was $10 million, an improvement of $294 million from a year ago, with an EBIT margin of 0.2%.",
        "target": [
            "|   |   |   | **First Half ** |   |",
            "|   | **2022 ** | **H / (L) ** | **2021 ** | **H / (L) ** |",
            "| --- | --- | --- | --- | --- |",
            "| **Cash Flows from Operating Activities ($B) ** | $ 2.9  | $ 2.2  | - | - |",
            "| **Net Income/(Loss) ($M) ** | 667  | $ 106  | - | - |",
            "| **Net Income/(Loss) Margin (%) ** | 1.7 %  | (0.4) ppts  | - | - |",
            "| **Company Adj. Free Cash Flow ($B) ** | $ 3.6  | $ 8.7  | $ (5.5)  | - |",
            "| **Company Adj. EBIT ($M) ** | 3,722  | - | - | - |",
            "| **Company Adj. EBIT Margin (%) ** | 9.3 %  | 5.4 ppts  | - | 0.2 ppts  |",
            "| **Adjusted EPS (Diluted) ** | $ 0.68  | - | - | - |"
        ]
    },
    "ctlt-20230331_fileoutpart45": {
        "predict": "| **Year-Over-Year Change** | **2023 vs. 2022** | |<NEWLINE>| | **Three Months Ended March 31,** | |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Organic** | | |<NEWLINE>| **Constant-currency change** | | |\n| --- | --- | --- |\n| Biologics net revenue | -32% | |\n| Biologics Segment EBITDA | -98% | |",
        "target": [
            "| **Year-Over-Year Change ** | **2023 vs. 2022 ** |   |",
            "|   | **Three Months Ended March 31, ** |   |",
            "| --- | --- | --- |",
            "| **Organic ** | (32)%  | - |",
            "| **Constant-currency change ** | (32)%  | (98)%  |"
        ]
    },
    "ctlt-20230331_fileoutpart3": {
        "predict": "|   | **March 31, ** |   | **Nine Months Ended March 31, ** |   |\n| --- | --- | --- | --- | --- |\n|   | **2023** | **2022** | **2023** | **2022** |<NEWLINE>\n| **Goodwill impairment charges** |   |   | $210 million |   |<NEWLINE>\n| **Other operating expense, net** |   |   | $40 million | $26 million |<NEWLINE>\n| **Interest expense, net** |   |   | $130 million | $89 million |<NEWLINE>\n| **Other (income) expense, net** |   |   |   | $27 million |<NEWLINE>\n| **(Loss) earnings before income taxes** | ($282 million) | $176 million | ($165 million) | $394 million |<NEWLINE>\n| **Income tax (beneﬁt) expense** | $55 million | $35 million | ($19 million) | $63 million |<NEWLINE>\n\nGuidelines:\n- Other expense, net for the nine months ended March 31, 2022 of $25 million was primarily driven by $28 million of foreign currency losses, and $4 million of ﬁnancing charges related to our outstanding term loans, partially oﬀset by a $2 million gain related to the change in fair value of the derivative liability arising from the dividend-adjustment mechanism of our formerly outstanding series A preferred stock.\n- Our beneﬁt for income taxes for the nine months ended March 31, 2023 was $19 million relative to loss before income taxes of $165 million.\n- Other operating expense of $40 million for the nine months ended March 31, 2023 increased by $14 million, or 50%, compared to the nine months ended March 31, 2022, excluding the impact of foreign exchange.\n- The Company recorded a provision for income taxes for the three months ended March 31, 2022 of $35 million relative to earnings before income taxes of $176 million.\n- Our beneﬁt for income taxes for the three months ended March 31, 2023 was $55 million relative to loss before taxes of $282 million.\n- The evaluation performed resulted in an impairment charge of $210 million with respect to the Consumer Health reporting unit.\n- The Company recorded a provision for income taxes for the nine months ended March 31, 2022 of $63 million relative to earnings before income taxes of $394 million.\n- Our provision for income taxes for the three months ended March 31, 2022 was $35 million relative to earnings before income taxes of $176 million.\n- The ensuing quantitative testing resulted in an impairment charge of $210 million in the consumer health reporting unit within the Pharma and Consumer Health segment.\n- Our provision for income taxes for the nine months ended March 31, 2022 was $63 million relative to earnings before income taxes of $394 million.\n- The Company recorded a beneﬁt for income taxes for the three months ended March 31, 2023 of $55 million relative to loss before income taxes of $282 million.\n- Interest expense, net of $130 million for the nine months ended March 31, 2023 increased by $41 million, or 44%, compared to the nine months ended March 31, 2022, excluding the impact of foreign exchange.\n- The Company recorded a beneﬁt for income taxes for the nine months ended March 31, 2023 of $19 million relative to loss before income taxes of $165 million.\n- Interest expense, net of $51 million for the three months ended March 31, 2023 increased $18 million, or 53%, compared to the three months ended March 31, 202",
        "target": [
            "|   | **March 31, ** |   | **Nine Months Ended March 31, ** |   |",
            "|   | **2023 ** | **2022 ** | **2023 ** | **2022 ** |",
            "| **Goodwill impairment charges ** | 210  | - | 210  | - |",
            "| --- | --- | --- | --- | --- |",
            "| **Other operating expense, net ** | - | - | 40  | - |",
            "| **Interest expense, net ** | 51  | - | 130  | - |",
            "| **Other (income) expense, net ** | - | - | - | 25  |",
            "| **(Loss) earnings before income taxes ** | (282)  | 176  | (165)  | 394  |",
            "| **Income tax (beneﬁt) expense ** | (55)  | 35  | - | 63  |"
        ]
    },
    "ctlt-20230331_fileoutpart48": {
        "predict": "|   | **2023 vs. 2022** |<NEWLINE>|   | **Nine Months Ended** |<NEWLINE>| --- | --- |<NEWLINE>| **Organic** | -9% |<NEWLINE>| **Impact of acquisitions** | +3% |<NEWLINE>| **Constant-currency change** |   |<NEWLINE>| **Total % change** | -6% |",
        "target": [
            "|   | **2023 vs. 2022 ** |",
            "|   | **Nine Months Ended ** |",
            "| --- | --- |",
            "| **Organic ** | (9)%  |",
            "| **Impact of acquisitions ** | 3%  |",
            "| **Constant-currency change ** | (6)%  |",
            "| **Total % change ** | (9)%  |"
        ]
    },
    "ctlt-20230331_fileoutpart47": {
        "predict": "| **(Dollars in millions)** | **Nine Months Ended March 31, 2023** | **Nine Months Ended March 31, 2022** | **Change $** | **Change %** |\n| --- | --- | --- | --- | --- |\n| **Net revenue** | $3,002 | $3,199 | -$197 | -6% |\n| **Gross margin** | $846 | $1,144 | -$298 | -26% |\n| **Selling, general, and administrative expenses** | $178 | $192 | -$14 | -7% |\n| **Goodwill impairment charges** | $210 | - | $210 | - |\n| **Other operating expense** | $54 | $40 | $14 | 50% |\n| **Interest expense, net** | $134 | $93 | $41 | 44% |\n| **Other (income) expense, net** | -$21 | $25 | -$46 | - |\n| **(Loss) earnings before income taxes** | -$146 | $394 | -$540 | - |\n| **Income tax (beneﬁt) expense** | -$19 | $63 | -$82 | - |\n\n**FX Impact:** Excluded from the above table.\n\n**Constant Currency Increase (Decrease):** Excluded from the above table.\n\nGuidelines:\n\n- Gross margin decreased by $298 million, or 26%, compared to the nine months ended March 31, 2022, excluding the impact of foreign exchange, primarily due to an unfavorable shift in product mix, lower levels of utilization across the network, inventory write-offs, operational challenges that meaningfully reduced productivity, and higher costs from increased spending on operational and engineering enhancements in our Biologics segment.\n\n- Other expense, net for the nine months ended March 31, 2022 of $25 million was primarily driven by $28 million of foreign currency losses, and $4 million of financing charges related to our outstanding term loans, partially offset by a $2 million gain related to the change in fair value of the derivative liability arising from the dividend-adjustment mechanism of our formerly outstanding series A preferred stock.\n\n- Other operating expense of $40 million for the nine months ended March 31, 2023 increased by $14 million, or 50%, compared to the nine months ended March 31, 2022, excluding the impact of foreign exchange.\n\n- Our benefit for income taxes for the nine months ended March 31, 2023 was $19 million relative to loss before income taxes of $165 million.\n\n- The evaluation performed resulted in an impairment charge of $210 million with respect to the Consumer Health reporting unit.\n\n- Net revenue decreased by $197 million, or 6%, excluding the impact of foreign exchange, compared to the nine months ended March 31, 2022.\n\n- The Company recorded a provision for income taxes for the nine months ended March 31, 2022 of $63 million relative to earnings before income taxes of $394 million.\n\n- The ensuing quantitative testing resulted in an impairment charge of $210 million in the consumer health reporting unit within the Pharma and Consumer Health segment.\n\n- Our provision for income taxes for the nine months ended March 31, 2022 was $63 million relative to earnings before income taxes of $394 million.\n\n- As a result of the amendments affected by the Bylaws, in addition to satisfying the advance notice eligibility and procedural requirements in our Bylaws, to comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide a notice that sets forth the information required by Rule 14a-19 no earlier than June 29, 2023 and no later than July 29, 2023.\n\n- Interest expense, net of $130 million for the nine months ended March 31, 2023",
        "target": [
            "| **(Dollars in millions) ** | **Nine Months Ended March 31, ** |   | **FX Impact ** | **Constant Currency Increase (Decrease) ** |   |",
            "|   | **2023 ** | **2022 ** |   | **Change $ ** | **Change % ** |",
            "| --- | --- | --- | --- | --- | --- |",
            "| **Net revenue ** | - | - | - | $ (197)  | (6)%  |",
            "| **Gross margin ** | - | - | (29)  | (298)  | (26)%  |",
            "| **Selling, general, and administrative expenses ** | - | - | - | 7  | - |",
            "| **Goodwill impairment charges ** | 210  | - | - | 210  | - |",
            "| **Other operating expense ** | 40  | 25  | - | - | 50 %  |",
            "| **Interest expense, net ** | 130  | - | - | 41  | 44 %  |",
            "| **Other (income) expense, net ** | - | 25  | - | - | - |",
            "| **(Loss) earnings before income taxes ** | (165)  | 394  | - | - | - |",
            "| **Income tax (beneﬁt) expense ** | - | 63  | - | - | - |"
        ]
    },
    "ctlt-20230331_fileoutpart42": {
        "predict": "|(Dollars in millions) | Three Months Ended March 31, | FX Impact | Constant Currency Increase (Decrease) |   |\n| --- | --- | --- | --- | --- |\n| **Net revenue** |   |   |   |   |\n| Biologics | $222 |   | ($222) |   |\n| Pharma and Consumer Health | $6 |   | $6 |   |\n| Total | $216 |   | ($216) |   |\n| **Segment EBITDA** |   |   |   |   |\n| Biologics | $214 |   | ($214) |   |\n| Total |   |   |   |   |\n| **Gross Margin as % of Revenue** |   |   |   |   |\n| Constant-currency basis |   |   | (1,570) basis points |   |\n| Three Months Ended March 31, 2023 |   |   |   |   |\n| Prior-year period |   |   |   | 33.2% |\n|<NEWLINE>|\n| **Segment EBITDA** |   |   |   |   |\n| Excluding impact of acquisitions |   |   | 6% decrease |   |\n| Nine months ended March 31, 2022 |   |   |   |   |\n|<NEWLINE>|\n| **Net revenue** |   |   |   |   |\n| Biologics |   |   |   |   |\n| Pharma and Consumer Health |   |   |   |   |\n| Total |   |   |   |   |",
        "target": [
            "| **(Dollars in millions) ** | **Three Months Ended March 31, ** | **FX Impact ** | **Constant Currency Increase (Decrease) ** |   |",
            "|   | **2023 ** |   | **Change $ ** | **Change % ** |",
            "| --- | --- | --- | --- | --- |",
            "| **Net revenue ** | - | - | $ (222)  | (32)%  |",
            "| **Segment EBITDA ** | 6  | - | (214)  | (98)%  |",
            "| **Net revenue ** | - | (17)  | 6  | 1%  |",
            "| **Net revenue ** | - | - | $ (216)  | (17)%  |"
        ]
    },
    "ctlt-20230331_fileoutpart17": {
        "predict": "| **(Dollars in millions)** | **Preliminary Purchase Price Allocation** |<NEWLINE>| --- | --- |<NEWLINE>| **Other intangibles, net** | $52 million (multi-period, excess-earnings method) |<NEWLINE>| **Goodwill** |   |<NEWLINE>| **Total assets acquired and liabilities assumed** | $474 million (cash, subject to customary adjustments) |",
        "target": [
            "| **(Dollars in millions) ** | **Preliminary Purchase Price Allocation ** |",
            "| --- | --- |",
            "| **Other intangibles, net ** | 52  |",
            "| **Goodwill ** | 216  |",
            "| **Total assets acquired and liabilities assumed ** | $ 474  |"
        ]
    },
    "medies_i10q-053123_fileoutpart4": {
        "predict": "|   | **For the period ended May 31, 2023** | **For the period ended May 31, 2022** |\n| --- | --- | --- |\n| **Net loss** | ($6,336) | ($9,939) |\n|   |   |   |\n| **Amortization** | $3,265 | $2,223 |\n|   |   |   |\n| **Depreciation** | $1,947 | $1,947 |\n|   |   |   |\n| **Net cash provided by (used in) Operating activities** | ($1,012) | ($3,500) |\n|   |   |   |\n| **Increase (decrease) in cash and equivalents** |   |   |\n|   |   |   |\n| **Cash and equivalents at end of the period** | $850 |   |\n\nGuidelines:\n- Our net loss for three months ended May 31, 2022 was $9,939\n- For the quarter ended May 31, 2023 & 2022 the company recorded $1,947 in depreciation expense\n- For the quarter ended May 31, 2023 & 2022 the company recorded $3,265 & $2,223 in amortization expenses respectively\n- Our net loss for the three months ended May 31, 2023 was $6,336\n- For three months ended May 31, 2023 & 2022, net cash flows used in operating activities were ($1,012) & ($3,500) respectively\n- In February 2022, the Company issued 4,000,000 shares of its common stock at $0.0001 per share for total proceeds of $400\n- As of May 31, 2023, our total assets were $54,546 consisting of intangibles $24,918, equipment $28,778 and cash and cash equivalents of $850.",
        "target": [
            "|   | **For the period ended May 31, 2023 ** | **For the period ended May 31, 2022 ** |",
            "| **Net loss ** | $ (6,336)  | $ (9,939)  |",
            "| --- | --- | --- |",
            "| **Amortization ** | 3,265  | 2,223  |",
            "| **Depreciation ** | 1,947  | 1,947  |",
            "| **Net cash provided by (used in) Operating activities ** | (1,012)  | (3,500)  |",
            "| **Increase (decrease) in cash and equivalents ** | (1,012)  | - |",
            "| **Cash and equivalents at end of the period ** | $ 850  | $ 400  |"
        ]
    },
    "medies_i10q-053123_fileoutpart1": {
        "predict": "|   | **MAY 31, 2023 (Unaudited)** | **FEBRUARY 28, 2023 (Audited)** |\n| --- | --- | --- |\n| **Cash & cash equivalents** | $850 |   |\n| **Intangibles (net)** | $24,918 |   |\n| - Software |   | $1,180 |\n| - Website (Meta Movement & related property rights) |   | $25,500 |\n| **Equipment (net)** | $28,778 |   |\n| **TOTAL ASSETS** | $54,546 |   |\n| **Total current liabilities** | $56,580 |   |\n| - Accrued expenses |   |   |\n| - Related party loans |   |   |\n| **Note Payable - RP** |   |   |\n| **Accounts Payable** |   |   |\n| **Total non-current liabilities** |   | $38,000 |\n| - Notes payable to related party |   | $12,500 |\n| - Accounts payable |   | $25,500 |\n| **Total Liabilities** | $94,580 |   |\n| **Accumulated Deficit** | $67,600 |   |\n\nGuidelines:\n- The Company has approximately $67,600 of net operating losses (“NOL”) carried forward to offset taxable income, if any, in future years which expire in fiscal 2041\n- While total non-current liabilities of $38,000 comprises of notes payable to related party $12,500 and accounts payable of $25,500\n- As on May 31, 2023, $12,500 stands as Note payable to Mr\n- As of May 31, 2023, our total liabilities were $94,580\n- The company acquired Intangible consisting of various software for $1,180 as on February 10, 2022 while Intangible consisting of website (Meta Movement & related property rights) of $25,500 was purchased as on February 28, 2022\n- The Company has accumulated losses from inception (February 08, 2022) to May 31, 2023 of $67,600\n- As of May 31, 2023, our total assets were $54,546 consisting of intangibles $24,918, equipment $28,778 and cash and cash equivalents of $850\n- Total current liabilities were $56,580 consisting of accrued expenses and related party loans",
        "target": [
            "|   | **MAY 31, 2023 (Unaudited) ** | **FEBRUARY 28, 2023 (Audited) ** |",
            "| --- | --- | --- |",
            "| **Cash & cash equivalents ** | $ 850  | - |",
            "| **Intangibles (net) ** | 24,918  | - |",
            "| **Equipment (net) ** | 28,778  | - |",
            "| **TOTAL ASSETS ** | $ 54,546  | - |",
            "| **Total current liabilities ** | 56,580  | - |",
            "| **Note Payable - RP ** | 12,500  | 12,500  |",
            "| **Accounts Payable ** | 25,500  | 25,500  |",
            "| **Total non-current liabilities ** | 38,000  | 38,000  |",
            "| **Total Liabilities ** | 94,580  | - |",
            "| **Accumulated Deficit ** | (67,600)  | - |"
        ]
    },
    "form10-q_fileoutpart30": {
        "predict": "|   | **Nine Months Ended July 31, ** | **Increase (Decrease) ** |   |<NEWLINE>|   | **2022 ** | **$ ** | **% ** |<NEWLINE>| --- | --- | --- | --- |<NEWLINE>| **Hotspot/Off-the-Shelf therapies ** |   | $3,076,000 | 22% |<NEWLINE>| **Prostate cancer ** |   | $85,000 | 59% |<NEWLINE>| **HPV-associated cancers ** |   | $337,000 | 82% |<NEWLINE>| **Personalized neoantigen-directed therapies ** |   | $8,000 | 98% |<NEWLINE>| **Other expenses ** |   | ($1,743,000) | (48%) |",
        "target": [
            "|   | **Nine Months Ended July 31, ** | **Increase (Decrease) ** |   |",
            "|   | **2022 ** | **$ ** | **% ** |",
            "| --- | --- | --- | --- |",
            "| **Hotspot/Off-the-Shelf therapies ** | $ 3,076  | - | 22%  |",
            "| **Prostate cancer ** | - | (122)  | (59)%  |",
            "| **HPV-associated cancers ** | - | (1,533)  | (82)%  |",
            "| **Personalized neoantigen-directed therapies ** | - | (392)  | (98)%  |",
            "| **Other expenses ** | - | (1,743)  | (48)%  |"
        ]
    },
    "form10-q_fileoutpart27": {
        "predict": "|   | **Preferred Stock Redemption Liability** | **Warrant Liabilities** | **Total** |\n| --- | --- | --- | --- |\n| **Fair value at October 31, 2021** |   |   | $4,929,000 |\n| **Additions** |   |   |   |\n| **Change in fair value** | $44,000 | $4,642,000 | $4,685,000 |\n| **Redemption** | ($44,000) |   |   |\n| **Fair value at July 31, 2022** |   | $287,000 |   |\n\nGuidelines:\n\n- At April 6, 2022 and January 31, 2022, the fair value of the preferred stock redemption liability was approximately $44,000 and $87,000, respectively.\n- For the nine months ended July 31, 2022, we recorded non-cash income from changes in the fair value of derivative liabilities of approximately $4,685,000.\n- On April 6, 2022, the Series D convertible preferred stock was redeemed, and the $44,000 preferred stock redemption liability was reclassified into other paid-in capital (see Note 10).\n- At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $4,225,000, which is the $4,312,000 net proceeds less the $87,000 value of the bifurcated preferred stock redemption liability (see below).\n- For the three months and nine months ended July 31, 2022, the Company reported income of approximately $0 and $44,000, respectively, due to a change in the fair value of the preferred stock redemption liability.\n- For the nine months ended July 31, 2022 and 2021, the Company reported income of approximately $4,642,000 and $1,814,000, respectively, due to changes in the fair value of the warrant liability.\n- At July 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $287,000 and $4,929,000, respectively.",
        "target": [
            "|   | **Preferred Stock Redemption Liability ** | **Warrant Liabilities ** | **Total ** |",
            "| --- | --- | --- | --- |",
            "| **Fair value at October 31, 2021 ** | - | $ 4,929  | $ 4,929  |",
            "| **Additions ** | 87  | - | 87  |",
            "| **Change in fair value ** | - | (4,642)  | (4,685)  |",
            "| **Redemption ** | (44)  | - | (44)  |",
            "| **Fair value at July 31, 2022 ** | - | $ 287  | $ 287  |"
        ]
    },
    "form10-q_fileoutpart28": {
        "predict": "|   | **Three Months Ended July 31, ** |   | **Increase (Decrease) ** |   |<NEWLINE>|   | **2022 ** | **2021 ** | **$ ** | **% ** |<NEWLINE>| --- | --- | --- | --- | --- |<NEWLINE>| **Hotspot/Off-the-Shelf therapies ** |   | $1,271,000 |   | +133% |<NEWLINE>| **Prostate cancer ** |   | $32,000 | $114,000 | $(82,000) | -72% |<NEWLINE>| **HPV-associated cancers ** |   | $(173,000) | $(292,000) | $119,000 | -41% |<NEWLINE>| **Personalized neoantigen-directed therapies ** |   | $62,000 | $69,000 | $(7,000) | -10% |<NEWLINE>| **Other expenses ** |   |   |   |   |<NEWLINE>| **Stock-based compensation expense included in research and development expense ** |   |   |   |   |\n\nGuidelines:\n\nOther expenses for the three months ended July 31, 2022 increased approximately $66,000, or 11%, compared to the same period in 2021\n\nHPV-associated costs for the three months ended July 31, 2022 decreased approximately $173,000, or 41%, compared to the same period in 2021\n\nResearch and development costs associated with our prostate cancer therapy for the nine months ended July 31, 2022 decreased approximately $122,000, or 59%, compared to the same period in 2021\n\nResearch and development costs associated with personalized neoantigen-directed therapies for the three months ended July 31, 2022 decreased approximately $7,000 compared to the same period in 2021\n\nResearch and development costs associated with our hotspot mutation-based therapy for the three months ended July 31, 2022 increased approximately 133% to $1,271,000 compared to the same period in 2021\n\nOn March 25, 2021, the Company entered into a new one-year lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses\n\nResearch and development costs associated with our prostate cancer therapy for the three months ended July 31, 2022 decreased 72% to $32,000 compared to the same period in 2021",
        "target": [
            "|   | **Three Months Ended July 31, ** |   | **Increase (Decrease) ** |   |",
            "|   | **2022 ** | **2021 ** | **$ ** | **% ** |",
            "| --- | --- | --- | --- | --- |",
            "| **Hotspot/Off-the-Shelf therapies ** | $ 1,271  | - | - | 133%  |",
            "| **Prostate cancer ** | 32  | - | - | (72)%  |",
            "| **HPV-associated cancers ** | - | - | (173)  | (41)%  |",
            "| **Personalized neoantigen-directed therapies ** | - | 7  | (7)  | - |",
            "| **Other expenses ** | - | - | 66  | 11%  |",
            "| **Stock-based compensation expense included in research and development expense ** | - | $ 29  | - | (59)%  |"
        ]
    },
    "form10-q_fileoutpart4": {
        "predict": "|   | **Nine Months Ended July 31, ** |   |\n| --- | --- | --- |\n| **Gain on change in value of warrants ** | $4,642,000 | $1,814,000 |\n| **Loss on disposal of property and equipment ** |   | $1,530,000 |\n| **Abandonment of intangible assets ** | $159,000 | $90,000 |\n| **Impairment charges on intangible assets ** | $6,010,000 |   |\n| **Depreciation expense ** | $45,000 | $366,000 |\n| **Amortization expense of intangible assets ** | $210,000 | $203,000 |\n| **Net gain on write-off of right-of-use asset and lease liability ** | $116,000 |   |\n| **Net cash used in operating activities ** | $12,307,000 | $11,703,000 |\n| **Net cash used in investing activities ** | $201,000 | $104,000 |\n| **Net proceeds of issuance of Series D preferred stock ** | $4,225,000 |   |\n| **Redemption of Series D preferred stock ** |   | $44,000 |\n| **Net cash (used in) provided by financing activities ** | ($956,000) | $31,886,000 |\n| **Reclassification of preferred stock redemption liability into equity upon redemption of preferred stock ** |   | $44,000 |\n| **Accretion of discount and redemption feature of convertible preferred stock ** | $1,025,000 |   |\n\nGuidelines:\n\n- Net cash used in operating activities was approximately $12,307,000 for the nine months ended July 31, 2022 compared to $11,703,000 for the nine months ended July 31, 2021\n- The $1,025,000 accretion of the Series D convertible preferred stock to its redemption value was recorded as a reduction in additional paid-in capital (see Note 10)\n- At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $4,225,000, which is the $4,312,000 net proceeds less the $87,000 value of the bifurcated preferred stock redemption liability (see below)\n- Net cash used in investing activities was approximately $201,000 for nine months ended July 31, 2022 compared to $104,000 for the nine months ended July 31, 2021\n- During the three months ended July 31, 2022, the Company recorded an impairment charge for patents owned and in-licensed intellectual property of approximately $3,005,000 in its condensed consolidated statement of operations\n- During the nine months ended July 31, 2021, the Company incurred a loss on disposal of equipment of approximately $1,530,000, $968,000 of which is reflected in the research and development expenses and $562,000 of which is reflected in the general and administrative expenses in the condensed consolidated statement of operations\n- Patent applications having a net book value of approximately $159,000 and $90,000 were abandoned and were charged to general and administrative expenses in the condensed consolidated statement of operations for the nine months ended July 31, 2022 and 2021, respectively\n- Net cash used in financing activities was approximately $956,000 for the nine months ended July 31, 2022 compared to net cash provided by financing activities of $31,886,000 for the nine months ended July 31, 2021\n- Depreciation expense for the nine months ended July 31, 2022 and 2021 was approximately $45,000 and $366,000, respectively\n- Amortization expense for intangible assets that was charged",
        "target": [
            "|   | **Nine Months Ended July 31, ** |   |",
            "|   | **2022 ** | **2021 ** |",
            "| --- | --- | --- |",
            "| **Gain on change in value of warrants ** | (4,642)  | (1,814)  |",
            "| **Loss on disposal of property and equipment ** | - | 1,530  |",
            "| **Abandonment of intangible assets ** | 159  | 90  |",
            "| **Impairment charges on intangible assets ** | 3,005  | - |",
            "| **Depreciation expense ** | 45  | 366  |",
            "| **Amortization expense of intangible assets ** | 210  | 203  |",
            "| **Net gain on write-off of right-of-use asset and lease liability ** | - | (116)  |",
            "| **Net cash used in operating activities ** | (12,307)  | (11,703)  |",
            "| **Net cash used in investing activities ** | (201)  | (104)  |",
            "| **Net proceeds of issuance of Series D preferred stock ** | 4,312  | - |",
            "| **Redemption of Series D preferred stock ** | (5,250)  | - |",
            "| **Net cash (used in) provided by financing activities ** | (956)  | 31,886  |",
            "| **Reclassification of preferred stock redemption liability into equity upon redemption of preferred stock ** | 44  | - |",
            "| **Accretion of discount and redemption feature of convertible preferred stock ** | 1,025  | - |"
        ]
    },
    "form10-q_fileoutpart18": {
        "predict": "|   | **July 31, 2022** | **October 31, 2021** |\n| --- | --- | --- |\n| **Exercise Price** | $20.00 to $224.00 per share | $20.00 to $224.00 per share |\n| **Stock Price** | $3.73 | $38.80 |\n\nGuidelines:\n\n- As of July 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase 377,818 shares of our common stock with exercise prices ranging from $20.00 to $224.00 per share\n- The decrease in the derivative liabilities was attributable to a decrease in our share price from $38.80 at October 31, 2021 to $3.73 at July 31, 2022\n- As of July 31, 2022, the down round feature was triggered four times and the exercise price of the warrants were reduced from $1,800.00 to $20.00",
        "target": [
            "|   | **July 31, 2022 ** | **October 31, 2021 ** |",
            "| --- | --- | --- |",
            "| **Exercise Price ** | $ 20.00  | - |",
            "| **Stock Price ** | $ 3.73  | $ 38.80  |"
        ]
    },
    "pir-10q_20181201_fileoutpart15": {
        "predict": "|   | **13 Weeks December 1, 2018** | **Ended November 25, 2017** | **39 Weeks December 1, 2018** | **Ended November 25, 2017 .1** |\n| --- | --- | --- | --- | --- |\n| **EBITDA (non-GAAP)** | ($16.9) million | $26.7 million | ($84.8) million | $41.2 million |\n| **Less: Income tax provision (beneﬁt)** | $17.9 million | $3.7 million |   |   |\n| **Depreciation** | $12.4 million | $12.8 million | $38.1 million | $40.0 million |\n| **Net income (loss) (GAAP)** | ($50.4) million or ($0.62) per share | $7.4 million or $0.09 per share | ($130.0) million or ($1.62) per share | ($3.4) million or ($0.04) per share and adjusted net income (non-GAAP) of $0.3 million or $0.01 per share |\n<NEWLINE>\nGuidelines:\n- EBITDA for the third quarter of fiscal 2019 was ($16.9) million, compared to $26.7 million for the same period in fiscal 2018.\n- Depreciation expense for the year-to-date period of fiscal 2019 was $38.1 million, compared to $40.0 million for the same period last year.\n- For the year-to-date period of fiscal 2019, gross profit was $344.1 million, or 30.2% of sales, compared to $468.4 million, or 36.4% of sales, for the same period last year, a decrease of 620 basis points.\n- The Company reported a net loss of $50.4 million, or ($0.62) per share, compared to net income of $7.4 million, or $0.09 per share, for the same period in fiscal 2018.\n- For the year-to-date period of fiscal 2019, the Company reported a net loss of $130.0 million, or ($1.62) per share, compared to a net loss of $3.4 million, or ($0.04) per share, and adjusted net income (non-GAAP) of $0.3 million or $0.01 per share, for the same period in fiscal 2018.\n- Depreciation expense for the third quarter of fiscal 2019 was $12.4 million, compared to $12.8 million for the same period last year.\n- The income tax provision for the third quarter of ﬁscal 2019 was $17.9 million, compared to $3.7 million during the same period in the prior ﬁscal year.\n- For the year-to-date period of fiscal 2019, EBITDA was ($84.8) million, compared to $41.2 million, and after excluding the legal and regulatory costs referred to above, adjusted EBITDA of $47.8 million for the same period last year.\n- Adjusted net income (non-GAAP) for the year-to-date period of fiscal 2018 excludes $6.6 million ($3.7 million net of tax) of expense for legal and regulatory costs relating to a California wage-and-hour matter and an ongoing CPSC inquiry.\n- Stock-based awards totaling 2,442,000 and 2,127,000 were excluded from the computation for the 13 and 39 weeks ended December 1, 2018, respectively, as the eﬀect would be antidilutive.\n- Legal and regulatory costs relating to a California wage",
        "target": [
            "|   | **13 Weeks December 1, 2018 ** | **Ended November 25, 2017 ** | **39 Weeks December 1, 2018 ** | **Ended November 25, 2017 .1** |",
            "| --- | --- | --- | --- | --- |",
            "| **EBITDA (non-GAAP) ** | $ (16.9 )  | $ 26.7  | $ (84.8 )  | $ 41.2  |",
            "| **Less: Income tax provision (beneﬁt) ** | 17.9  | 3.7  | (2.3 )  | (4.2)  |",
            "| **Depreciation ** | 12.4  | 12.8  | 38.1  | 40.0  |",
            "| **Net income (loss) (GAAP) ** | $ (50.4 )  | $ 7.4  | $ (130.0 )  | $ (3.4)  |"
        ]
    },
    "pir-10q_20181201_fileoutpart11": {
        "predict": "|   | **13 Weeks Ended ** |   | **39 Weeks Ended ** |   |\n| --- | --- | --- | --- | --- |\n| **Key Performance Indicators** | **December 1, 2018** | **November 25, 2017** | **December 1, 2018** | **November 25, 2017** |\n| --- | --- | --- | --- | --- |\n| **Total sales decline** |   |   |   |   |\n| **Company comparable sales growth (decline)** | -10.5% |   | -10.1% |   |\n| **Gross proﬁt as a % of sales** | 31.6% | 37.7% | 30.2% | 36.4% |\n| **Selling, general and administrative expenses as a % of sales** |   | 32.1% |   | 33.3% |\n| **Operating income (loss) as a % of sales** | -7.0% | 2.9% |   |   |\n| **Net income (loss) (in millions)** | -50.4 | 7.4 | -130.0 | -3.4 |\n| **EBITDA (in millions) (1)** | -16.9 | 26.7 | -84.8 | 41.2 |\n\nGuidelines:\n\nFor the third quarter of fiscal 2019, the Company reported a net loss of $50.4 million, or ($0.62) per share, including the negative impact of $20.8 million, or ($0.26) per share, related to a non-cash charge to increase the valuation allowance against certain deferred tax assets, compared to net income of $7.4 million, or $0.09 per share, for the same period in fiscal 2018.\n\nEBITDA for the third quarter of fiscal 2019 was ($16.9) million, compared to $26.7 million for the same period in fiscal 2018.\n\nFor the year-to-date period of fiscal 2019, the Company reported a net loss of $130.0 million, or ($1.62) per share, compared to a net loss of $3.4 million, or ($0.04) per share, and adjusted net income (non-GAAP) of $0.3 million or $0.01 per share, for the same period in fiscal 2018.\n\nCompany comparable sales for the third quarter of fiscal 2019 decreased 10.5%, compared to the same period last year.\n\nGross profit for the third quarter of fiscal 2019 was $130.5 million, or 31.6% of sales, compared to $176.7 million, or 37.7% of sales, in the same period last year, a decrease of 610 basis points.\n\nNet Income (Loss) and EBITDA — For the third quarter of fiscal 2019, the Company reported a net loss of $50.4 million, or ($0.62) per share, compared to net income of $7.4 million, or $0.09 per share, for the same period in fiscal 2018.\n\nCompany comparable sales for the year-to-date period of fiscal 2019 decreased 10.1%, compared to the same period last year.\n\nDuring the first nine months of fiscal 2019, operating activities used $38.3 million of cash, primarily as a result of a net loss of $130.0 million and an increase in inventories.\n\nFor the year-to-date period of fiscal 2019, gross profit was $344.1 million, or 30.2% of sales, compared to $468.4 million, or 36.4% of sales, for",
        "target": [
            "|   | **13 Weeks Ended ** |   | **39 Weeks Ended ** |   |",
            "| **Key Performance Indicators ** | **December 1, 2018 ** | **November 25, 2017 ** | **December 1, 2018 ** | **November 25, 2017 ** |",
            "| --- | --- | --- | --- | --- |",
            "| **Total sales decline ** | (11.9 %)  | - | (11.3%)  | - |",
            "| **Company comparable sales growth (decline) ** | (10.5 %)  | - | (10.1%)  | - |",
            "| **Gross proﬁt as a % of sales ** | 31.6 %  | 37.7%  | 30.2%  | 36.4%  |",
            "| **Selling, general and administrative expenses as a % of sales ** | 35.6 %  | 32.1%  | 37.6%  | 33.3%  |",
            "| **Operating income (loss) as a % of sales ** | (7.0 %)  | 2.9%  | - | - |",
            "| **Net income (loss) (in millions) ** | $ (50.4 )  | $ 7.4  | $ (130.0)  | $ (3.4)  |",
            "| **EBITDA (in millions) (1) ** | $ (16.9 )  | $ 26.7  | $ (84.8)  | $ 41.2  |"
        ]
    },
    "pir-10q_20181201_fileoutpart14": {
        "predict": "|   | **13 Weeks Ended ** |   |   |   | **39 Weeks Ended ** |   |   |   |<NEWLINE>|   | **December 1, 2018 ** |   | **November 25, 2017 ** |   | **December 1, 2018 ** |   | **November 25, 2017 ** |   |<NEWLINE>| --- | --- | --- | --- | --- | --- | --- | --- | --- |<NEWLINE>| **Total selling, general and administrative ** | $147.0 million (35.6% of sales) |   |   |   | $428.7 million (37.6% of sales) |   |   |   |<NEWLINE>| **Depreciation and amortization ** |   |   |   |   |   |   |   |   |\n \nGuidelines:\nSG&A expenses for the year-to-date period of fiscal 2019 were $428.7 million, or 37.6% of sales, compared to $428.7 million, or 33.3% of sales, for the same period in fiscal 2018\n\nSG&A Expenses, Depreciation and Operating Income (Loss) — For the third quarter of fiscal 2019, SG&A expenses were $147.0 million, or 35.6% of sales, compared to $150.4 million, or 32.1% of sales, for the same period in fiscal 2018",
        "target": [
            "|   | **13 Weeks Ended ** |   |   |   | **39 Weeks Ended ** |   |   |   |",
            "|   | **December 1, 2018 ** |   | **November 25, 2017 ** |   | **December 1, 2018 ** |   | **November 25, 2017 ** |   |",
            "| --- | --- | --- | --- | --- | --- | --- | --- | --- |",
            "| **Total selling, general and administrative ** | $ 147.0  | 35.6%  | $ 150.4  | 32.1%  | $ 428.7  | 37.6%  | $ 428.7  | 33.3%  |"
        ]
    },
    "pir-10q_20181201_fileoutpart16": {
        "predict": "|   | **13 Weeks Ended ** |   | **39 Weeks Ended ** |   |\n| --- | --- | --- | --- | --- |\n|   | **December 1, 2018 ** | **November 25, 2017 ** | **December 1, 2018 ** | **November 25, 2017 ** |<NEWLINE>|\n| **EBITDA (Non-GAAP) ** | ($16.9) million | $26.7 million | ($84.8) million | $41.2 million |<NEWLINE>|\n| **Add back: Legal and regulatory matters ** |   |   |   |   |<NEWLINE>|\n| **Adjusted EBITDA (Non-GAAP) ** |   |   | $47.8 million |   |<NEWLINE>|\n| **Net income (loss) (GAAP) ** | ($50.4) million | $7.4 million | ($130.0) million | ($3.4) million |<NEWLINE>|\n| **Add back: Legal and regulatory matters, net of tax (1) ** |   |   |   |   |<NEWLINE>|\n| **Adjusted net income (loss) (Non-GAAP) ** |   |   | $0.3 million | $3.7 million |<NEWLINE>|\n| **Earnings (loss) per share (GAAP) ** | ($0.62) | $0.09 | ($1.62) | ($0.04) |<NEWLINE>|\n| **Adjusted earnings (loss) per share (Non-GAAP) ** |   |   | $0.01 |   |<NEWLINE>|\n\nGuidelines:\n- For the third quarter of fiscal 2019, the Company reported a net loss of $50.4 million, or ($0.62) per share, including the negative impact of $20.8 million, or ($0.26) per share, related to a non-cash charge to increase the valuation allowance against certain deferred tax assets, compared to net income of $7.4 million, or $0.09 per share, for the third quarter of fiscal 2018.\n- EBITDA for the third quarter of fiscal 2019 was ($16.9) million, compared to $26.7 million for the same period in fiscal 2018.\n- For the year-to-date period of fiscal 2019, the Company reported a net loss of $130.0 million, or ($1.62) per share, compared to a net loss of $3.4 million, or ($0.04) per share, and adjusted net income (non-GAAP) of $0.3 million or $0.01 per share, for the same period in fiscal 2018.\n- For the year-to-date period of fiscal 2019, EBITDA was ($84.8) million, compared to $41.2 million, and after excluding the legal and regulatory costs referred to above, adjusted EBITDA of $47.8 million for the same period last year.\n- Adjusted net income (non-GAAP) for the year-to-date period of fiscal 2018 excludes $6.6 million ($3.7 million net of tax) of expense for legal and regulatory costs relating to a California wage-and-hour matter and an ongoing CPSC inquiry.\n- Net Income (Loss) and EBITDA — For the third quarter of fiscal 2019, the Company reported a net loss of $50.4 million, or ($0.62) per share, compared to net income of $7.4 million, or $0.09 per share, for the same period in fiscal 2018. EBITDA (earnings before interest, taxes, depreciation and amortization) for",
        "target": [
            "|   | **13 Weeks Ended ** |   | **39 Weeks Ended ** |   |",
            "|   | **December 1, 2018 ** | **November 25, 2017 ** | **December 1, 2018 ** | **November 25, 2017 ** |",
            "| --- | --- | --- | --- | --- |",
            "| **EBITDA (Non-GAAP) ** | $ (16.9 )  | $ 26.7  | $ (84.8)  | $ 41.2  |",
            "| **Add back: Legal and regulatory matters ** | - | - | - | 6.6  |",
            "| **Adjusted EBITDA (Non-GAAP) ** | $ (16.9 )  | $ 26.7  | $ (84.8)  | $ 47.8  |",
            "| **Net income (loss) (GAAP) ** | $ (50.4 )  | $ 7.4  | $ (130.0)  | $ (3.4)  |",
            "| **Add back: Legal and regulatory matters, net of tax (1) ** | - | - | - | 3.7  |",
            "| **Adjusted net income (loss) (Non-GAAP) ** | $ (50.4 )  | - | $ (130.0)  | $ 0.3  |",
            "| **Earnings (loss) per share (GAAP) ** | $ (0.62 )  | $ 0.09  | $ (1.62)  | $ (0.04)  |",
            "| **Adjusted earnings (loss) per share (Non-GAAP) ** | $ (0.62 )  | $ 0.09  | $ (1.62)  | $ 0.01  |"
        ]
    },
    "eaco-20230531x10q_fileoutpart14": {
        "predict": "|   | **Nine Months Ended May 31, ** |   | **$ Change ** |<NEWLINE>|   | **2023 ** | **2022 ** |   |<NEWLINE>| --- | --- | --- | --- |<NEWLINE>| **Income tax provision ** | $5,216,000 | $5,471,000 | ($255,000) |<NEWLINE>| **Percent of pre-tax income ** | 25.6% | 26.1% |   |\n\nGuidelines:\n\nThe income tax provision as a percent of pre-tax income decreased from 26.1% at Q3 2022 to 25% at Q3 2023, which was primarily due to the state tax rate mix and permanent book tax differences.\n\nThe income tax provision as a percent of pre-tax income decreased from 26.1% for the nine months ended May 31, 2022 to 25.6% in the current year period, which was primarily due to the state tax rate mix and permanent book tax differences.\n\nThe provision for income taxes decreased by $255,000 for the nine months ended May 31, 2023 when compared to the prior year period.\n\nDuring the three and nine months ended May 31, 2022, the Company recorded an income tax provision of $1,878,000 and $5,471,000, respectively, resulting in an effective tax rate of 26.1%.\n\nDuring the three and nine months ended May 31, 2023, the Company recorded an income tax provision of $1,772,000 and $5,216,000, respectively, resulting in an effective tax rate of 25% and 25.6%, respectively.",
        "target": [
            "|   | **Nine Months Ended May 31, ** |   | **$ Change ** |",
            "|   | **2023 ** | **2022 ** |   |",
            "| --- | --- | --- | --- |",
            "| **Income tax provision ** | $ 5,216  | $ 5,471  | $ 255  |",
            "| **Percent of pre-tax income ** | 25.6 %  | 26.1 %  |   |"
        ]
    },
    "eaco-20230531x10q_fileoutpart10": {
        "predict": "|   | **Three Months Ended May 31, ** |   | **$ Change ** |<NEWLINE>|   | **2023 ** | **2022 ** |   |<NEWLINE>| --- | --- | --- | --- |<NEWLINE>| **Income tax provision ** | $1,772,000 | $1,878,000 | ($106,000) |<NEWLINE>| **Percent of pre-tax income ** | 25% | 26.1% |   |\n\nGuidelines:\nThe income tax provision as a percent of pre-tax income decreased from 26.1% at Q3 2022 to 25% at Q3 2023, which was primarily due to the state tax rate mix and permanent book tax differences.\n\nThe income tax provision as a percent of pre-tax income decreased from 26.1% for the nine months ended May 31, 2022 to 25.6% in the current year period, which was primarily due to the state tax rate mix and permanent book tax differences.\n\nDuring the three and nine months ended May 31, 2022, the Company recorded an income tax provision of $1,878,000 and $5,471,000, respectively, resulting in an effective tax rate of 26.1%.\n\nThe provision for income taxes decreased by $106,000 in Q3 2023 over the prior year period.\n\nDuring the three and nine months ended May 31, 2023, the Company recorded an income tax provision of $1,772,000 and $5,216,000, respectively, resulting in an effective tax rate of 25% and 25.6%, respectively.",
        "target": [
            "|   | **Three Months Ended May 31, ** |   | **$ Change ** |",
            "|   | **2023 ** | **2022 ** |   |",
            "| --- | --- | --- | --- |",
            "| **Income tax provision ** | $ 1,772  | $ 1,878  | $ (106)  |",
            "| **Percent of pre-tax income ** | - | 26.1 %  |   |"
        ]
    },
    "riv10q123120_fileoutpart39": {
        "predict": "|   | **December 31, 2020** | **March 31, 2020** |\n| --- | --- | --- |\n| **Total nonperforming assets** | $393,000 or 0.03% of total assets | $1.4 million or 0.12% of total assets |\n| **Foregone interest on non-accrual loans (1)** | $42,000 | $57,000 |\n| **Total nonperforming loans to total loans** |  |  |\n| **Total nonperforming loans to total assets** |  |  |\n| **Total nonperforming assets to total assets** |  |  |\n\nGuidelines:\n\n- At December 31, 2020, loans delinquent 30 - 89 days were 0.04% of total loans compared to 0.03% at March 31, 2020.\n- Nonperforming assets, consisting of nonperforming loans were $393,000 or 0.03% of total assets at December 31, 2020 compared with $1.4 million or 0.12% of total assets at March 31, 2020.\n- Interest income foregone on non-accrual loans was $42,000 and $57,000 for the nine months ended December 31, 2020 and 2019, respectively.",
        "target": [
            "|   | **December 31, 2020 ** | **March 31, 2020 ** |",
            "| --- | --- | --- |",
            "| **Total nonperforming assets ** | $ 393  | - |",
            "| **Foregone interest on non-accrual loans (1) ** | $ 42  | - |",
            "| **Total nonperforming loans to total loans ** | 0.04%  | - |",
            "| **Total nonperforming loans to total assets ** | 0.03%  | 0.12%  |",
            "| **Total nonperforming assets to total assets ** | 0.03%  | 0.12%  |"
        ]
    },
    "algn-20200630_fileoutpart45": {
        "predict": "|   | **Three Months Ended June 30, ** |   | **Six Months Ended June 30, ** |   |\n| --- | --- | --- | --- | --- |\n| **Provision for (benefit from) income taxes ** | $32.9 million (44.8%) |   | $1,497.7 million (7,437.0%) | $51.9 million (18.6%) |\n| **Effective tax rates ** | 44.8% |   | 7,437.0% | 18.6% |",
        "target": [
            "|   | **Three Months Ended June 30, ** |   | **Six Months Ended June 30, ** |   |",
            "|   | **2020 ** | **2019 ** | **2020 ** | **2019 ** |",
            "| --- | --- | --- | --- | --- |",
            "| **Provision for (benefit from) income taxes ** | $ (32.9)  | $ 43.1  | $ (1,497.7)  | $ 51.9  |",
            "| **Effective tax rates ** | 44.8 %  | 22.2 %  | 7,437.0 %  | 18.6 %  |"
        ]
    },
    "pssr-20220131_fileoutpart7": {
        "predict": "| **Revenue by type of customer: ** | **Three Months Ended January 31, 2022 ** | **Three Months Ended January 31, 2021 ** |\n| --- | --- | --- |\n| **Other ** |   |   |\n| **Total Revenue ** | $1,512,000 | $1,698,000 |<NEWLINE>\n\nGuidelines:\n- For the three months ended January 31, 2022, total revenues decreased by $186,000, or 11%, to $1,512,000, as compared with $1,698,000 for the same period in 2021\n- For the three months ended January 31, 2022, research and development expenses increased by $20,000, or 42%, to $68,000, as compared with $48,000 for the same period in fiscal year 2021\n- The provision for doubtful accounts was $192,000 and $183,000 as of January 31, 2022 and October 31, 2021, respectively\n\nOutput:\n\n| **Revenue by type of customer: ** | **Three Months Ended January 31, 2022 ** | **Three Months Ended January 31, 2021 ** |\n| --- | --- | --- |\n| **Other ** |   |   |\n| **Total Revenue ** | $1,512,000 | $1,698,000 |<NEWLINE>",
        "target": [
            "| **Revenue by type of customer: ** | **Three Months Ended January 31, 2022 ** | **Three Months Ended January 31, 2021 ** |",
            "| --- | --- | --- |",
            "| **Other ** | 192,000  | 68,000  |",
            "| **Total Revenue ** | $ 1,512,000  | $ 1,698,000  |"
        ]
    },
    "brhc10031933_10qa_fileoutpart2": {
        "predict": "|   | **Three Months Ended September 30, ** | **Nine Months Ended September 30, ** | **For the Period from January 24, 2020 (Inception) Through September 30, ** |\n| --- | --- | --- | --- |\n| **Operating and formation costs ** |   |   | $531,533 |\n| **Loss from operations ** |   |   |  |\n| **Change in fair value of warrants ** | $8,640,000 | $10,240,000 |  |\n| **Transaction costs allocated to warrants ** |   | $853,386 |  |\n| **Interest earned on investments held in Trust Account ** | $14,169 | $32,532 |  |\n| **Net income (loss) ** | $8,382,522 | $8,887,613 | ($5,056) |\n| **Weighted average shares outstanding, Class A ordinary shares ** |   |   |  |\n| **Weighted average shares outstanding, Class B ordinary shares ** |   |   |  |\n\nGuidelines:\n- For the nine months ended September 30, 2021, we had a net income of $8,887,613, which consists of a change in the fair value of warrant liability of $10,240,000 and interest earned on marketable securities held in the Trust Account of $32,532, offset by transaction costs allocated to warrants of $853,386 and formation and operating cost of $531,533\n- Accordingly, at September 30, 2021, 20,000,000 Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity section of the Company’s condensed balance sheets\n- Net loss of $5,056 was offset by formation cost paid by Sponsor in exchange for issuance of founder shares of $5,000\n- On February 17, 2021, the Company consummated the Initial Public Offering of 20,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units sold, the “Public Shares”), which includes the partial exercise by the underwriter of its over-allotment option in the amount of 2,500,000 Units, at $10.00 per Unit, generating gross proceeds of $200,000,000 which is described in Note 4\n- As of November 12, 2021, there were 20,000,000 Class A ordinary shares, $0.0001 par value and 5,000,000 Class B ordinary shares, $0.0001 par value, issued and outstanding\n- As of September 30, 2021, we had marketable securities held in the Trust Account of $200,032,532 (including approximately $32,532 of interest income) consisting of U.S\n- For the three months ended September 30, 2021, we had a net income of $8,382,522, which consists of a change in the fair value of warrant liability of $8,640,000 and interest earned on marketable securities held in the Trust Account of $14,169, offset by formation and operating costs of $271,647\n- Offering costs amounted to $11,766,856, of which $10,913,470 were charged to shareholders’ equity upon the completion of the Initial Public Offering and $853,386 were expensed to the condensed statement of operations\n- For the period from January 24, 2020 (inception) through September 30, 2020, we had a net loss of $5,056 which consists of formation and operational costs\n- Net income of $8,887,613 was affected by interest earned on marketable securities held in the Trust Account of $32,532, a change in the fair value of warrant",
        "target": [
            "|   | **Three Months Ended September 30, ** | **Nine Months Ended September 30, ** | **For the Period from January 24, 2020 (Inception) Through September 30, ** |",
            "|   | **2021 ** | **2021 ** | **2020 ** |",
            "| --- | --- | --- | --- |",
            "| **Operating and formation costs ** | - | - | $ 5,056  |",
            "| **Loss from operations ** | - | - | (5,056)  |",
            "| **Change in fair value of warrants ** | 8,640,000  | 10,240,000  | - |",
            "| **Transaction costs allocated to warrants ** | - | (853,386)  | - |",
            "| **Interest earned on investments held in Trust Account ** | 14,169  | 32,532  | - |",
            "| **Net income (loss) ** | - | - | $ (5,056)  |",
            "| **Weighted average shares outstanding, Class A ordinary shares ** | 20,000,000  | - | - |",
            "| **Weighted average shares outstanding, Class B ordinary shares ** | 5,000,000  | - | - |"
        ]
    },
    "brhc10031933_10qa_fileoutpart5": {
        "predict": "|   | **Nine Months Ended September 30, 2021 ** | **For the Period from January 24, 2020 (Inception) Through September 30, 2020 ** |\n| --- | --- | --- |\n| **Net income (loss)** | $8,887,613 | ($5,056) |\n| **Adjustments to reconcile net income (loss) to net cash used in operating activities: Formation cost paid by Sponsor in exchange for issuance of founder shares** | $5,000 | $0 |\n| **Interest earned on marketable securities held in Trust Account** | $32,532 | $0 |\n| **Change in fair value of warrants** | $10,240,000 | $0 |\n| **Transaction costs allocated to warrants** | ($853,386) | $0 |\n| **Net cash used in operating activities** | ($636,628) | ($56) |\n| **Investment of cash in Trust Account** | $200,000,000 | $0 |\n| **Net cash used in investing activities** | $0 | $0 |\n| **Proceeds from issuance of Class B ordinary shares to Sponsor** | $25,000 | $0 |\n| **Proceeds from sale of Private Placements Warrants** | $6,000,000 | $0 |\n| **Repayment of promissory note – related party** | $250,000 | $0 |\n| **Cash – End of period** | $724,452 | $0 |\n| **Deferred underwriting fee payable** | $7,000,000 | $0 |\n\nGuidelines:\n- On February 10, 2020, the Company issued 5,750,000 Class B ordinary shares to the Sponsor for an aggregate purchase price of $25,000 (the “Founder Shares”).\n- Class A Ordinary Shares — The Company is authorized to issue 200,000,000 Class A ordinary shares with a par value of $0.0001 per share.\n- We incurred $11,766,856 in Initial Public Offering related costs, including $4,000,000 of underwriting fees, $7,000,000 of deferred underwriting fees and $766,856 of other costs.\n- Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 6,000,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to TCAC Sponsor, LLC (the “Sponsor”), generating gross proceeds of $6,000,000, which is described in Note 5.\n- At September 30, 2021, there were 6,000,000 Private Placement Warrants outstanding and as of December 31, 2020, there were no private warrants outstanding.\n- The underwriters are entitled to a deferred fee of $0.35 per Unit, or $7,000,000 in the aggregate.\n- Following the Initial Public Offering, the partial exercise of the over-allotment option, and the sale of the Private Placement Warrants, a total of $200,000,000 was placed in the Trust Account.\n- Of the gross proceeds received from the Initial Public Offering, the exercise of the over-allotment option and the Private Placement Warrants, an aggregate of $200,000,000 was placed in the Trust Account.\n- For the nine months ended September 30, 2021, cash used in operating activities was $636,628.\n- Net loss of $5,056 was offset by formation cost paid by Sponsor in exchange for issuance of founder shares of $5,000.\n- Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000.\n",
        "target": [
            "|   | **Nine Months Ended September 30, 2021 ** | **For the Period from January 24, 2020 (Inception) Through September 30, 2020 ** |",
            "| --- | --- | --- |",
            "| **Net income (loss) ** | - | $ (5,056)  |",
            "| **Adjustments to reconcile net income (loss) to net cash used in operating activities: Formation cost paid by Sponsor in exchange for issuance of founder shares ** | - | 5,000  |",
            "| **Interest earned on marketable securities held in Trust Account ** | (32,532)  | - |",
            "| **Change in fair value of warrants ** | (10,240,000)  | - |",
            "| **Transaction costs allocated to warrants ** | 853,386  | - |",
            "| **Net cash used in operating activities ** | (636,628)  | (56)  |",
            "| **Investment of cash in Trust Account ** | (200,000,000)  | - |",
            "| **Net cash used in investing activities ** | (200,000,000)  | - |",
            "| **Proceeds from issuance of Class B ordinary shares to Sponsor ** | - | 25,000  |",
            "| **Proceeds from sale of Private Placements Warrants ** | 6,000,000  | - |",
            "| **Repayment of promissory note – related party ** | (250,000)  | - |",
            "| **Cash – End of period ** | $ 724,452  | - |",
            "| **Deferred underwriting fee payable ** | $ 7,000,000  | - |"
        ]
    },
    "iot-20220730_fileoutpart38": {
        "predict": "|   | **July 31, 2021** | **%** | **July 31, 2021** | **%** |\n| --- | --- | --- | --- | --- |\n| **Sales and marketing** |   |   |   |   |\n| Sales and marketing expense | $71.4 million | 66% |   |   |\n| Percentage of revenue |   |   |   |   |\n| **Cost of revenue** |   |   |   |   |\n| Cost of revenue | $29.9 million | 55% |   |   |\n| Percentage of revenue |   |   |   |   |\n| **Revenue** |   |   |   |   |\n| Revenue |   |   | $52.5 million (3 months) $107.4 million (6 months) | 52% (3 months) 57% (6 months) |\n| Percentage of revenue |   |   |   |   |\n\nGuidelines:\n- Sales and marketing expense increased by $71.4 million, or 66%, for the six months ended July 30, 2022 compared to the six months ended July 31, 2021, primarily due to a $57.0 million increase in employee-related costs, which included a $28.6 million increase in stock-based compensation expense, a $25.7 million increase in salaries and benefits and related employer taxes primarily driven by an increase in headcount to support our sales organization, and a $2.8 million increase in sales commissions\n- Cost of revenue increased by $29.9 million, or 55%, for the six months ended July 30, 2022 compared to the six months ended July 31, 2021, primarily due to increased product costs of $30.6 million, which were mainly due to $13.1 million of increased amortization of deferred IoT device costs and $10.4 million of increased direct labor costs, of which $4.1 million was an increase in stock-based compensation expense\n- Revenue increased by $52.5 million and $107.4 million, or 52% and 57%, for the three and six months ended July 30, 2022, respectively, compared to the three and six months ended July 31, 2021, primarily due to an increase in customer count and increased purchases by existing customers of our subscription offerings\n- Sales and marketing expense increased by $36.3 million, or 65%, for the three months ended July 30, 2022 compared to the three months ended July 31, 2021, primarily due to a $29.4 million increase in employee-related costs, which included a $14.2 million increase in stock-based compensation expense, a $13.8 million increase in salaries and benefits and related employer taxes primarily driven by an increase in headcount to support our sales organization, and a $1.3 million increase in sales commissions\n- For our six months ended July 30, 2022 and July 31, 2021, our revenue was $296.2 million and $188.8 million, respectively, representing year-over-year growth of 57%",
        "target": [
            "|   | **July 31, 2021 ** | **% ** | **July 31, 2021 ** | **% ** |",
            "| **Sales and marketing ** | - | 65 %  | - | 66 %  |",
            "| --- | --- | --- | --- | --- |",
            "| **Percentage of revenue ** | 55 %  |   | 57 %  |   |"
        ]
    },
    "iot-20220730_fileoutpart42": {
        "predict": "|   | **Three Months Ended ** |   |   | **Six Months Ended ** |   |   |\n| --- | --- | --- | --- | --- | --- | --- |\n| **July 30, 2022 ** | **July 31, 2021 ** | **% ** | **July 30, 2022 ** | **July 31, 2021 ** | **% ** |\n|<NEWLINE>| Provision for income taxes | $(0.3) million |   |   | $0.4 million |   |   |\n|<NEWLINE>| Effective tax rate | (0.1)% | (1.2)% |   | (0.6)% | (0.5)% |   |\n\nGuidelines:\n- The provision for income taxes decreased by $0.3 million, or 89%, for the three months ended July 30, 2022 compared to the three months ended July 31, 2021, primarily driven by our international operations.\n- The Company had an effective tax rate of (0.1)% and (1.2)% for the three months ended July 30, 2022 and July 31, 2021, respectively, and (0.6)% and (0.5)% for the six months ended July 30, 2022 and July 31, 2021, respectively.\n- The provision for income taxes increased by $0.4 million, or 107%, for the six months ended July 30, 2022 compared to the six months ended July 31, 2021, primarily driven by the expansion of our international operations.",
        "target": [
            "|   | **Three Months Ended ** |   |   | **Six Months Ended ** |   |   |",
            "|   | **July 30, 2022 ** | **July 31, 2021 ** | **% ** | **July 30, 2022 ** | **July 31, 2021 ** | **% ** |",
            "| --- | --- | --- | --- | --- | --- | --- |",
            "| **Provision for income taxes ** | - | - | (89)%  | - | - | 107 %  |",
            "| **Effective tax rate ** | (0.1 %)  | (1.2 %)  |   | (0.6 %)  | (0.5 %)  |   |"
        ]
    },
    "sodi_10q_fileoutpart6": {
        "predict": "|   | **For the three months ended May 31, 2020** | **For the three months ended May 31, 2019** |\n| --- | --- | --- |\n| **Net income (loss)** | $369,000 | ($249,000) |\n| **Depreciation and amortization** | $59,000 |   |\n| **Accounts receivable** | $79,000 | ($357,000) |\n| **Inventories** | $420,000 | ($547,000) |\n| **Prepaid expenses and other current assets** | $61,000 |   |\n| **Net cash provided by operating activities** | $293,000 | $538,000 |\n| **Proceeds from sale of securities** | $169,000 | $35,000 |\n| **Purchases of securities** | ($222,000) | ($19,000) |\n| **Purchases of property and equipment** | ($23,000) | ($3,000) |\n| **Net cash (used in) provided by investing activities** | ($76,000) | $13,000 |\n| **Cash and cash equivalents - beginning of the year** | $1,332,000 | $945,000 |\n| **Cash and cash equivalents - end of period** | $1,549,000 |   |",
        "target": [
            "|   | **For the three months ended May 31, 2020 ** | **For the three months ended May 31, 2019 ** |",
            "| --- | --- | --- |",
            "| **Net income (loss) ** | $ 369  | $ (249)  |",
            "| **Depreciation and amortization ** | 59  | - |",
            "| **Accounts receivable ** | 79  | 357  |",
            "| **Inventories ** | (420)  | 547  |",
            "| **Prepaid expenses and other current assets ** | (61)  | - |",
            "| **Net cash provided by operating activities ** | 293  | 538  |",
            "| **Proceeds from sale of securities ** | 169  | 35  |",
            "| **Purchases of securities ** | (222)  | (19)  |",
            "| **Purchases of property and equipment ** | (23)  | (3)  |",
            "| **Net cash (used in) provided by investing activities ** | (76)  | 13  |",
            "| **Cash and cash equivalents - beginning of the year ** | 1,332  | - |",
            "| **Cash and cash equivalents - end of period ** | $ 1,549  | $ 945  |"
        ]
    },
    "sodi_10q_fileoutpart4": {
        "predict": "|   | **For the three months ended** | **For the three months ended .1** |<NEWLINE>|   | **May 31, 2020** | **May 31, 2019** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Net sales** | $2,498,000 | $2,557,000 |<NEWLINE>| **Cost of sales** | $1,642,000 | $2,366,000 |<NEWLINE>| **Gross proﬁt** | $856,000 | $191,000 |<NEWLINE>| **Selling, general and administrative expenses** | $486,000 | $444,000 |<NEWLINE>| **Operating income (loss)** | $370,000 | ($253,000) |<NEWLINE>| **Dividend income** | $6,000 | $1,000 |<NEWLINE>| **Realized gain (loss) on investments** | $15,000 | ($16,000) |<NEWLINE>| **Unrealized gain (loss) on investments** | ($22,000) | $19,000 |<NEWLINE>| **Net income (loss)** | $369,000 | ($249,000) |\n\nGuidelines:\n- Net cash provided by operating activities was $293,000 for the three months ended May 31, 2020 primarily reflecting net income of $369,000, an increase in accrued expenses of $252,000, an increase in accounts receivable of $79,000, and depreciation of $59,000 partially offset by increases in inventories of $420,000 and prepaid and other expenses of $61,000.\n- Net sales for the three months ended May 31, 2020 decreased 2% to $2,498,000 as compared to $2,557,000 for the three months ended May 31, 2019.\n- Realized gains on investments for the three months ended May 31, 2020 increased to $15,000 as compared to a loss of ($16,000) for the three months ended May 31, 2019.\n- Operating income for the three months ended May 31, 2020 increased to $370,000 as compared to an operating loss of ($253,000) for the three months ended May 31, 2019.\n- Net cash provided by operating activities was $538,000 for the three months ended May 31, 2019 primarily reflecting a net loss of ($249,000) offset by a decrease in inventory of $547,000 and a decrease in accounts receivable of $357,000.\n- Selling, general, and administrative expenses increased to $486,000 for the three months ended May 31, 2020 from $444,000 for the same period in the prior year.\n- Cost of sales for the three months ended May 31, 2020 decreased to $1,642,000 from $2,366,000 for the three months ended May 31, 2019, due to decreased inventory obsolescence, raw materials and labor costs, and improved productivity.\n- Unrealized gains (losses) on investments for the three months ended May 31, 2020 were a loss ($22,000) as compared to a gain of $19,000 for the three months ended May 31, 2019.\n- Gross profit for the three months ended May 31, 2020 increased to $856,000 from $191,000 for the three months ended May 31, 2019, due primarily to lower cost of sales.\n- Interest and dividend income for the three months ended May 31, 2020 increased to $6,000 as compared to $1,000 for the three months ended May 31,",
        "target": [
            "|   | **For the three months ended ** | **For the three months ended .1** |",
            "|   | **May 31, 2020 ** | **May 31, 2019 ** |",
            "| --- | --- | --- |",
            "| **Net sales ** | $ 2,498  | $ 2,557  |",
            "| **Cost of sales ** | 1,642  | 2,366  |",
            "| **Gross proﬁt ** | 856  | 191  |",
            "| **Selling, general and administrative expenses ** | 486  | 444  |",
            "| **Operating income (loss) ** | 370  | (253)  |",
            "| **Dividend income ** | 6  | 1  |",
            "| **Realized gain (loss) on investments ** | 15  | (16)  |",
            "| **Unrealized gain (loss) on investments ** | (22)  | 19  |",
            "| **Net income (loss) ** | $ 369  | $ (249)  |"
        ]
    },
    "EAPHEDGARfilingSept30_21_fileoutpart9": {
        "predict": "|   | **September 30, 2021** | **December 31, 2020** |\n| --- | --- | --- |\n| **Cash Flows from Operating Activities Net Income (Loss)** | ($84,350) | ($46,315) |\n| **Net Cash Flows from Operating Activities** | ($59,350) | ($43,415) |\n| **Cash Flows from Investing Activities Deposit on real estate** | ($18,797) | ($18,797) |\n| **Net Cash Flows from Investing Activities** |   |   |\n\nGuidelines:\n- The Company had a net loss of $84,350 for the three months ended September 30, 2021 compared to $46,315 for the year ended December 31, 2020.\n- We used approximately $18,797 in investing activities during the three months ended June 30, 2021 and for the Year Ended December 31, 2020.\n- Operating expenses: During the quarter ended September 30, 2021, we incurred operating expenses in the amount of $84,350 compared to $46,315 for the Year Ended December 31, 2020.\n- For the three months ended September 30, 2021, net cash flows used in operating activities was ($59,350) compared to ($43,415) for the year ended December 31, 2020.",
        "target": [
            "|   | **September 30, 2021 ** | **December 31, 2020 ** |",
            "| --- | --- | --- |",
            "| **Cash Flows from Operating Activities Net Income (Loss) ** | $(84,350)  | $(46,315)  |",
            "| **Net Cash Flows from Operating Activities ** | (59,350)  | (43,415)  |",
            "| **Cash Flows from Investing Activities Deposit on real estate ** | (18,797)  | (18,797)  |",
            "| **Net Cash Flows from Investing Activities ** | (18,797)  | (18,797)  |"
        ]
    },
    "fvt-20210930_fileoutpart6": {
        "predict": "|   | **For the nine months ended September 30, 2021** | **For the period from August 28, 2020 (inception) through September 30, 2020** |\n| --- | --- | --- |\n| **Net loss** | $238,057 | $17,217 |\n| **Interest income from investments held in Trust Account** | $21,750 |   |\n| **Decrease in fair value of warrant liabilities** | ($7,574,721) |   |\n| **Fair value in excess of cash received for Private Placement Warrants** | ($2,396,195) |   |\n| **Offering costs related to warrant liabilities** | $495,479 |   |\n| **Accounts payable and accrued expenses** |   |   |\n| **Franchise tax payable** | $149,589 |   |\n| **Cash deposited in Trust Account** | $230,000,000 |   |\n| **Proceeds from issuance of Class F common stock to Sponsor** |   | $25,000 |\n| **Repayment of Sponsor loan** |   | ($61,000) |\n| **Proceeds received from issuance of Private Placement Warrants** | $7,600,000 |   |\n| **Cash - end of the period** | $323,244 |   |\n| **Deferred underwriting commissions payable in connection with the Initial Public Offering** | $8,050,000 |   |\n\nGuidelines:\n- Following the closing of the Initial Public Offering and the sale of Private Placement Warrants, an aggregate of $230,000,000 was placed in the Trust Account.\n- Upon the closing of the Initial Public Offering and Private Placement, $230,000,000 ($10.00 per Unit) of the aggregate net cash proceeds of the sale of the Units in the Initial Public Offering and the Private Placement was placed in a U.S.-based trust account (the “Trust Account”), maintained by Continental Stock Transfer & Trust Company, acting as trustee.\n- Substantially concurrently with the closing of the Initial Public Offering, the Company consummated a private placement (“Private Placement”) of 5,066,667 warrants (the “Private Placement Warrants” and together with the “Public Warrants”, the “Warrants”), at a price of $1.50 per Private Placement Warrant, with the Company’s sponsor, Fortress Acquisition Sponsor III LLC (the “Sponsor”), generating gross proceeds of $7,600,000 (see Note 4).\n- These losses and expenses were partially offset by $21,750 in interest income and a non-cash $7,574,721 decrease in fair value of warrant liabilities.\n- On January 7, 2021, we consummated the Initial Public Offering of 23,000,000 units (“Units” and, with respect to the Class A common stock included in the Units being offered, the “Public Shares”), which included the issuance of 3,000,000 Units as a result of the underwriters’ exercise of their over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000 and incurring offering costs of $13,193,049, inclusive of $8,050,000 in deferred underwriting commissions.\n- The Private Placement Warrants had an estimated fair value of $9,996,195 as of the closing of the Initial Public Offering, resulting in a $2,396,195 non-cash loss to the Company equal to the fair value in excess of cash received for the Private Placement Warrants.\n- Following the closing of the Initial Public Offering, the exercise of the over-allotment option, and the sale of Private Placement Warrants, which resulted in $230,000,000 ($10.00 per Unit) being placed into a Trust Account and payment of expenses, we had $",
        "target": [
            "|   | **For the nine months ended September 30, 2021 ** | **For the period from August 28, 2020 (inception) through September 30, 2020 ** |",
            "| --- | --- | --- |",
            "| **Net loss ** | $ (238,057)  | $ (17,217)  |",
            "| **Interest income from investments held in Trust Account ** | (21,750)  | - |",
            "| **Decrease in fair value of warrant liabilities ** | (7,574,721)  | - |",
            "| **Fair value in excess of cash received for Private Placement Warrants ** | 2,396,195  | - |",
            "| **Offering costs related to warrant liabilities ** | 495,479  | - |",
            "| **Accounts payable and accrued expenses ** | - | 17,217  |",
            "| **Franchise tax payable ** | 149,589  | - |",
            "| **Cash deposited in Trust Account ** | (230,000,000)  | - |",
            "| **Proceeds from issuance of Class F common stock to Sponsor ** | - | 25,000  |",
            "| **Repayment of Sponsor loan ** | (61,000)  | - |",
            "| **Proceeds received from issuance of Private Placement Warrants ** | 7,600,000  | - |",
            "| **Cash - end of the period ** | $ 323,244  | - |",
            "| **Deferred underwriting commissions payable in connection with the Initial Public Offering ** | $ 8,050,000  | - |"
        ]
    },
    "fvt-20210930_fileoutpart3": {
        "predict": "|   | **For the three months ended September 30, 2021 ** | **For the nine months ended September 30, 2021 ** | **For the period from August 28, 2020 (inception) through September 30, 2020 ** |\n| --- | --- | --- | --- |\n| **General and administrative expenses ** | $307,395 | $4,793,265 | $17,217 |\n| **Franchise tax expense ** | $50,411 | $149,589 |   |\n| **Loss from operations ** |   |   | $17,217 |\n| **Interest income ** | $2,960 | $21,750 |   |\n| **Decrease in fair value of warrant liabilities ** | $3,664,000 | $2,396,195 | $7,574,721 |\n| **Fair value in excess of cash received for Private Placement Warrants ** |   | ($2,396,195) |   |\n| **Offering costs related to warrant liabilities ** |   | $495,479 |   |\n| **Net income (loss) ** | $3,309,154 | ($238,057) |   |\n| **Weighted average shares outstanding, Class A common stock ** |   |   |   |\n| **Weighted average shares outstanding, Class F common stock ** |   |   | 5,750,000 |\n\nGuidelines:\n- Accordingly, as of September 30, 2021, 23,000,000 shares of Class A common stock subject to possible redemption at the redemption value were presented as temporary equity, outside of the stockholders’ equity section of our condensed balance sheets\n- Accordingly, as of September 30, 2021, 23,000,000 shares of Class A common stock subject to possible redemption at the redemption value were presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed balance sheets (see Note 7)\n- As of September 30, 2021, there were 23,000,000 shares of Class A common stock issued and outstanding and all shares of Class A common stock were subject to possible redemption and included in temporary equity (see Note 7)\n- Net income (loss) per common share, basic and diluted for Class F common stock for the period from August 28, 2020 (inception) through September 30, 2020 were calculated by dividing (i) the net loss of $17,217 by (ii) the weighted average number of shares of Class F common stock outstanding for the respective period\n- For the three months ended September 30, 2021, we had net income of $3,309,154 which consisted of $2,960 in interest income and a non-cash $3,664,000 decrease in fair value of warrant liabilities, partially offset by $307,395 in general and administrative expenses and $50,411 in franchise tax expense\n- The Private Placement Warrants had an estimated fair value of $9,996,195 as of the closing of the Initial Public Offering, resulting in a $2,396,195 non-cash loss to the Company equal to the fair value in excess of cash received for the Private Placement Warrants\n- For the nine months ended September 30, 2021, we had a net loss of $238,057 which consisted of a non-cash loss of $2,396,195 on the excess of fair value over cash received for the Private Placement Warrants, $495,479 in offering costs related to warrant liabilities, $4,793,265 in general and administrative expenses and $149,589 in franchise tax expense\n- As of September 30, 2021, there were 23,000,000 shares of Class A common stock outstanding, all of which were subject to",
        "target": [
            "|   | **For the three months ended September 30, 2021 ** | **For the nine months ended September 30, 2021 ** | **For the period from August 28, 2020 (inception) through September 30, 2020 ** |",
            "| --- | --- | --- | --- |",
            "| **General and administrative expenses ** | $ 307,395  | $ 4,793,265  | $ 17,217  |",
            "| **Franchise tax expense ** | 50,411  | 149,589  | - |",
            "| **Loss from operations ** | - | - | (17,217)  |",
            "| **Interest income ** | 2,960  | 21,750  | - |",
            "| **Decrease in fair value of warrant liabilities ** | 3,664,000  | 7,574,721  | - |",
            "| **Fair value in excess of cash received for Private Placement Warrants ** | - | (2,396,195)  | - |",
            "| **Offering costs related to warrant liabilities ** | - | (495,479)  | - |",
            "| **Net income (loss) ** | $ 3,309,154  | $ (238,057)  | $ (17,217)  |",
            "| **Weighted average shares outstanding, Class A common stock ** | 23,000,000  | 23,000,000  |   |",
            "| **Weighted average shares outstanding, Class F common stock ** | 5,750,000  | - | - |"
        ]
    },
    "pse_10q_fileoutpart3": {
        "predict": "|   | **As of November 30, ** | **As of August 31, ** |\n| --- | --- | --- |\n| **Cash and cash equivalents** | $22,509 | $22,690 |\n| **Inventory** | $2,177 | $2,269 |\n| **Total Current Assets** | $24,686 | $24,959 |\n| **TOTAL ASSETS** |  |  |\n| **Accounts payable and accrued liabilities** | $24,444 |  |\n| **Common stock payable** | $1,500 |  |\n| **Total Current Liabilities** | $26,041 | $25,944 |\n| **Common stock: 220,000,000 shares authorized; $0.001 par value; 14,375,000 and 14,100,000 shares issued and outstanding respectively.** |  |  |\n| **Total Stockholders' Deﬁcit** |  |  |\n| **TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |\n\n* On September 6, 2020, pursuant to our S-1 Registration Statement declared eﬀective on September 30, 2019, the Company issued 275,000 shares of Common Stock to unaﬃliated individuals, for total proceeds of $5,500, of which $1,500 was received prior to year-end and reported as Common Stock payable in the November 30, 2020 balance sheet\n* As of November 30, 2020 and August 31, 2020, the Company had 14,375,000 and 14,100,000 shares of Common Stock issued and outstanding, respectively\n* 14,375,000 shares of Common Stock issued and outstanding as of January 13, 2020\n* As of November 30, 2020, our current and total assets were $24,686, consisting of cash of $22,509 and inventory of $2,177\n* As of August 31, 2020, liabilities consisted of $24,444 accounts payable and accrued liabilities and $1,500 common stock payable\n* As of November 30, 2020, we had current assets of $24,686 (August 31, 2020 - $24,959) and current liabilities of $26,041 (August 31, 2020 - $25,944)\n* As of November 30, 2020, we had a working capital deficiency of $1,355 compared to working capital deficiency of $985 as of August 31, 2020\n* As of August 31, 2020, our current and total assets were $24,959, consisting of cash of $22,690 and inventory of $2,269.",
        "target": [
            "|   | **As of November 30, ** | **As of August 31, ** |",
            "|   | **2020 ** | **2020 ** |",
            "| --- | --- | --- |",
            "| **Cash and cash equivalents ** | $ 22,509  | $ 22,690  |",
            "| **Inventory ** | 2,177  | 2,269  |",
            "| **Total Current Assets ** | 24,686  | 24,959  |",
            "| **TOTAL ASSETS ** | $ 24,686  | $ 24,959  |",
            "| **Accounts payable and accrued liabilities ** | $ 26,041  | $ 24,444  |",
            "| **Common stock payable ** | - | 1,500  |",
            "| **Total Current Liabilities ** | 26,041  | 25,944  |",
            "| **Common stock: 220,000,000 shares authorized; $0.001 par value; 14,375,000 and 14,100,000 shares issued and outstanding respectively. ** | 14,375  | 14,100  |",
            "| **Total Stockholders' Deﬁcit ** | (1,355)  | (985)  |",
            "| **TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT ** | $ 24,686  | $ 24,959  |"
        ]
    },
    "pse_10q_fileoutpart4": {
        "predict": "|   | **Three Months Ended November 30, ** |   |<NEWLINE>|   | **2020 ** | **2019 ** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **General and administrative ** | $113 | $555 |<NEWLINE>| **Professional fees ** | $7,625 | $18,835 |<NEWLINE>| **Net loss before income taxes ** |   |   |<NEWLINE>| **Net loss ** | ($5,870) | ($19,300) |",
        "target": [
            "|   | **Three Months Ended November 30, ** |   |",
            "|   | **2020 ** | **2019 ** |",
            "| --- | --- | --- |",
            "| **General and administrative ** | 113  | 555  |",
            "| **Professional fees ** | 7,625  | 18,835  |",
            "| **Net loss before income taxes ** | (5,870)  | (19,300)  |",
            "| **Net loss ** | $ (5,870)  | $ (19,300)  |"
        ]
    },
    "pse_10q_fileoutpart9": {
        "predict": "|   | **November 30, 2020** | **August 31, 2020** |\n| --- | --- | --- |\n| **Cash** | $22,509 | $22,690 |\n| **Total Assets** | $24,686 | $24,959 |\n| **Total Liabilities** | $26,041 | $25,944 |\n| **Working Capital (Deﬁciency)** | ($1,355) | ($985) |",
        "target": [
            "|   | **November 30, 2020 ** | **August 31, 2020 ** |",
            "| --- | --- | --- |",
            "| **Cash ** | $ 22,509  | $ 22,690  |",
            "| **Total Assets ** | 24,686  | 24,959  |",
            "| **Total Liabilities ** | 26,041  | 25,944  |",
            "| **Working Capital (Deﬁciency) ** | $ (1,355)  | $ (985)  |"
        ]
    },
    "pse_10q_fileoutpart10": {
        "predict": "| **The following table presents our working capital (deﬁciency) position as at November 31, 2020: ** | **30, 2020 November 30, 2020 ** | **and August August 31, 2020 ** |\n| --- | --- | --- |\n| **Current Assets ** |   |   |\n| Cash | $22,509 | $22,690 |\n| Inventory | $2,177 | $2,269 |\n| Total Current Assets | $24,686 | $24,959 |\n| **Current Liabilities ** |   |   |\n| Current Liabilities | $26,041 | $25,944 |\n| **Working Capital (Deﬁciency) ** |   |   |\n| Working Capital (Deﬁciency) | ($1,355) | ($985) |",
        "target": [
            "| **The following table presents our working capital (deﬁciency) position as at November 31, 2020: ** | **30, 2020 November 30, 2020 ** | **and August August 31, 2020 ** |",
            "| --- | --- | --- |",
            "| **Current Assets ** | $ 24,686  | $ 24,959  |",
            "| **Current Liabilities ** | 26,041  | 25,944  |",
            "| **Working Capital (Deﬁciency) ** | $ (1,355)  | $ (985)  |"
        ]
    },
    "jbt-20220630_fileoutpart40": {
        "predict": "|   | **Six Months Ended June 30, ** |   | **Favorable/(Unfavorable) ** |<NEWLINE>| **(In millions, except %) ** | **2022 ** | **2021 ** | **Change ** |<NEWLINE>| --- | --- | --- | --- |<NEWLINE>| **Total revenue ** |   | $118.2 |   |<NEWLINE>| **Gross profit % ** |   | 28.7% | (300) bps |<NEWLINE>| **Selling, general and administrative expense ** |   |   | $20.7 |<NEWLINE>| **Operating income % ** |   | 7.2% | (230) bps |",
        "target": [
            "|   | **Six Months Ended June 30, ** |   | **Favorable/(Unfavorable) ** |",
            "| **(In millions, except %) ** | **2022 ** | **2021 ** | **Change ** |",
            "| --- | --- | --- | --- |",
            "| **Total revenue ** | - | - | $ 118.2  |",
            "| **Gross profit % ** | 28.7 %  | 31.7 %  | -300 bps  |",
            "| **Selling, general and administrative expense ** | - | - | (20.7)  |",
            "| **Operating income % ** | 7.2 %  | 9.5 %  | -230 bps  |"
        ]
    },
    "jbt-20220630_fileoutpart38": {
        "predict": "|   | **Three Months Ended June 30, ** |   | **Favorable/(Unfavorable) ** |\n| --- | --- | --- | --- |\n| **(In millions, except %) ** | **2022 ** | **2021 ** | **Change ** |\n| **Total revenue ** | $541.4 | $474.6 | $66.8 or 14%<NEWLINE> |\n| **Gross profit % ** | 27.9% | 31.5% | (360) bps<NEWLINE> |\n| **Selling, general and administrative expense ** | $152.3 | $145.6 | $6.7 or 5%<NEWLINE> |\n| **Operating income % ** | 7.8% | 9.9% | (210) bps<NEWLINE> |\n\nNote: Some cells may remain empty based on the guidelines.",
        "target": [
            "|   | **Three Months Ended June 30, ** |   | **Favorable/(Unfavorable) ** |",
            "| **(In millions, except %) ** | **2022 ** | **2021 ** | **Change ** |",
            "| --- | --- | --- | --- |",
            "| **Total revenue ** | - | - | $ 66.8  |",
            "| **Gross profit % ** | 27.9 %  | 31.5 %  | -360 bps  |",
            "| **Selling, general and administrative expense ** | - | - | (6.7)  |",
            "| **Operating income % ** | 7.8 %  | 9.9 %  | -210 bps  |"
        ]
    },
    "jbt-20220630_fileoutpart43": {
        "predict": "| **(In millions) ** | **Six Months Ended June 30, ** |   |<NEWLINE>|   | **2022 ** | **2021 ** |<NEWLINE>| --- | --- | --- |<NEWLINE>| **Cash provided by operating activities ** | $44.8 | $130.3 |<NEWLINE>| **Cash required by investing activities ** | ($44.2) | ($34.5) |<NEWLINE>| **Cash (required by) provided by financing activities ** | ($9.3) | $59.8 |\n\nGuidelines:\n\nCash required by financing activities was $9.3 million during the six months ended June 30, 2022, which is a decrease of $69.1 million compared to same period in 2021.\n\nFor the six months ended June 30, 2022, we had total operating cash flow of $44.8 million.\n\nSpecifically the cash provided by financing activities of $59.8 million during the six months ended June 30, 2021 was primarily due to proceeds from the issuance of the convertible notes, bond hedge and warrant transactions, partially offset by paying down borrowings under our revolving credit facility and payment of acquisition date earn-out liability.\n\nCash provided by operating activities during the six months ended June 30, 2022 was $44.8 million, representing an $85.5 million decrease compared to the same period in 2021.\n\nCash required by investing activities during the six months ended June 30, 2022 was $44.2 million, an increase of $9.7 million compared to the same period in 2021 primarily due to increased capital expenditures partially offset by lower spending on acquisitions year over year.",
        "target": [
            "| **(In millions) ** | **Six Months Ended June 30, ** |   |",
            "|   | **2022 ** | **2021 ** |",
            "| --- | --- | --- |",
            "| **Cash provided by operating activities ** | $ 44.8  | - |",
            "| **Cash required by investing activities ** | (44.2)  | - |",
            "| **Cash (required by) provided by financing activities ** | (9.3)  | 59.8  |"
        ]
    }
}